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Chapter 1  
  
General introduction into the pharmaceutical 
industry, Cytochrome P450(BM3) enzymes and 
NMR spectroscopy 
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1.1 History of the pharmaceutical industry 
The pharmaceutical industry is involved in the discovery, development, production 
and marketing of drugs. The development of drugs was in the past not as common 
as it is now-a-days. The first papyrus document, describing a variety of herbal and 
other remedies to treat diseases dates back to 1550BC(1). The discovery of remedies 
did not have a scientific foundation until the mid-19th century, but was more based 
on empiricism and common sense. Nevertheless, many plant extracts were 
discovered with good pharmacological properties which are still being used today: 
e.g. opium alkaloids(2), cannabis(3) and ephedrine(4). The growing scientific 
interest in using herbals as medicines started in the 18th century. At the beginning 
of the 20th century, chemistry and biology progressed sufficiently to give a 
scientific basis for the discovery and development of novel drugs. Especially the 
developments in biomedicine and chemistry, with the introduction of the cell 
theory and the birth of pharmacology and organic synthetic chemistry, have given a 
tremendous boost to the pharmaceutical industry(1). In the beginning of the 20th 
century many synthetic drugs were produced and barbitone, a hypnotic, sedative 
and antiepileptic drug, was the first blockbuster. From the last quarter of the 20th 
century, when molecular biology was introduced, the discovery of drugs followed 
mainly three approaches: 1) chemistry-driven approaches; 2) target-directed 
approaches and 3) accidental clinical discoveries. In the chemistry-driven 
approaches, drugs were classified and designed based on their chemical structure 
rather than on the mode of action. This started changing in the 1970s when biology 
obtained a more dominant role in the pharmaceutical industry. Here, the target-
directed drug discovery was introduced by Ehrlich amongst others(5). They 
defined the drug specificity as an interaction between a drug molecule and a target 
molecule inducing a therapeutic effect. This definition set the stage for drug 
discovery as we know it now-a-days and will be discussed in more detail in the 
next paragraph. The third approach by which drugs are discovered is the accidental 
clinical discoveries. As the name would suggest, unexpected observations in the 
clinical laboratories resulted in numerous discoveries of new drugs(6, 7). One of 
the most well-known examples is Sildenafil(8). While testing this potential drug in 
the clinical trials to cure angina, severe chest pain due to a lack of oxygen of the 
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heart muscle, it was observed that this drug cures erectile dysfunction(9). This 
compound is on the market since 1998 and is one of the largest blockbusters of 
Pfizer, yearly turnover of Viagra (brandname of Sildenafil) is approximately 1 
billion dollars. Before drugs can be brought on the market, they have to be 
approved by the regulatory affairs. In the early 1900s, the USA and UK started 
approving drugs where priority was given to controlling poisonous or addictive 
substances or contaminations(1). The approval of drugs is now-a-days much more 
controlled, which basically means that all new drugs, including mixtures of known 
compounds and formulations, have to be approved before clinical trials can be 
started. Before drugs are licensed to bring on the market, the regulatory affairs 
have carefully confirmed the evidence of safety, efficacy and chemical purity. This 
is in short how the pharmaceutical industry has evolved from the early era, herbal 
remedies, to the modern drug discovery and development process. More detailed 
information about the development of the pharmaceutical industry has been 
described in literature to which is referred(1, 10, 11). In the next paragraph a more 
detailed overview of the modern drug discovery and development process will be 
given.  
 
1.2 Drug discovery and development 
Three main phases can be defined in the process of developing a novel drug, 
namely drug discovery, drug development and commercialization. These three 
phases of the drug development process do not necessarily act sequentially, but are 
closely related throughout the project. In this paragraph however, it was chosen for 
simplicity reasons to treat the different phases of the drug discovery and 
development sequentially as it is schematically shown in Figure 1.1. 
 
  
Figure 1.1 Overview of the drug discovery and development process. Reproduced from(1). 
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The total time to bring a new drug on the market is approximately 11-14 years and 
the total costs are ~ € 1 billion(12). The total number of compounds used in the 
initial stage of drug discovery is approximately 107. Where only one of these 
compounds, in most cases a synthetically modified version, makes it to the market.  
1.2.1 Target identification   
The first step in the drug discovery process is the identification of a drug target. In 
the so-called target-based drug design, the lock-key model plays a dominant 
role(1). In this model, a small molecule (key) binds to a target (lock). The way a 
small molecule binds to a target determines its affinity, potency, and efficacy. It is 
very difficult to generalize the effect of a small molecule binding in-vivo to a 
target. Here, two well-known classes of compounds are considered, namely 
agonists and antagonist. An agonist has affinity with a receptor on a cell. The 
structural change which the receptor then undergoes influences the function of a 
cell. An antagonist is a type of ligand which has affinity for a receptor, but does not 
influence the function of a cell. An antagonist blocks the binding site of an agonist 
or another compound and thus reduces the response given by a receptor. The lock-
key model is a very strong didactic and educative model, but suffers in general 
from an over-simplification of the real situation. Binding modes can be much more 
complex, e.g. induced fit, conformational capture and dynamics of binding play an 
important role as well(13, 14). The first step in the drug discovery process is thus 
the identification of a target. Hopkins and Groom found in 2002 that there are 
approximately 120 drug targets which can be accounted for the activities of 
compounds used therapeutically(15). These targets can be divided into classes 
(Figure 1.2) and from this it can be seen that the enzymes and G-protein coupled 
receptors (GPCR’s) are the two most frequently observed targets(16).  
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Figure 1.2 Small molecule drug targets as ordered by their biochemical class. Adapted 
from (15). 
 
Furthermore, Hopkins and Groom estimated that 600-1500 targets exist in the 
human genome which can be targeted by drugs. Although this number always 
remains a point of discussion, it is clear that there are large numbers of targets to be 
discovered. The conventional strategies to discover new drug targets are based on 
the analysis of pathophysiology and mechanism of action of existing therapeutic 
drugs. On average, only 3-4 novel drug targets are covered by newly registered 
drugs each year(1, 15).  
1.2.2 High-throughput screenings  
Once a drug target has been identified, high-throughput screening starts. High-
throughput screenings (HTS) are one of the most common used strategies in the 
pharmaceutical industry to identify chemistry starting points for drug discovery 
programs(17). Pharmaceutical companies have compound libraries of hundreds of 
thousands up to several million compounds. In HTS, these, or a selection of these 
compounds are screened for affinity with a drug target. Compounds which show 
affinity for a drug target are named ‘hits’. There are mainly two types of HTS used, 
namely biochemical and cell-based assays(1, 17). The biochemical assay can 
involve enzyme/ligand interactions, receptor binding, protein-protein interactions 
and/or in-vitro transcription systems. Obviously, the biochemical assays lack the 
cellular context, whereas the cell-based assays mimic more closely the in-vivo 
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situation. In the cell-based assays, not necessarily the interaction between a 
compound and receptor is monitored, but more importantly, the growth of the cells, 
changes in cell metabolism, membrane transport, antibacterial actions, and many 
other parameters can be quantified. In a biochemical assay, the interaction between 
a compound and a target can be monitored by radiolabelled or fluorescent 
compounds(17). Fluorescent compounds are in 
general more suited for automated screenings 
and also the radioactive waste from the 
radiolabelled compounds makes that fluorescent 
compounds are more frequently used in HTS(1, 
17). In Chapter 2 of this thesis, a dual affinity 
hyphenated screening assay is presented where 
the fluorescence enhancement of a ligand 
(coumestrol) bound to the Estrogen receptors 
alpha and bèta is used to probe the affinity of 
drug metabolites produced by Cytochrome P450 
enzymes. To the best of our knowledge, the 
physical basis for the enhanced fluorescence of 
coumestrol when bound to the Estrogen 
receptors is not well understood yet and no in-
depth information can be given. Although HTS 
is the most common used strategy to screen for 
lead compounds, structure activity relationship 
(SAR) by NMR/MS, structure-based drug 
design (SBD) and computational approaches are 
gaining in interest as well. The SAR by NMR 
approach is schematically represented in Figure 
1.3. Here, low affinity binders are detected 
based on, primarily, chemical shift mapping 
Figure 1.3 Structure activity   (e.g. 1H-15N HSQC). This is in contrast to HTS 
relationship ) by NMR.    where  generally  only  high  affinity binders are 
Adapted fr ).    detected. Subsequently, the ligands are   
      structurally optimized to become
      and finally they are linked in order to produce a 
 (SAR
om (18
 tighter binders 
Ard Kolkman 20
                                                                                        General introduction 
                                                                                         
(21).  
higher affinity binder(18-20). Another approach to produce high-affinity ligands 
based on NMR spectroscopy is the so-called SHAPES screening. Here, the binding 
of small molecules is monitored using NMR techniques that observe the ligand 
(e.g. differential line broadening, saturation transfer difference (STD), 
WaterLOGSY or transferred NOE). On the basis of a low affinity hit (most of them 
would be missed in a standard enzymatic assay), a library of analogues with further 
derivatization can be prepared in order to obtain high affinity ligands. An example 
of the SHAPES screening is the design of inhibitors of the mitogen-actived protein 
kinase p38
The most common used technique in structure based drug design is however 
crystallography. Here, the crystal structure of a drug target is first determined, after 
which it is co-crystallized with a ligand. The ligand-target complex is then 
analyzed in detail to reveal binding interactions. Subsequently, new ligands are re-
designed and co-crystallized with the drug target in order to find the optimal drug-
target interaction(22). In most computational approaches, ‘virtual’ compounds are 
generated and docked into a 3D model of a drug target. Based on the binding 
energy of the complex, the affinity for a target can be estimated. Like this a subset 
of compounds can be selected after which they can be physically screened for 
affinity with a drug target(23).  
High-throughput screenings and/or the above-mentioned strategies result in the 
identification of several bioactive compounds (‘hits’). When the bioactivity of 
these compounds is confirmed by successive applied screenings and resynthesis, 
the compound is named a lead compound and advances into the lead optimization 
process. A lead compound is generally defined as a new chemical entity (NCE) 
that has bioactivity and could potentially be developed into a drug compound. 
1.2.3 Lead optimization    
Once a lead compound is discovered, the lead optimization process starts. Here, a 
lead compound is optimized to generate a drug candidate for pre-clinical 
development(1). In the lead optimization process, many parameters have to be 
optimized simultaneously, from which potency, selectivity, stability, chirality, 
plasma half-life and oral bioavailability are, amongst others, the most important 
ones. This also makes that the lead optimization process is one of the most difficult 
aspects, since many criteria have to be fulfilled simultaneously. The first stage in 
Ard Kolkman 21
Chapter 1                        
the lead optimization process is to produce, by parallel synthesis, a wide range of 
structural analogues of the lead compound. Like this the boundaries, concerning 
the above mentioned parameters, of a lead compound are discovered. In a later 
stage of the lead optimization process, where compounds are in-vivo tested for drug 
metabolism, pharmacokinetics (DMPK) and pharmacological activities, single 
compounds at a hundreds of milligram scale are synthesized.  
1.2.4 DMPK studies  
DMPK studies are originally performed after a drug candidate has been identified.  
Nowadays, DMPK studies are more and more incorporated in the lead discovery 
and lead optimization process(24). In DMPK studies, the solubility, pKa, 
lipophilicity, permeability (passive and active) and other physicochemical 
properties of lead compounds are determined and optimized. Profiling the 
metabolic stability of a compound is also an important part in DMPK studies(25). 
Cytochrome P450 (CYP) is a super-family consisting of heme containing 
monooxygenase enzymes. These enzymes play an important role in the oxidative 
metabolism of endogenous compounds, natural products and xenobiotics(26). 
Paragraph 1.4 of this thesis describes in more detail the role of Cytochrome P450s 
in the metabolism of drugs. Here, only a short overview is given. The liver is the 
main drug-metabolizing organ and thus contains most of the CYPs(27). Drug 
metabolism studies are mainly performed with liver microsomes (from many 
species, including human), S9 fraction (microsomal and cytosolic components, low 
activity) and intact hepatocytes(1, 28). First estimate of metabolic stability of 
compounds is obtained by determining the disappearance of a compound over 
time, mostly followed by Liquid Chromatography (LC) and Mass Spectrometry 
(MS)(29). In a later stage of the drug discovery process, the disappearance of the 
parent compound is not enough and adequate predictions of in-vivo clearance 
should be known, e.g. kinetic parameters are monitored for each metabolite(1, 25). 
In order to discover the weak points in a compound, the produced metabolites have 
to be structurally identified (metabolic profiling) by LC-MS and if necessary, new 
compounds with less weak points can be synthesized. Metabolites which are 
produced by CYPs can cause adverse drug reactions and/or toxicological 
responses(30). These responses are of course undesirable and any indication of 
such a response weights strongly against a drug before it advances into clinical 
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development. On the other hand, hydroxylation of drugs by CYPs reduces 
lipophilicity which in turn improves excretion from the body. 
1.2.5 Pharmacology 
When the DMPK parameters of a lead compound have been monitored, a detailed 
pharmacological evaluation takes place. Here the effects of a lead compound on a 
range of test systems up to living animals are investigated(1). Most of the work of 
pharmacology takes place before clinical trials begin. First, binding assays are 
developed, which mimic more closely the in-vivo situation. In these binding assays, 
there is especially screened for selectivity and affinity of the lead compound for a 
target. In pharmacological profiling, the effect of a lead compound in intact tissues 
(in-vitro) and animals (in-vivo) is studied. Obviously, actions of the lead compound 
on its target are monitored, but also side-effects are studied, pharmacokinetic 
properties, potency at molecular, effects on tissue and whole animal level and long-
term effects(31). 
1.2.6 Drug development  
Once a drug candidate is identified, the drug development process starts, which is 
the topic of this paragraph. The drug development process constitutes all 
disciplines which are involved in transforming a drug candidate into a product 
approved for marketing. The first important aspect in drug development is the 
safety of a drug. Before a drug can be administered by humans, the drug safety has 
to be tested. In these pre-clinical tests, animal models are used to study the 
toxicology and adverse drug effects(32). The procedures of these tests are well 
documented and carefully reviewed by the regulatory authorities. The pre-clinical 
tests have to be performed under good laboratory practice (GLP) and can easily 
take 24 months in order to study the long-term effects and reproducibility(1). 
Another important aspect before clinical trials can start is the formulation of a 
drug, i.e. what is the best delivery system for an active compound. The choice of 
formulations depend on route of administration, particle size of the active 
compound, solubility, stability, permeability, access to site of action, plasma half-
life and many others. Common used contents of formulations are polymers, 
surfactants, micelles, liposomes and cyclodextrines(33). The decision on what is 
the best formulation requires many tests and takes a lot of time and is generally not 
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ready before phase I clinical trials start, but is continued throughout later stages of 
clinical trials(1).  
1.2.7 Clinical trials  
In clinical development, the candidate drugs that passed pre-clinical tests are tested 
for efficacy and safety in humans in clinical trials. These clinical trials last many 
years and the costs constitute approximately 70% of the total drug development 
costs(1, 34). The clinical trials can be roughly divided in four stages(34): Phase I, 
II, III and IV clinical trials. In phase I clinical trials, approximately 20-80 healthy 
volunteers participate and obtain a low dose of candidate drug. Phase I clinical 
trials are not designed to observe a therapeutic effect, but the emphasis is on 
assessing safety, tolerability and pharmacokinetics of this candidate drug in 
humans. In phase II clinical trials, approximately 100 - 250 patients participate, in 
which the safety is further assessed and a first indication of efficacy is obtained. 
Once the efficacy of a drug is confirmed, the optimal dosing is determined. In 
phase III clinical trials, 300 up to several thousands of patients participate. In these 
large scale studies, the safety, efficacy and tolerability have to be proven compared 
to placebos. In cases where treatments already exist for a certain disease type, the 
advantages of the newly developed drug over the existing treatments have to be 
proven as well. After phase III clinical trials, the drug has to be approved by 
regulatory affairs to be licensed on the market. In Phase IV, the post market effect 
of drugs on a very large number of patients is monitored. Here, safety and efficacy 
are further assessed, as well as unwanted side-effects, drug-drug interactions, rare 
and long term effects. Besides the scientific disciplines which are involved in 
developing a drug, also regulatory affairs, patenting, sales and marketing are 
crucial aspects in the development, licensing and sales of drugs on the market. It 
therefore makes that the discovery and development of drugs is a complex but 
exciting science in which experts from many different disciplines join forces.  
Finally, it is worthwhile to mention that the overall costs of R&D projects 
increased drastically in the past decades while the number of drugs approved for 
use as medication decreased. The pharmaceutical industry therefore faces a number 
of significant challenges to reduce the costs and increase the output of R&D 
projects in the near future. Although nobody knows the exact answers, possibilities 
might lie in improving the efficacy of R&D projects, shifting (pre-) clinical trials to 
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earlier stages in the R&D projects, more intensive multidisciplinary collaborations, 
development of novel state-of-the-art analytical technologies, application of 
biocatalysts (such as P450 enzymes) to predict human metabolism and toxicity in 
early stages of R&D projects, amongst many others. 
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1.3 Analytical sciences in drug discovery 
Analytical sciences, i.e. analytical chemistry, can best be described as a discipline 
in which separation, identification and quantification of matter is the core business, 
i.e. the chemical nature of substances is studied. Analytical chemistry has a 
widespread use in the drug discovery and development process: e.g. metabolite 
identification in drug metabolism studies(35, 36), structure and impurity 
identification in lead finding and lead optimization studies(37), determination of 
biofluid composition in pre-clinical and clinical studies(38, 39) and its role in 
quality assurance and quality control(40, 41). Liquid chromatography coupled to 
mass spectrometry (LC/MS) is one of the most common used analytical 
methodologies to study the chemical nature of substances. Other methodologies 
commonly used in analytical chemistry are gas chromatography coupled to MS 
(GC/MS), nuclear magnetic resonance (NMR) spectroscopy, Raman spectroscopy, 
infrared (IR) spectroscopy, UV-VIS spectroscopy and fluorescence spectroscopy 
amongst others. GC and LC are methodologies to separate analytes from each 
other, where in GC the analytes are vaporized and in LC the analytes stay in 
solution. There are mainly three types of LC systems used in drug discovery to 
separate small molecules from each other: nano-LC, high performance liquid 
chromatography (HPLC) and ultra performance liquid chromatography (UPLC), 
where UPLC is superior in both resolution and experimental time. The type of LC 
column to be used depends on polarity (normal-phase chromatography and reverse 
phase chromatography), ionic strength (ion-exchange chromatography), size (size-
exclusion chromatography) or other chemical properties of the analytes.   
1.3.1 Mass spectrometry   
For structural elucidation of analytes, LC is generally coupled to a mass 
spectrometer. High resolution mass spectrometry (HR-MS) provides accurate 
information about the mass of analytes as well as of their fragmentation patterns 
formed in tandem mass spectrometry (MS-MS). The development of atmospheric 
pressure ionization (API) allows for direct coupling of LC and MS (LC/MS) and 
was introduced in drug metabolism studies in 1997(42). The two most common 
API ionization techniques are electrospray ionization (ESI) and atmospheric 
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pressure chemical ionization (APCI)(36). In ESI, the analytes are charged in 
solution by spraying the solution through a capillary probe upon voltage(36). In 
APCI, both solvent and analytes are nebulised within the source by using a high 
temperature (~450 – 550 ˚C) and inert carrier gas(36). The analyte is subsequently 
ionized by corona discharge around a needle tip. ESI and APCI are complementary 
ionization techniques, where APCI is more effective in ionizing less-polar species 
than ESI. In addition, the analyte has to be volatile and thermally inert in APCI, 
whereas in ESI these chemical properties are not required. The mass analyzer is the 
part of the mass spectrometer where ions are sorted based on their mass-to-charge 
ratio (m/z). The most common used mass analyzer in the pharmaceutical industry is 
the quadrupole MS (43). Quadrupole mass analyzer consist of four round 
electrodes, in which the RF/DC voltage applied determines the stability of certain 
m/z values. In single quadrupole MS, only one set of quadrupoles is present, 
whereas in triple quadrupole MS, three sets of quadrupoles is present. Here, the 
first and the third quadrupole are mass analyzers, whereas the second quadrupole is 
a collision cell where collision induced dissociation (CID) occurs. This thus makes 
that quadrupole MS is capable of performing MS2 experiments, whereas single 
quadrupole MS only produces first order MS spectra. The use of MSn experiments 
in metabolite identification is of immense importance for structure identification, 
since the accurate mass of the parent ion is often not sufficient. Time-of-flight 
(TOF) is another mass analyzer commonly used in the pharmaceutical 
industry(43). In TOF-MS, all ions initially get the same kinetic energy. In the flight 
tube, the lighter ions will travel faster than the heavier ions. The time it takes for 
the ions to reach the detector can be related to the mass and charge of the ions. In 
TOF-MS all ions are therefore detected and not only a selection like for example is 
the case in quadrupole MS. Wright recently reviewed the use of mass spectrometry 
for metabolite identification in drug discovery and development(35). Here it was 
shown that many types of mass spectrometer hybridization have been reported in 
order to obtain higher resolution, higher sensitivity and higher accuracy in 
quantification. Examples of hybridized mass spectrometers are: Q-TOF 
(quadrupole and time-of-flight), Q-trap (quadrupole and ion trap) and IT-TOF (ion 
trap and time-of-flight).  
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1.3.2 LC-SPE-NMR-MS   
NMR spectroscopy is the second most used, next to LC/MS, analytical method to 
obtain detailed structural and quantitative information. Since NMR spectroscopy is 
the major method used in this thesis, paragraph 1.6 is devoted to the basics of 
NMR spectroscopy, theoretical background and experiments used in this thesis. It 
is worthwhile to mention here that MS and NMR give mainly complementary 
information(44) and the combination of both techniques is extremely powerful to 
obtain full structural information. NMR spectroscopy is commonly applied off-line 
(as described in chapter 2 of this thesis), but the hyphenation of LC-solid phase 
extraction (SPE)-NMR-MS in one analytical platform has gained large interest in 
the past decade(36, 45, 46). Such an analytical platform is a key technology for fast 
and thorough structure elucidation of (mass-limited) samples. 
1.3.3 Chemometric analysis  
In the field of analytical sciences, large amounts of LC/MS or NMR data, amongst 
others, are typically generated, which is often difficult to analyze individually. In 
order to extract most information from these complex datasets, chemometric 
analysis can be used. Unsupervised chemometric methods(47-49), i.e. the ones that 
do not assume any prior knowledge, are used to explore and discover the overall 
structure of the data, find trends and grouping in the data. There are several 
unsupervised methods available, e.g. Principal Component Analysis (PCA), robust-
PCA, Hierarchical cluster analysis (HCA) and K-means. Supervised chemometric 
methods(47-50) can be used to classify samples. These methods learn patterns and 
rules based on a training set of known samples in order to predict the class of an 
unknown sample. There is a large number of supervised methods available, e.g. 
principal components regression (PCR), partial least square (PLS) or linear 
discriminant analysis (PCA-LDA).  
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1.4 Cytochrome P450 
Cytochrome P450s (CYPs) are monooxygenase enzymes catalyzing a variety of 
reactions, e.g. insertion of oxygen into C-H bonds, N- and S-oxygenation, 
epoxidation, dealkylation, dehydration and others (51). CYP is an NAD(P)H 
dependent, heme-b containing enzyme super family with 57 CYPs occurring in 
mammalians (26). Although CYPs are present in most tissues, the liver is the main 
organ for drug metabolism and approximately 75% of all drugs are metabolized by 
CYPs (27). Although CYPs (mainly CYP19 and CYP51) have been identified as 
drug targets (52), their role within the pharmaceutical industry is much larger. 
Hence, CYPs play, amongst others, an important role in (I) elimination or 
systematic clearance of drugs, (II) bioavailability of drugs, (III) (de-) toxification 
of drug compounds, (IV) determining metabolic weak points in lead compounds, 
(V) introducing new functional groups into drugs which would be difficult to 
introduce chemically and (VI) drug-drug interactions (26, 51-53).  
1.4.1 Classification 
All CYPs consist of a heme domain and one or more associated reductase 
components to provide the required electrons for the enzymatic reaction. CYPs can 
be classified according to the nature of the reductase components (51). Class I 
CYPs are mitochondrial and bacterial CYPs, consisting of three components: heme 
domain, ferrodoxin and an NADH-dependent FAD-containing reductase domain. 
Class II CYPs are microsomal CYPs, consisting of two components: heme and 
diflavin reductase (FAD and FMN), both components are membrane bound. Class 
III CYPs are soluble CYPs with the same components as class II CYPs, but then 
covalently fused in one polypeptide chain. A well known example of a class III 
CYP is P450BM3 from Bacillus megaterium. Class IV P450s are soluble one 
component enzymes, containing NADPH-dependent, FMN-containing reductase 
and ferrodoxin covalently fused to the heme domain. To facilitate catalysis, P450 
enzymes require electrons and these electrons are transported from NAD(P)H via 
one or more reductase partner proteins to the heme domain. The generally accepted 
catalytic cycle is shown in Figure 1.4(26, 54, 55).  
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Figure 1.4 General accepted catalytic cycle(26, 54, 55) of Cytochrome P450, including the 
electron transfer from the FAD domain to the heme via the FMN domain.  
 
1.4.2 Catalytic cycle  
Binding of a substrate leads to the dissociation of a weakly bound water molecule 
as the sixth ligand of the heme iron (1 to 2, Figure 1.4), which results in a change 
of the heme iron spin state from low to high spin. An electron is subsequently 
transferred from the redox partner to the heme iron (2 to 3), after which a dioxygen 
binds to the ferrous form of the heme iron (3 to 4) to form a ferrous-oxy 
intermediate. A second electron forms the ferric peroxy (4 to 5) form which is 
rapidly protonated to the ferric hydroperoxy state (5 to 6). A second protonation (6 
to 7) results in the loss of water and in the formation of the reactive ferryl-oxo 
form. It should be noted that the ferric hydroperoxy- and ferryl-oxo form are 
transient and very difficult to characterise spectroscopically, so the evidence for the 
existence of these intermediates is not very convincing(54). The ferryl-oxo form 
attacks and oxygenates the substrate (7 to 8), after which the product is dissociated 
and a water molecule is binding as the sixth ligand of the heme iron (8 to 1), 
completing the catalytic cycle.  
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1.5 Cytochrome P450BM3 
Cytochrome P450BM3 (CYP102A1) from Bacillus megaterium was first isolated 
by Miura and Fulco(56). P450BM3 enzymes typically hydroxylate fatty acids, 
which are their natural substrates, at the ω-1, ω-2 and ω-3 positions. Since the 
reductase domains (FAD and FMN) are covalently bound to the heme domain, 
electron transfer from the NADPH cofactor to the heme domain is very efficient, 
which makes that P450BM3 enzymes have the highest catalytic activity for 
monooxygenases(57). Other proficient features of the P450BM3 enzyme are its 
high solubility in aqueous buffers, its lack of membrane anchors, its stability and 
the ease of overexpression in E. coli. Wild-type P450BM3 has a limited substrate 
specificity which can easily by improved by genetically engineering P450BM3 
enzymes. Several mutants are reported to convert compounds like alkanes, steroids, 
polycyclic aromatic hydrocarbons, indole, propranolol, diclofenac and many 
others. One of the most important features of genetically engineered P450BM3 
enzymes is the ability to metabolize drug and drug-like compounds in order to 
mimic human P450 activities(58, 59). Mainly because of the high regio- and 
stereoselectivity, P450BM3 has found a widespread use as bio- and fine chemical 
catalyst, whereas less selective mutants are used in drug discovery to generate 
broad metabolic profiles of compounds(58, 60-62).  
1.5.1 Crystal structure 
The crystal structure of the P450BM3 heme domain was first determined by 
Ravichandran et al. in 1993(63), since then several crystal structures of (mutated) 
P450BM3 heme domains were determined in the native form as well as in the 
presence of ligands. Figure 1.5 shows for example the heme domain of P450BM3 
in complex with palmitoleiate (PDB: 1FAG). Both the heme group, where the 
oxidative reaction takes place, and the ligand (palmitoleiate) are clearly visible.  
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Figure 1.5 Left, crystal structure of P450BM3 heme in complex with palmitoleiate (PDB: 
1FAG). Right, zoomed at the heme active site where metabolism occurs. The heme group is 
colored in red and palmitoleiate is colored blue.  
 
Sevrioukova(64) determined for the first time in 1999 the crystal structure of the 
heme domain linked to the FAD reductase domain, whereas the full length 
P450BM3 was not yet successfully crystallized, most likely due to the large 
flexibility in the linkers between the different domains. The atomic structures of 
the heme domain have provided a large basis for a structural (re-)design of 
P450BM3 in order to meet specific needs. For example, mutation F87A was found 
to oxygenate laurate at the ω carbon, whereas in the wild-type the phenyl ring of 
F87 protects the ω carbon from oxidative attack(65); short chain fatty acids (< C12) 
are converted by P450BM3 enzymes after a rational re-design of the substrate 
binding site(66); terminal alkane hydroxylation by P450BM3 mutants have been 
reported by Meinfold et al.(67) and hydroxylation of testosterone at the C-16 
position was shown to be inverted by a single active site mutation S72I in 
M01A82W(68).  
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1.5.2 Biophysical methods 
Cytochrome P450BM3 has been studied by many other biophysical methods than 
X-ray crystallography in order to provide a better understanding of its structure as 
well as the biotransformation process, as schematically visualized in Figure 1.6. 
 
 
Figure 1.6 Biophysical methods commonly used to provide a better understanding of the 
structure as well as the biotransformation process of the Cytochrome P450BM3 enzymes.  
 
Resonance RAMAN has for example been used to study vibrations in the heme 
group which give information about the oxidation state, spin state and coordination 
state, amongst others (69-72). Isothermal Titration Calorimetry has mainly been 
used to study the thermodynamic parameters of ligand binding to other CYPs than 
P450BM3 (e.g. CYP3A4, CYP2B4) (26, 73). The only study, to our knowledge, 
involving calorimetry (differential scanning calorimetry) and P450BM3 was 
published by Munro et al. (74), where the thermal stability of the P450BM3 heme 
domain, its reductase domains as well as the holoenzyme was analyzed. 
Fluorescence-based methods have been used to detect ligands binding P450BM3 
enzymes(75) and Khan et al.(76) showed that time-resolved fluorescent 
spectroscopy can be used to study conformational changes of the P450BM3 heme 
domain upon binding sodium laurate.  
1.5.3 UV-VIS spectroscopy 
UV-VIS spectroscopy is commonly used to characterize changes in the UV-VIS 
heme Soret region upon binding ligands. Replacement of a water molecule at the 
sixth coordinate position of the heme iron by a ligand results in a peak at ~390nm 
and a trough at ~418nm (type I substrate)(26, 77). Binding of a type II substrate 
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results in low spin heme-iron, with a shift of the corresponding Soret band to ~440 
nm(26, 77). Binding of a reverse type I substrate (e.g. acetone, ethanol or propanol-
2(78)) gives a mirror image of a type I difference spectrum, with a maximum at 
~420 nm and a trough at ~390 nm. The latter two substrate types are inhibitory, 
they can replace the water molecule and stabilize the low spin state by a direct 
association of nitrogen (type II) or oxygen (reverse type I) to the heme-iron(77). 
These spectral changes have been valuable in studying the binding of ligands to 
CYPs by acquiring UV-VIS difference spectra in order to estimate spectral binding 
constants (Kd or Ks)(26, 79, 80). Absolute UV-VIS spectra can be used to 
determine the percentage low and high spin in the substrate-free and substrate-
bound ferric form(79-81). This can be done by deconvoluting the Soret region of 
the optical absorbance spectra in three Gaussian curves, which corresponds to the 
low spin (~418 nm), high spin (~390 nm) and δ-band (~360 nm). This method can 
simply be expanded to the holo enzyme by adding the ~456 nm band, caused by 
the flavin prosthetic groups(82). UV-VIS spectroscopy is also the predominant 
method for assessing P450 concentrations(83, 84). Here, the UV-VIS spectrum of 
the reduced P450 enzyme is subtracted from UV-VIS spectrum of the CO-reduced 
enzyme. The resulting CO-difference spectrum gives an accurate estimation of the 
P450 concentration as well as the amount of ‘inactive’ P420. UV-VIS spectroscopy 
is furthermore commonly used to determine the coupling of NADPH consumption 
to product formation by following NADPH consumption during biotransformation 
at 340nm(85, 86).  
1.5.4 EPR spectroscopy 
Since most intermediates in the P450 catalytic cycle (shown in Figure 1.4) are 
paramagnetic, electron paramagnetic resonance (EPR) spectroscopy can be used to 
study changes in the heme electronic environment. Spin states upon binding 
substrates have been identified using EPR spectroscopy as well as short-lived 
intermediates, both at cryogenic temperatures(70, 87, 88).  
1.5.5 NMR spectroscopy 
Nuclear Magnetic Resonance (NMR) spectroscopy is mainly used to obtain 
structural information of the metabolites produced by Cytochrome P450BM3 
enzymes. The most common used NMR experiments to derive structural 
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information of the produced metabolites include 1D-1H, 1D 1H decoupled 13C, 2D 
1H J-resolved, 1H-1H NOESY, 1H-1H COSY, 1H-1H TOCSY, 1H-13C HSQC and 
1H-13C HMBC experiments. An introduction to NMR spectroscopy as well as the 
above-mentioned experiments is given in paragraph 1.6. Besides providing 
structural information of the produced metabolites, NMR spectroscopy plays a 
pivotal role in deriving structural information of the P450BM3 proteins as well as 
ligand-protein interactions. T1 relaxation studies have been used to determine the 
orientation of ligands in the active site of P450BM3 enzyme, in both the oxidized 
and reduced form(65, 79, 89-91). Not only the re-orientation of a ligand in the 
active site by mutating P450BM3 enzymes at specific positions have been 
determined, but also the 6Å movement of a substrate after reducing P450BM3 was 
determined by T1 relaxation NMR(90). Fantuzzi et al.(92) labeled flavodoxin, 
which has a high sequence similarity with the FMN domain of P450BM3, 
uniformly with 15N. By mapping chemical shift perturbation upon titrating 
flavodoxin with the P450BM3 heme domain, detailed structural information about 
the complex as well as the electrostatic and hydrophobic interactions was obtained. 
In the papers published by Jovanovic et al.(55, 93, 94) pairs of amino acids, in the 
full-length Cytochrome P450BM3, were selectively isotope labeled, followed by 
2D solid state magic angle spinning NMR experiments (i.e. 13C-13C, 15N-13C) in 
order to probe differences in chemical shift and relaxation times. In the first 
study(94), it was shown that the amino acid residue Phe87 moves upon ligation and 
a ligand screening method for large paramagnetic proteins, based on pseudocontact 
shifts, 15N T1 relaxation and 1D 13C spectroscopy, was proposed. Furthermore, 
Jovanovic et al.(55, 93) showed, using solid state NMR and computational 
modeling, that there is a difference in spin state and structure of the Cytochrome 
P450BM3 at low temperature, where X-ray crystallography is carried out, and high 
temperature, where biotransformation takes place. Not only structural differences 
of the enzyme were probed, but it was also observed that the ligand (N-
palmitoylglycine) binds proximal to the heme iron at high temperatures and distant 
at low temperatures. Ravindranathan et al.(95) calculated NMR order parameters, 
based on solid state line shape analysis (replica exchange molecular dynamics 
simulations), of the ligand N-palmitoylglycine in the active site of P450BM3. Here 
it was shown that the conformational dynamics of this ligand in the active site of 
P450BM3 could be analyzed at different temperatures, which corresponds well 
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with observations of Jovanovic et al.(55, 93). Isozymes other than P450BM3 have 
been studied more extensively with NMR spectroscopy, as for example P450CAM. 
The group of Pochapsky plays a major role and they solved the solution structure 
of the heme domain of P450CAM for example, as well as conformational changes of 
this domain upon binding Pdx(96, 97). The reason why similar liquid NMR studies 
have not been performed with Cytochrome P450BM3 remains illusive.  
In conclusion, Cytochrome P450BM3 enzymes are biocatalysts which can easily 
be engineered to suite a particular application. It is relatively straightforward to 
produce libraries of P450BM3 enzymes with broad substrate specificity. Especially 
the ability of P450BM3 enzymes to produce broad metabolic profiles and 
metabolites with high regio- and stereo-selectivity makes that P450BM3 enzymes 
are extremely powerful biocatalysts. It is therefore expected that the role of 
P450BM3 enzymes in the pharmaceutical industry, food, nutrition as well as other 
fields will increase in the near future. 
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1.6 Nuclear Magnetic Resonance Spectroscopy 
Nuclear Magnetic Resonance (NMR) was discovered in 1946 by Purcell and 
Bloch(98, 99). They discovered, almost simultaneously from each other, the 
response of atomic nuclei to radio frequency pulses for which they received the 
Nobel Prize in Physics in 1952. Since then the field of NMR spectroscopy emerged 
rapidly and NMR spectroscopy is now-a-days an important analytical technique for 
studying the structure and dynamics of molecules and materials in both the liquid 
and solid state. The contributions of Richard Ernst, for the methodological 
development of high resolution NMR spectroscopy, and Kurt Wüthrich, for the 
development of NMR spectroscopy for determining the three-dimensional structure 
of biological macromolecules in solution, resulted in the award of Nobel Prizes in 
Chemistry of 1991 and 2001, respectively. In this paragraph the principles of NMR 
spectroscopy will be discussed.  
 
1.6.1 Basic principles of NMR Spectroscopy 
Atoms consist of electrons and a nucleus. The most important property of a nucleus 
for NMR spectroscopy is its spin. In its most simple form, spins can be described 
as an electric charge rotating around its own axis. This rotation generates a small 
magnetic moment which interacts with an external applied magnetic field. The 
interaction of a single isolated nuclear spin I, with a magnetic moment hr ⋅⋅= Iγμ , 
and a static field along the z-direction, 0B
r
, is called the Zeeman interaction. The 
Hamiltonian describing this interaction is: 
0
ˆ BIH zz ⋅⋅⋅−= hγ        1.1 
Most nuclei which are studied in liquid state NMR spectroscopy (1H, 13C, 15N, 19F 
and 31P) have a spin quantum number I of 1/2. This thus means that for spin-1/2 
nuclei two spin energy levels exist, i.e. +1/2 and -1/2 or commonly denoted as α 
and ß, respectively.  
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The energy difference between both states is called the Zeeman splitting and 
equals: 
00 ϖγ ⋅=⋅⋅−=Δ hh BE       1.2 
as schematically represented in Figure 1.7. The observed frequency 0ϖ  is called 
the Larmor frequency.  
 
 
 
Figure 1.7 The two energy levels for a single spin-1/2 nucleus in a magnetic field with 
strength B0. The energy difference between both states is called the Zeeman splitting and 
gives rise to a single line in the NMR spectrum at the Larmor frequency 0ϖ . 
1.6.2 Boltzmann distribution  
The population of the energy states  obey the Boltzmann distribution 
(100): 
),( βα NN
TkBTkE ee
N
N ⋅⋅⋅−⋅Δ == // 0hγ
β
α       1.3 
The Boltzmann distribution tells us that there is a minute difference in population 
between both states. It is slightly more probable that, in a bulk sample, the nuclear 
spins are driven towards an orientation with low magnetic energy ( ) than 
towards an orientation with high magnetic energy ( ). For example, at a 
magnetic field strength B0 of 18.8 T, the population of  is only 0.01 % larger 
than the population of . This thus makes that NMR is a relatively insensitive 
technique, since only 1 out of 104 nuclear spins is detected. As a result of this 
difference in population, the net distribution of magnetic moments is not longer 
isotropic (as in the absence of an external magnetic field), but becomes anisotropic 
αN
βN
αN
βN
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with the net magnetic moment pointing in the direction of the static magnetic field 
as schematically shown in Figure 1.8.  
 
 
Figure 1.8 Schematic representation of the alignment of nuclear spins in the presence of a 
static magnetic field B0. The net magnetic moment points in the direction of the static 
magnetic field. Reproduced from (101). 
 
1.6.3 Radio-frequency pulses 
Radio-frequency (RF) pulses are used to manipulate this magnetization by rotating 
it with either 90˚ or 180˚, although any other angle can be used as well. A 90˚ RF 
pulse flips the magnetization from its initial +z-direction (along the static magnetic 
field) into the xy-plane, as schematically shown in Figure 1.9.  
 
Figure 1.9 Pulse angle α and position of the magnetization vector M in the rotating 
coordinate system after applying a B1 RF pulse in the x-direction; (b) 90˚ pulse; (c) 180˚ 
pulse. Reproduced from Günther, NMR Spectroscopy(100).  
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Subsequently, magnetization starts rotating (precession) around the static magnetic 
field. This precession induces a small current in a receiver coil surrounding the 
sample. This signal is recorded by the spectrometer and is called free induction 
decay (FID). The resulting time-domain signal (FID) is the sum of sinusoids with 
frequencies close to the Larmor frequency. Fourier transformation is subsequently 
performed to obtain a frequency-domain NMR spectrum.  
1.6.4 Relaxation 
RF-pulses disturb the thermal equilibrium of a spin system and relaxation is the 
process by which thermal equilibrium is re-established through interaction of the 
spin system with the molecular environment. Figure 1.10 shows the trajectory of 
the tip of the magnetization vector after a 90˚ pulse.  
 
 
Figure 1.10 Trajectory taken by the tip of the magnetization vector after a 90˚ pulse with 
T1=T2=2s. Adapted from (101).  
 
There are two distinct relaxation processes, namely spin-lattice relaxation and spin-
spin relaxation. Spin-lattice, or T1-relaxation, describes the relaxation from an 
excited state back to thermal equilibrium:  
)1()( 1/0
Tt
z eMtM
−−⋅=       1.4 
where, Mz and M0 are the magnetization along the z-direction at time t and thermal 
equilibrium, respectively and T1 is the T1 relaxation time. The T1 relaxation time 
depends on many parameters like the nuclear isotope, size of the molecule, 
temperature and viscosity. Spin-spin relaxation, or T2 relaxation, is the dephasing 
of magnetization in the xy-plane. This dephasing is caused by a slightly different 
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phase of each individual spin, i.e. microscopic field fluctuations. This results in 
different resonance frequencies and a decay of the total net magnetization in the 
xy-plane. T2 relaxation is mathematically expressed by:  
2/)0()( Ttxx eMtM
−⋅=        1.5 
2/)0()( Ttyy eMtM
−⋅=       1.6 
Where Mx and My are the magnetization along the x- and y-axis, respectively. The 
rate of decay of an FID is determined by T2 relaxation time. Shorter T2-values, 
typical for large molecules like proteins and nucleic acids, yield short-lived signals 
and relatively broad signals in the NMR spectrum ( νΔ at half height corresponds 
to
2
1
T⋅π  as well as field inhomogeneity). Luckily, T2 values for small molecules 
are relatively long and signals in NMR spectra of small molecules typically have 
narrow lines (~1 Hz). There are mainly two types of relaxation mechanisms 
dominant for spin-1/2 nuclei, namely the dipolar and the chemical shift anisotropy 
mechanism(102). These relaxation mechanisms are caused by fluctuating local 
magnetic fields in the NMR sample. The theory of these and other types of 
relaxation mechanisms is rather complex and to other texts is referred for more in-
depth information(100, 102-104).  
 
1.6.5 Chemical shift 
Nuclear spins do not resonate at exactly the Larmor frequency, but there are small 
variations for the individual nuclear spins. These variations depend on local 
magnetic fields around a nucleus which are induced by currents of electrons in the 
molecular orbitals. This effect is called (de-)shielding and can either strengthen or 
decrease the main static magnetic field. Therefore, the location of a nucleus in a 
molecule and its electronic surroundings determines its resonance frequency, hence 
chemical shift. The chemical shift thus depends on the shielding effect of electrons 
surrounding the nucleus and is mathematically represented by:  
0)1( B⋅−⋅= σγϖ        1.7 
where ϖ  is the resonance frequency and σ  is the shielding factor. The chemical 
shift (δ) is commonly expressed in parts per million (ppm), rather than in frequency 
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units, relative to the frequency of a reference compound, e.g. tetramethylsilaan 
(TMS): 
TMS
TMS
0
00
ϖ
ϖϖδ −=        1.8 
where 0ϖ  is the Larmor frequency of a particular nucleus, and  is the Larmor 
frequency of the same isotope in a reference compound (here, TMS). 
TMS
0ϖ
Figure 1.11 
shows schematically the chemical shift range of the most common proton nuclei in 
organic compounds.  
 
Figure 1.11 Chemical shift range of the most common proton nuclei in organic 
compounds.  
 
1.6.6 J-coupling 
The splitting of a resonance in an NMR spectrum is caused by the J-coupling, also 
named spin-spin coupling or scalar coupling. The spin state of one nucleus can 
influence the spin state of another nucleus through polarization of the bonding 
electrons between the nuclei. Figure 1.12 shows an energy level diagram of a two-
spin system.  
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Figure 1.12 Energy levels for a two spin system in the absence (A) and presence (B) of 
scalar coupling interactions between spins I and S. The allowed transitions are indicated 
with arrows as well as the corresponding resonance lines in the NMR spectrum. 
Reproduced from Cavanagh et al.(103).  
 
In the absence of JIS-coupling (A), four different states for two nuclei (I and S) are 
present. The transitions for the I nucleus (1-3 and 2-4) have the same energy, as 
well as for the S nucleus (1-2 and 3-4). For each nucleus one resonance line is thus 
observed. In the presence of JIS-coupling (B), the eigenvalues of the spin system 
are stabilized or destabilized due to the J-coupling. It can now be seen that the 
transitions for the I and S nuclei are not of equal energy and this has the effect of 
splitting the line of both resonances into a doublet. The value of J-coupling is 
independent of the static magnetic field strength and is therefore commonly 
expressed in Hertz. In addition, the value of J-coupling becomes smaller with 
increasing number of bonds and generally long range couplings (i.e. number of 
bond lengths n > 3) are not observed. The importance of J-couplings in liquid state 
NMR spectroscopy should not be underestimated. Two examples are given here. 
First, hetereonuclear J-coupling (i.e. J1H-13C and J1H-15N) forms the basis for multi-
dimensional NMR experiments, due to transfer of magnetization from one nucleus 
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to another (e.g. INEPT(105)). Second, homonuclear J-couplings, both in one 
dimensional and multidimensional spectra, provide a wealth of information, since 
the (number of) coupling partners can be determined and three-bond coupling (3J) 
gives, amongst others, information about the dihedral angle φ  between C-H bonds. 
This correlation is best estimated using the Karplus equation:  
CBAJ +⋅+= φcos3        1.9 
where A, B and C are empirically derived constants dependent on the nuclei 
involved. Figure 1.13 shows for example the multiplet corresponding to H15ß of 
testosterone.  
 
Figure 1.13 Multiplet corresponding to H15ß of testosterone and its four J-coupling 
partners shown as a tree diagram.  
 
By carefully analyzing this multiplet, four coupling partners can be distinguished 
(H14α, H15α, H16α and H16ß). Furthermore, from the 3J-coupling constants it can 
be concluded that two protons have a relatively large dihedral angle (H14α and 
H16α, ~180˚) and one proton has a dihedral angle of ~ 90˚ (H16ß), since this 
proton has the smallest 3J-coupling strength.  
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1.6.7 Two-dimensional NMR 
Two-dimensional (2D) NMR spectroscopy is of unprecedented value for structure 
determination by NMR. In this paragraph, the general concepts of 2D NMR 
spectroscopy and the 2D experiments used in this thesis will be shortly introduced. 
To other texts is referred for more in-depth information(100-102, 104). There are 
two frequency axes in a 2D NMR spectrum and it is possible to generate cross-
peaks between connected resonances. The nature of these cross-peaks and the 
structural information which can be extracted from such a spectrum depends on the 
type of 2D experiment used. The basic scheme of a 2D NMR experiment is shown 
in Figure 1.14 and is characterized by four time intervals: preparation, evolution, 
mixing and detection period.  
 
 
Figure 1.14 Basic scheme of a two-dimensional NMR experiment.  
 
During the preparation time, a single 90˚ pulse can be applied to generate 
transverse magnetization or, for example, a set of pulses is applied to transfer 
magnetization from one nucleus to another (e.g. INEPT(105)). The t1-evolution 
period is incremented systematically in a series of separate experiments. During 
this period, magnetization evolves under influence of chemical shift and/or J-
coupling. The mixing period is applied to either transfer unobservable 
magnetization into observable magnetization (e.g. COSY) or to transfer 
magnetization from one nucleus to another by for example cross-relaxation 
(NOESY) or J-coupling (TOCSY). During the detection time t2, magnetization 
evolves under influence of chemical shift and J-coupling and is detected. 
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Subsequent Fourier transformation in both dimension (t1 and t2) results in 2D NMR 
spectra with frequency domains in both dimensions. Cross peaks in Correlation 
Spectroscopy (COSY) spectra reveal the network of J-couplings in a molecule. 
This information is of great value for structural determination and 2D COSY is 
therefore one of the most commonly used 2D NMR experiments. Double Quantum 
Filtered COSY (DQF-COSY) experiments have the preference over the 
conventional COSY experiment, since diagonal and cross peaks have absorption 
line shapes, whereas in conventional COSY spectra, there is a 90˚ phase difference 
between the diagonal and cross peaks. This leads to long dispersion tails of the 
diagonal peaks which hide cross peaks resonating close to the diagonal peaks. The 
only disadvantage of DQF-COSY experiments is the two-fold reduction in 
sensitivity compared to the conventional COSY experiment. Total Correlation 
Spectroscopy (TOCSY) is also a homonuclear 2D NMR experiment. TOCSY has 
large similarities with COSY, since TOCSY gives also information about the 
network of J-couplings in a molecule. In TOCSY spectra, however, also cross 
peaks between spins which are indirectly coupled to each other are present. For 
example, if spin A is coupled to spin B and spin B is coupled to spin C, a cross 
peak between A and C will be present in a TOCSY spectrum, even though there is 
no J-coupling between those spins. TOCSY spectra have absorption mode 
lineshapes and are extremely valuable in identifying spins which belong to an 
extended network of couplings. Nuclear Overhauser effect spectroscopy (NOESY) 
spectra show cross peaks for all spins for which cross relaxation has occurred. In 
other words, NOESY spectra show only correlations between spins which are 
reasonable close in space to each other (<5Å). The intensity of a correlation in a 
NOESY spectrum is directly proportional to the distance between spins(101, 103) 
and NOESY spectra are therefore commonly used to obtain conformational and 
geometric information from biomolecules as well as small molecules. The final 2D 
NMR experiments which will be introduced here are the Hetereonuclear Single 
Quantum Coherence (HSQC) and Hetereonuclear Multiple Bond Coherence 
(HMBC) experiments. The resulting spectra of these experiments provide 
information about protons which are directly attached to a carbon (1H-13C HSQC) 
or between protons and carbons which are separated from each other with two or 
more chemical bonds (1H-13C HMBC). The latter one is commonly used to assign 
quaternary, carbonyl or other carbons which are not bound to a proton. NMR 
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experiments with higher dimensionalities (e.g. three and four dimensional) are 
based on the same principle as 2D NMR experiments, with the main difference 
being the additional evolution periods. The spectra resulting from these 
experiments are simplified significantly, since spectral overlap is reduced. NMR 
experiments with higher dimensionalities are commonly applied to derive 
structural information of larger molecules like nucleic acids and proteins. The most 
important requirement of these NMR experiments is the isotope labelling (13C, 15N 
and/or 2H), since the natural abundance of these isotopes is in general too low to 
obtain spectra of sufficient quality.  
1.6.8 Homonuclear decoupling in 1D-1H NMR spectroscopy 
The 1D-1H NMR experiment (“pulse-acquire”) is undoubtedly the most popular 
and most common used experiment in NMR spectroscopy. This experiment allows 
to easily identify, quantify and derive structural information of analytes and has 
therefore found a wide-spread use in for example the fields of analytical chemistry, 
organic chemistry and metabonomics. One of the major concerns in the analysis of 
complex 1D-1H NMR spectra is the spectral overlap which hampers spectral 
interpretation, assignment, quantification and accurate chemical shift determination 
significantly. The relative large spectral overlap in 1D-1H NMR spectra has mainly 
two origins. First, the spectral region where proton nuclei resonate is relatively 
small (~20ppm), compared to, for example, the spectral region where carbon nuclei 
resonate (~250ppm). Second, the widths of multiplets are relatively broad, which is 
determined by homonuclear J-couplings. In order to increase the resolution and 
hence reduce the spectral overlap in NMR spectra, spectrometers with stronger 
magnetic fields are continuously being developed. A different approach to increase 
the resolution of 1D-1H NMR spectra is by eliminating homonuclear J-couplings: 
homonuclear decoupling. Here, multiplets collapse to single lines, which obviously 
reduce the spectral overlap significantly. Homonuclear decoupling is unfortunately 
not as easily achieved as for example hetereonuclear decoupling, where numerous 
decoupling schemes are available, e.g. WALTZ-16(106), MLEV(107) and 
GARP(108). Nevertheless, several NMR experiments are reported to obtain 
homonuclear decoupled 1D-1H NMR spectra, with varying degrees of success.  
Double resonance experiments can be used to saturate one nucleus, using a low 
power RF-pulse, while observing all other nuclei in the spectrum. As a result, the 
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nuclei which are J-coupled to the saturated nucleus lack this J-coupling. Although 
it is practically impossible to obtain broadband homonuclear decoupled spectra 
using double resonance experiments, this experiment has proven to be valuable in 
identifying spin systems and simplifying complex multiplet patterns for further 
analysis(100).  
Constant time COSY experiments can be used to obtain homonuclear decoupled 
1D-1H NMR spectra(109-111). A serious restriction of this experiment however, is 
the limited range of J-couplings which can be suppressed. 
The J-resolved experiment, as first introduced by Aue et al.(112), can also be used 
to obtain broadband homonuclear decoupled 1D-1H NMR spectra. The J-resolved 
experiment is a two-dimensional NMR experiment with only spin multiplets in the 
F1-dimension and a conventional proton spectrum (with J-couplings) in the F2-
dimension. As a result, the spin multiplets are aligned along a 45˚ diagonal of the 
spectrum. By tilting the spectrum with 45˚ and making a projection of this 2D 
spectrum on the F2-axis, a homonuclear decoupled spectrum can be obtained. The 
major disadvantage of the 2D J-resolved experiment is however the phase-twisted 
lineshape. In order to obtain a good 45˚ projection, J-resolved spectra are typically 
processed using a echo-like window function (e.g. sine) followed by a magnitude 
calculation of the final spectrum(113). This comes however at the cost of a poor 
lineshape and distorted integrals. Several modifications of the original J-resolved 
experiment are reported which try to solve the problems associated with the phase-
twisted lineshapes(113-122). For example, Xu et al.(114) introduced in 1991 a 
methodology called ‘purged J-spectroscopy’, where at the end of the t1-evolution 
period, a spin-lock or adiabatic pulse is applied. These pulses suppress the anti-
phase term which is present at the end of the t1-evolution period of the original J-
resolved experiment. A third method to remove the undesirable anti-phase term 
uses a z-filter(115). The nature of the multiplet patterns changes when applying one 
of these elements; hence, multiplets have C4-symmetry and absorption mode 
lineshapes. Since the signals in the 2D J-resolved spectrum now have C4-
symmetry, a data-processing algorithm can be applied to extract the symmetry 
centres of the multiplets to construct a homonuclear decoupled proton spectrum. 
Pell and Keeler(116) introduced in 2007 a new method for recording J-resolved 
experiments with absorption mode lineshapes and rather correct integrals. Here, J-
resolved spectra and anti J-resolved spectra are acquired and combined in order to 
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cancel the effects of the anti-phase term in the spectrum. An anti J-resolved 
spectrum is obtained by applying a selective 180˚ in combination with a 
simultaneous applied weak gradient at the end of the t1-evolution period. This 
elegant pulse sequence element was first introduced by Zangger and Sterk(123) 
and separately inverts all spins while leaving their coupling partners unaffected. 
This beautiful element has however the major disadvantage of a large reduction in 
sensitivity, which makes that the experiment described by Pell and Keeler can not 
be applied for samples with sub-mM concentrations.  
The final homonuclear decoupled 1D-1H NMR experiments which will be 
introduced here are the so-called pure shift experiments(123, 124). Pure shift 
experiments allow the acquisition of broadband homonuclear decoupled 1D-1H 
NMR experiments with absorption mode lineshapes and a high resolution (peak 
width at half height being ~1 Hz). In addition, pure shift experiments can be 
acquired fast: within a couple of minutes. The most important pulse sequence 
element of the pure shift experiments is the combination of a selective and a hard 
180˚ pulse simultaneously applied with a weak gradient in the center of the t1-
evolution period. This allows chemical shift evolution during t1, whereas the J-
coupling is refocused at the echo point. Since J-coupling evolution is a relatively 
slow process, a pseudo 2D experiment can be recorded in order to reconstruct a 1D 
FID which thus only contains chemical shift information and no J-coupling 
information. The main disadvantages however of the pure shift NMR experiments 
are the poor sensitivity and relative large errors in the integrals.  
In conclusion, several NMR experiments exist for the acquisition of homonuclear 
decoupled 1D-1H NMR spectra. These experiments have however major 
drawbacks, which is most likely the reason why they are not commonly used. 
There is thus a great demand for a homonuclear decoupled 1D-1H NMR 
experiment which does not have these drawbacks. Chapter 5, 6 and 7 of this thesis 
describes a newly developed experiment for the acquisition of broadband 
decoupled 1D-1H NMR spectra. This experiment has largest similarities with the 
original pure shift experiments(123, 124) and possesses the following properties: 
broadband homonuclear decoupling, high sensitivity, substantial correct integrals, 
high resolution and a short measurement time. The developed experiment is most 
likely not only of interest for NMR spectroscopists, but for many scientists using 
liquid state NMR spectroscopy routinely.  
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Figure 1.15 (top) shows the Huygens building (background) and the Goudsmit 
Pavilion (foreground) of the Radboud University Nijmegen where the NMR 
spectrometers of the departments ´biophysical chemistry´ and ´solid state NMR´ 
are located. Figure 1.15 (bottom) shows the three liquid state NMR spectrometers 
in the Goudsmit Pavilion which have been used for the NMR work presented in 
this thesis.  
 
 
Figure 1.15 (Top) Huygens building (background) and Goudsmit Pavilion (foreground) of 
the Radboud University Nijmegen. (Bottom) Three liquid state NMR spectrometers in the 
Goudsmit Pavilion, from left to right: 11.7 Tesla (500 MHz 1H frequency), 14.1 Tesla (600 
MHz 1H frequency) and 18.8 Tesla (800 MHz 1H frequency). The latter two are equipped 
with a cryogenic cooled probe.  
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1.7 Outline of this thesis 
The research described in this thesis is mainly devoted to the application of liquid 
state NMR spectroscopy into a variety of disciplines particularly related to the 
pharmaceutical industry. The aim of this thesis is to describe the application and 
development of NMR based methodologies for a better understanding of P450BM3 
drug metabolism, metabolite identification and mixture analysis. Cytochrome 
P450BM3 enzymes play a central role in this thesis and have mainly been used as 
biocatalysts, as shown in Chapter 2, 3 and 6, to metabolize drug and drug-like 
compounds. Chapter 1 therefore provides a general introduction into the 
pharmaceutical industry, Cytochrome P450 enzymes and Nuclear Magnetic 
Resonance spectroscopy. Chapter 2 describes the formation and identification of 
estrogenic compounds generated by P450BM3 enzymes. A hyphenated screening 
assay is described where, in parallel, the bioactivity of the generated compounds 
towards the human Estrogen receptors α and β is determined and HR-MS is used as 
quick tool for fast first line structure identification. NMR spectroscopy is 
subsequently used to obtain full structural information of a set of metabolites. In 
Chapter 3 it is shown that Cytochrome P450BM3 enzymes can be designed in 
such a way to suite a particular application. It is shown that a single mutation 
(A82W) in the active site of P450BM3 mutants M01 and M11 results in a strong 
increase in the regioselectivity of steroid hydroxylation at position 16β. The A82W 
mutation further improved both binding affinity and coupling efficiency, thereby 
strongly improving the catalytic activity. As shown by T1 paramagnetic relaxation 
NMR, this single mutation changes the orientation of testosterone in the 
M11A82W mutant as compared to the orientation in M11. The preferred 
orientation of testosterone in the A82W mutant might explain its increased 
selectivity for hydroxylation in the D-ring (position 16β). Chapter 4 demonstrates 
a microfluidic high-resolution NMR flow probe. Two applications of this probe 
will be discussed. First, the acetylation of benzyl alcohol in the presence of DIPEA 
is followed over time. Secondly, the applicability of the microfluidic NMR probe 
for the analysis of mass-limited samples is demonstrated by analyzing 600 nL 
human cerebrospinal fluid. In Chapter 5, a pure shift NMR experiment is 
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described for the acquisition of broadband homonuclear decoupled 1D-1H NMR 
spectra of mass-limited samples. The experiment proves to be quantitative and can 
therefore be used to determine solutes concentrations. The sensitivity of this 
experiment is compared with the original pure shift NMR experiments and the 
resolution increase resulting from this pure shift NMR experiment is exemplified 
using a mixture containing two steroids. Chapter 6 shows an application of the 
pure shift NMR experiment described in Chapter 5. The complex 1D-1H NMR 
spectrum of a mixture containing testosterone and its three metabolites produced 
by a Cytochrome P450BM3 enzyme is greatly simplified by acquiring the pure 
shift NMR experiment. In particular we show that the spectral simplification 
allows the identification and quantification of the metabolites based on pure shift 
fingerprint profiles of the individual compounds. In Chapter 7, a detailed 
explanation of the pure shift NMR experiment introduced in Chapter 5 and 6 is 
given. First, the acquisition of this experiment is discussed and compared to the 
original pure shift NMR experiments. Secondly, the reconstruction and processing 
of the FIDs is explained and the parameters affecting the signal integral are 
discussed. Finally, Chapter 8 summarizes the main results presented in this thesis.  
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Abstract 
This chapter describes the determination and identification of active and inactive 
estrogenic compounds produced by biosynthetic methods. A hyphenated screening 
assay towards the human estrogen receptor ligand binding domain (hER)α and 
hERβ integrating target-ligand interactions and liquid chromatography - high 
resolution mass spectrometry was used. With this approach, information on both 
biologic activity and structure identity of compounds produced by bacterial 
mutants of Cytochrome P450s was obtained in parallel. Initial structure 
identification was achieved by high resolution MS/MS, while for full structure 
determination, P450 incubations were scaled up and the produced entities were 
purified using preparative liquid chromatography with automated fraction 
collection. NMR spectroscopy was performed on all fractions for 3D structure 
analysis; this included 1D-1H, 2D-COSY, 2D-NOESY, and 1H-13C-HSQC 
experiments. This multidimensional screening approach enabled the detection of 
low abundant biotransformation products which were not suitable for detection in 
either one of its single components. In total, the analytical scale biosynthesis 
produced over 85 compounds from 6 different starting templates. Inter and intra 
day variation of the biochemical signals in the dual receptor affinity detection 
system was less than 5 %. The multi-target screening approach combined with full 
structure characterization based on high resolution MS(/MS) and NMR 
spectroscopy demonstrated in this paper can generally be applied to e.g. 
metabolism studies and compound-library screening. 
 
2.1 Introduction 
Relatively new in early drug discovery is the use of biocatalysts capable of 
producing new chemical entities(1). Besides the fact that these procedures are used 
for the production of drug metabolites and being part of the metabolite 
identification process(2-4), this approach is increasingly showing its potentials in 
the extension of the so-called chemical space. Cytochrome P450BM3 is one of the 
most studied bacterial P450s and has the highest catalytic activity ever detected for 
a monooxygenase(5). Although its natural substrates are long-chain fatty acids, 
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several engineered mutants of P450BM3 are reported to convert drug and drug-like 
molecules(6-9). Biosynthesis using the engineered P450BM3s can lead to the 
formation of multiple (active) products simultaneously, requiring advanced 
analytical technologies for product identification and characterization. 
Conventional high throughput screening (HTS) assays lack the capability to fully 
structural characterize the hits in a mixture with multiple active compounds 
present. To individually assess the affinity of active compounds in mixtures 
towards selected drug targets, on-line high resolution screening (HRS) 
technologies were developed and recently applied to metabolism studies(10, 11). 
These receptor affinity detection (RAD) systems integrate liquid chromatography 
(LC) with affinity assessment and therefore allow the direct correlation between 
individual ligands and their affinity towards target proteins. Biochemical detection 
systems reported previously are based on fluorescence readout(12-14), fluorescent 
polarization(15) or mass spectrometry based reaction detection(16-20). LC coupled 
to mass spectrometry (MS) is by far the most used tool in drug metabolism studies. 
The metabolic stability of drug candidates is typically monitored by a short LC 
analysis coupled to a triple-quadrupole mass spectrometer, enabling quantification 
of the metabolic conversion of drug candidates. For metabolite identification, high 
resolution instruments are commonly used and provide information such as 
accurate mass on the metabolites and their fragment ions. Applying in-vitro 
metabolite screening in early drug discovery provides the medicinal chemists with 
information on the so-called soft spots in scaffold molecules(21). The development 
of MS based strategies enabling the identification of drug metabolites is regularly 
reported(22, 23). The implementation of algorithms pre and post acquisition to 
predict metabolites(24), to filter mass defects(25), neutral losses and isotope 
patterns(26) significantly enhances the rate of success in metabolite identification. 
By combining the advantages of on-line screening and high resolution mass 
spectrometry (HR-MS/MS) for first line structure identification, multidimensional 
data is obtained, and a quick selection can be made based on affinity and the 
modification introduced by e.g. (bio)synthesis, metabolism or degradation. In this 
chapter, the application of hyphenated screening assays, high resolution mass 
spectrometry and NMR for the determination and identification of biosynthetically 
produced estrogenic compounds is described. After biosynthesis, all compounds 
generated are directly characterized with the on-line high resolution screening 
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platform developed for this purpose to obtain information on structure and biologic 
activity in parallel. New biosynthetic products are characterized by a combination 
of HR-MS(/MS) and NMR. To demonstrate the strength of our approach, we have 
selected the human estrogen receptor subtypes α and β (hERα and hERβ) as model 
targets. These receptors belong to the nuclear receptor family and are involved in 
many hormonal regulation processes(27-29). Currently these targets are used in 
cancer therapy, contraception and other hormone related therapies(30, 31). 
 
2.2 Experimental 
2.2.1 Chemicals 
17α-estradiol (17α-E2), 17β-estradiol (17β-E2), 17α-ethinylestradiol (EE2), estriol 
(E3), monosodium dihydrogen phosphate, disodium monohydrogen phosphate, 
glucose-6-phosphate, glucose-6-phosphate dehydrogenase, polyethyleneglycol 
3350, dimethylsulfoxide-d6, 99.9 atom %D (DMSO-d6) and 3-
(trimethylsilyl)propionic-2,2,3,3-d4 acid, sodium salt, 98 atom %D (TSP) were 
purchased at Sigma-Aldrich (Schnelldorf, Germany). Maleic acid, 99%, was 
purchased from Acros Organics (Geel, Belgium). Applichem (Lokeren, Belgium) 
supplied β-nicotinamide adenine dinucleotide phosphate (NADPH) tetra sodium 
salt. Coumestrol was obtained from Fluka (Buchs, Germany). Sodium chloride was 
received from Riedel-de Haën (Seelze, Germany). Acetonitrile, methanol (ULC–
MS grade) and formic acid were obtained from Biosolve (Valkenswaard, The 
Netherlands). Water was produced by a Milli-Q device of Millipore (Amsterdam, 
The Netherlands). Enzyme-linked immunosorbent assay (ELISA) blocking reagent 
was purchased from Roche Diagnostics (Penzberg, Germany). Norethisterone 
(NET), Org X and Org Y were obtained from the library of the Schering-Plough 
Research Institute (Oss, the Netherlands). 
Human liver microsomes (HLM), pooled from 50 donors were obtained from 
Xenotech (Lenexa, USA) and contained 20 mg/mL protein (Lot No. 0710619). The 
bacterial P450BM3 M11his and M02his mutants were prepared according to the 
protocol described recently(32). The ligand binding domain (LBD) of the human 
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Estrogen Receptor α was expressed and purified using the protocol described by 
Eiler et al.(33), without 17β-E2 in the medium. Purified His-tagged LBD of the 
human Estrogen Receptor β was obtained from Schering-Plough Research Institute 
(Oss, the Netherlands). 
2.2.2 Compound generation by combinatorial biosynthesis 
Analytical Scale  The selected compounds were subjected to 
biotransformation by several enzymatic systems. Biosynthetic incubations with the 
P450BM3 mutants had a final volume of 1.5 mL and consisted of 250 nM enzyme, 
100 µM substrate in 100 mM potassium phosphate buffer pH 7.4 and were 
performed at 24 °C. The DMSO concentration was always below 2 %. An NADPH 
regenerating system was used to initiate the reactions, resulting in final 
concentrations of 0.2 mM NADPH, 0.3 mM glucose-6-phosphate, and 0.4 
units/mL glucose-6-phosphate dehydrogenase. Biotransformation reactions with 
HLM were performed at 37 °C having a final volume of 1.5 mL and consisted of 1 
mg/mL protein, 100 µM substrate in 100 mM potassium phosphate buffer pH 7.4 
containing 5 mM MgCL2. At time points 0 min, 10 min and 60 minutes, 500 µL 
samples were taken from the incubation and added to 1 mL of ice-cold methanol, 
vortexed for 30 seconds and centrifuged for 15 minutes at 6000 rpm. The 
supernatants were subsequently dried in a speedvac and reconstituted in 200 µL of 
dried methanol. All samples were analyzed using the on-line LC–MS dual receptor 
affinity detection system. 
Preparative scale  The metabolites originating from the 
biotransformation of NET were produced on a preparative scale using the bacterial 
P450 M02his mutant. A 40 mL reaction volume containing 250 nM of the M02his 
mutant, 500 µM of NET and the NADPH regenerating system was made in 100 
mM potassium phosphate buffer pH 7.4 at 24 °C. After 3 hours of reaction, the 
products were extracted from the reaction mixture using three times 20 mL 
dichloromethane. The organic layers were subsequently collected and transferred 
into a round-bottom flask for evaporation using a rotary evaporator. The dried 
product was redissolved in 250 µL DMSO and injected into a Waters preparative 
LC system, equipped with a Gilson Liquid Handler for injection and fractionation, 
a Waters Xbridge C18-MS (10 x 50 mm 3.5 µm particles) column, and a Waters 
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photodiode array detector. At a flow-rate of 5 mL/min the following gradient was 
used: 0 – 4 minutes 100 % A1 (90 % H2O, 10 % acetonitrile); 4 – 22 minutes linear 
increase to 50 % B1 (10 % H2O, 90 % acetonitrile), 22 – 24 minutes linear increase 
to 100 % B where kept constant for 2 minutes and finally a column equilibration 
time of 5 minutes with 100 % A. Fractions were collected triggered by UV 
absorbance at 243 nm. In addition, all other fractions were collected every minute 
to avoid the loss of samples showing no UV absorbance at the set wavelength.  All 
fractions were dried under nitrogen and dissolved in 500 µL DMSO-d6 with TSP 
for internal referencing in the subsequent NMR analysis. For quality control, all 
fractions were analyzed with the dual receptor affinity assay. 
2.2.3 On-line liquid chromatography – high resolution mass spectrometry 
dual receptor affinity detection system 
A Shimadzu LC-MS-IT-TOF in combination with a SPD20M photodiode array 
(PDA) detector was used for the liquid chromatography-high resolution mass 
spectrometry part of the screening assay while four additional Shimadzu 
LC10ADvp pumps and two Shimadzu RF10-XL fluorescence detectors were 
applied for the homogeneous dual receptor affinity assessment (Figure 2.1). The 
homogeneous dual receptor affinity detection system was developed based on the 
single line assay described by van Liempd et al.(11). In brief, the receptor solution 
is added post column to the flow enabling the binding of potential ligands in a 25 
µL reaction coil made from PEEK, thermo stated at 37 °C. Subsequently, the 
fluorescent tracer (coumestrol) is added to bind all free binding sites of the receptor 
and thereby enabling the detection of fluorescence enhancement of the receptor-
tracer complex. 
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Figure 2.1 Configuration of the on-line liquid chromatography – high resolution mass 
spectrometry dual receptor affinity detection (RAD) system: (1) Sample injection followed 
by gradient HPLC [P1& P2]; (2) Splitting the flow to PDA-ESI-MS and the two RADs 
(hERα and hERβ); (3) Infusing hERα and hERβ via superloops and reagent pumps 
[P3&P5] (4) Binding of  receptor and potential ligands in reaction coils; (5) Infusion of 
tracer solution via superloops and reagent pumps [P4&P6]; (6) Binding of fluorescent 
tracer to receptor in reaction coils; (7) Detection of receptor-tracer complex by 
fluorescence. 
 
Samples were injected using a Shimadzu SIL20 auto-injector. Separation was 
performed on a Waters Xterra C18MS column (2.1 x 100 mm, 3.5 µm particles) 
equipped with a guard column. Mobile phase A2 consisted of 99 % H2O and 1 % 
methanol, mobile phase B2 consisted of 1 % H2O and 99 % methanol. The 
following gradient was applied with a flow-rate of 125 µL/min: 0 – 3 minutes 
isocratic at 35 % B2, 3 – 45 minutes linear increase to 100 % B2, where kept 
constant for 5 minutes and followed by a quick descent in 30 seconds to 35 % B2 
for 10 minutes of equilibration prior to the next analysis. After separation, the flow 
was directed into both biochemical assays and the IT-TOF mass spectrometer by a 
flow-split made from fused silica (30 µm I.D. 375 µm O.D. from BGB Analytics 
AG, Boeckten, Switzerland) introducing 100 µL/min into the photodiode array and 
mass spectrometer and directing 12.5 µL/min of the flow into each of the lines for 
the homogeneous receptor affinity detection system (Figure 2.1). Receptor 
solutions of 15 nM were infused with 100 µL/min via 100 mL superloops (made in 
house by the VU University - Fine Mechanical Workshop). The receptor solution 
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and column effluent were incubated at 37 °C in a 25 µL reaction coil made from 
PEEK. Subsequently, coumestrol solutions of 433 nM for hERα and 144 nM for 
hERβ were infused with 100 µL/min via two other superloops and incubated at 
37°C in a 20 µL reaction coil made from PEEK before being directed to the 
fluorescence detectors  (λex =  340 nm, λem = 410 nm). Receptor and tracer 
solutions were in 10 mM phosphate buffer pH 7.4 containing 150 mM NaCl and 
0.4 mg/mL ELISA Blocking Reagent to prevent non-specific binding. All 
superloops containing receptor and tracer solutions were kept on ice. 
2.2.4 Mass spectrometer settings 
A Shimadzu IT-TOF instrument equipped with an electrospray (ESI) source was 
operated in the data dependent acquisition mode switching between full-spectrum 
MS and MS-MS modes and alternating between positive and negative ion mode 
(100 ms cycles). The temperature of the heating block and curved desolvation line 
was set to 200 °C. Interface voltage was set at 5 kV for positive ion mode and - 4.5 
kV for negative, the nebulizing gas flow (nitrogen, 99.999 % purity, Praxair, 
Oevel, Belgium) was 1.5 L/min and drying gas was applied at a rate of 10 L/min. 
Full MS scans were acquired between m/z 125 and 650. MS-MS data was obtained 
automatically with 10 ms accumulation time between m/z 100 and 650 and a 
precursor isolation width of 1.0 using Argon (99.9995 % purity, Praxair) as 
collision gas. 
2.2.5 Validation of the screening methodology 
The time correlation between assay response and response in the mass 
spectrometer was optimized with flow injection analysis. The length of the PEEK 
tubing between PDA and MS was adjusted in such a way, that it enabled direct 
correlation between the signals in MS and the biochemical detection system. To 
verify the time alignment, an incubation sample of estriol with cytochrome 
P450BM3 M11his was injected into the complete system. The dual receptor assay 
was performed in parallel using two times hERα to verify equal responses in both 
assay lines. After this, hERβ was implemented in the screening assay. A dilution 
range of the natural ligand 17β-E2 was made and injected in a 10 minutes LC run, 
isocratic elution at 70 % B2. As a quality control sample within every sequence of 
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ten runs, 5 µl of 17β-E2 were injected at a concentration of 50 µM. This also 
enabled the determination of intra and inter-day variability of the assay response. 
 
2.2.6 NMR measurements 
NMR analysis was performed on a Bruker DRX 600 MHz spectrometer equipped 
with a 5-mm TXI cryo probe and a Varian Inova 500MHz spectrometer equipped 
with a 5-mm probe both operating at 298K. The three-dimensional structure 
determination of the products is based on 1H-1H DQF-COSY, 1H-13C HSQC, 1H-
13C HMQC, 1H-1H NOESY and/or 1D-proton spectra. The proton and carbon 
chemical shifts were referenced to the internal reference TSP (proton, δ=0.00ppm; 
carbon, δ=0.00ppm). All chemical entities extracted from the preparative scale 
biosynthesis were first analyzed and afterwards quantified by addition of a known 
concentration maleic acid (20 µg)(34). Data were processed using ACDLabs 
software, version 11.03. 
 
2.3 Results and Discussion 
2.3.1 Validation of the screening methodology 
The implementation of target-ligand interactions in an analytical methodology 
requires a different approach in validation from the approach taken for 
conventional bioanalytical methods. The use of hyphenated screening assays in the 
hit to lead selection process has to provide answers on the novelty of a compound 
and whether it is active or inactive against the used drug-target. Validation of the 
approach is necessary to assess the characteristics of the products formed. Accurate 
time alignment between the biological assay and the identification technique used, 
in this case the mass spectrometer is the most crucial factor. As an example, Figure 
2.2 shows the alignment of the biochemical-detection assay and the extracted ion 
traces obtained in parallel. Clearly, the correlation between extracted ion 
chromatograms and the bioassay signal enables the positive identification of the 
m/z associated with the compounds binding to the biological target, not only in 
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flow injection mode but more importantly, in a gradient elution setting. The 
correlation of traces in the bioassay (peak minima) and MS (peak maxima) were 
always within six seconds.  
 
Figure 2.2 Correlation between biochemical detection (hERα, upper trace) and extracted 
ion traces from the mass-spectrometric detection (black m/z 303.1615 x 5 and gray m/z 
287.1653, base line shifted) in an incubation mixture using estriol as substrate for 
cytochrome P450BM3 M11his biocatalysis.  
 
The biological response in both assay lines was validated by using two times hERα 
subtype for both receptor affinity detection systems. With the injection of different 
concentrations (10 µL of 1 nM-100 µM) of the natural occurring ligand 17β-E2 
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into the complete system, the responses recorded for both assay lines were similar 
and thus proofing the validity of screening selectivity for both receptors. 
Subsequently, hERα and hERβ were mutually implemented in the screening assay 
and 17β-E2 was injected to verify the responses for screening selectivity in 
receptor affinity (Figure 2.3). Inter and intra day variation of the signals in the dual 
RAD system was less than 5 % and the detection limit for 17β-E2 was 4.7 ± 0.5 
nM, which is well within limits reported for other hyphenated screening methods 
(10, 35). With the MS settings used for the screening of biosynthesis products, the 
detection limit for 17β-E2 was 40 nM in negative ESI mode. This rather high 
detection limit compared to the bioassay is caused by the fact that 17β-E2 is a very 
high affinity ligand for the hER subtypes and that this compound belongs to a 
steroid class that is reported to be ionized very inefficiently(36) in a non-
derivatized form.  
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Figure 2.3 hERα (solid) and hERβ (dashed) affinity responses of the on-line dual receptor 
affinity detection system after injection of 5 µL 17β-E2 (50µM). 
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2.3.2 Metabolite identification 
Analytical scale biosynthesis and analysis  More than 85 products 
were formed using a test set of six compounds containing naturally occurring 
estrogens (17α-E2  and 17β-E2), synthetic estrogen receptor modulators and 
prodrugs (EE2, NET) and synthetic compounds from the Schering-Plough library 
(Org X and Org Y) . Of these 85 products, 55 compounds were identified as hits 
towards one or both hER’s. Mainly, active species are (di)hydroxylated forms of 
the used scaffold while other active species are dehydrogenated or a combination 
of both. Figure 2.4 shows the typical affinity profiles obtained with our screening 
platform for the NET related structures, profiles obtained for EE2, 17β-E2 and Org 
X are depicted in Figure S2.2.  All products were characterized based on HR-MS 
data and affinity towards both receptors.   
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Figure 2.4 hERα (solid) and hERβ (dashed) affinity traces obtained with the on-line LC–
MS dual RAD system of reaction mixtures produced by HLM, M02his and M11his mutants 
using NET as scaffold. (1) M02-6; (2) metabolite with m/z 311.1664 ([M-H]–); (3) 
metabolite with m/z 311.1658 ([M-H]–); (4) M02-7; (5) M02-8; (6) M02-9. Detailed 
information on the compounds can be found in Table 2.1. Structures of all identified 
compounds are depicted in Figure 2.5.  
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Table 2.1 provides an inventory of all formed NET related products and their 
characteristics. MS detection enabled the proposal of the chemical formula, in 
positive ion mode based on [M+H]+, [M+Na]+ and / or [M+K]+ and for some 
compounds in the negative ion mode based on [M-H]–. The PDA enables the 
determination of UV absorption maxima on all products formed. Based on the 
assumption that products with non-altered absorption profiles still have the same 
molar extinction coefficient, the quantity of new products can be estimated based 
on calibration curves obtained from available standards of the scaffold molecules. 
Relative affinity can therefore be rated by relating UV absorption of the produced 
compounds with their response in the biochemical assays, providing a quick 
evaluation of affinity towards the drug target(s) to support the medicinal chemistry 
follow up in lead optimization. A table with all products formed using 17α-E2, 
17β-E2, EE2, Org X and Org Y as scaffold molecules can be found in the 
supporting information (Table S2.1). 
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Table 2.1 Characterization of products using NET as scaffold. m/z indicated in bold 
represent the most abundant ion used for identification. Relative receptor affinity was 
ranked by relating UV absorbance and biochemical assay responses; - = no affinity,  + = 
low affinity, ++ = moderate affinity and +++ = high affinity.  
 
Product Identification NET analogues Enzymatic System 
 
Receptor 
Binding 
  High Resolution - MS    
Tr 
(min) Modification 
m/z  
positive ion mode 
m/z 
negative ion 
mode  Code M11his M02his HLM hERα hERβ 
          
8.8 + 2 x O [M+H]+ = 331.1914 [M–H]–  = 329.1770 M02-1 − √ − − − 
10.0 + 2 x O  [M–H]–  =  329.1762  − − √ − − 
11.2 + 2 x O [M+H]+ = 331.1912  M02-2 − √ − − − 
13.8 + 2 x O [M+Na]+ = 353.1713  [M–H]–  = 329.1771  M02-3 − √ √ − − 
16.0 + O [M+H]+ = 315.1968  [M–H]–  = 313.1817  M02-4 √ √ √ − − 
17.1 + O [M+H]+ = 315.1964   M02-5 √ √ √ − − 
18.5 - 2H + O [M+H]+ = 313.1810  [M–H]–  =311.1652  − − √ − − 
18.9 + O [M+H]+ = 315.1961 [M–H]–  = 313.1816 M02-6 − √ √ + − 
19.1 - 2H + O  [M–H]–  = 311.1664  − − √ ++ − 
19.9 - 2H + O  [M–H]–  = 311.1658  − − √ ++ − 
20.9 + O [M+H]+ = 315.1965 [M–H]–  = 313.1818  M02-7 √ √ √ + − 
22.0 + O [M+H]+ = 315.1962 [M–H]–  = 313.1819   − − √ − − 
22.6 - 2H + O  [M–H]–  = 311.1652 M02-8 − √ √ +++ − 
25.4 - 2H [M+H]+ = 297.1852    − − √ − + 
26.1 NET [M+H]+ = 299.2019  [M–H]–  = 297.1872   √ √ √ − − 
27.0 - 2H  [M–H]–  = 295.1714  M02-9 √ √ √ +++ +++ 
As recently described by Pozo et al. (37), the collision induced dissociation of 3-
keto steroids after ESI results in complex product ion spectra. Characteristic 
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fragment ions, indicating the site of modification of the steroid structure, would 
significantly facilitate metabolite identification. For example, in the case of the 
hydroxy metabolites M02-4 and M02-7 of norethisterone, elaborate spectra 
interpretation and comparison to the spectrum of the parent drug revealed that the 
m/z of several fragments containing the steroid D ring were incremented with the 
mass of an oxygen atom or reduced by the mass of two protons (due to water loss 
prior to the formation of that fragment) from the fragments of NET. Upon 
hydroxylation, an additional cleavage of H2O is observed in the D ring, indicating 
the site of biotransformation and thereby significantly accelerating the NMR 
identification.  
Preparative scale biosynthesis and NMR analysis  Full structure 
characterization was done on the products obtained from a preparative scale 
biosynthesis with NET as a substrate for biocatalysis. Using the highly active 
P450BM3 M02his mutant, a set of compounds was generated for isolation and 
identification. All fractions obtained from the preparative LC analysis were 
screened for purity and affinity in the dual receptor affinity detection system and 
were simultaneously measured with NMR for full structure characterization. Figure 
2.5 depicts the structures of the compounds generated by the large scale 
biosynthesis utilizing the P450BM3 M02his mutant.  
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Figure 2.5 Products derived from biosynthesis with Cytochrome P450BM3 M02his using 
norethisterone as scaffold. 
 
The main product is the 16β-hydroxylated product (M02-7), having a fairly low 
affinity towards hERα and no affinity towards hERβ. The second most abundant 
product is 15β-hydroxy NET (M02-4), which has no affinity for either of the 
receptors.  The position of the hydroxyl group in the isolated biosynthesis products 
was confirmed and determined by comparing the 13C-1H correlation spectra of the 
products with the spectra of NET. The analysis of M02-7 is described in the 
supporting information as an example. NOESY spectra, as well as J-coupling 
patterns in the 1D 1H spectra(38), were used to determine the 3D structures of the 
newly formed chemical entities. Interestingly, hydroxylation always occurred at the 
β position either at the A ring or D ring of the steroid, not at the α position or at the 
B or C ring. Jacobsen et al. found similar results when they studied the 
hydroxylation of testosterone, progesterone and androstenedione by CYP6A1(39). 
The hydroxylation at position 1 in M02-2 is assumed to be at the β position but this 
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could not be confirmed unambiguously by NMR due to the combination of low 
concentration of the compound and impurities present in the sample. NOESY 
spectra indicated that compounds with a hydroxyl at position 2, M02-1 and M02-3, 
have a folded A ring, identified by a strong NOE interaction between the proton at 
position 2 and the proton at position 9. This folding of the A ring into an inverted 
half chair conformation has been shown to be a common occurrence in steroids 
with a hydroxyl at this position (40-42). We were not able to determine the 
structures of M02-5 and M02-6. M02-5 is an inactive compound and the amount 
produced is insufficient for NMR experiments, HR-MS data indicates that the 
scaffold is hydroxylated. Product M02-6 degraded during the NMR data 
acquisition. Hence, based on the HR-MS, UV absorption data and its instability, 
this compound is probably the instable 4,5-epoxy-NET(43).  
Interestingly, the M02his mutant was able to form most of the active human relevant 
metabolites, albeit in different ratios. Recently, Korhonen et al. reported the 
elucidation of human CYPs involved in the metabolism of NET and proposed 
identities based on high resolution MS in positive ion mode and fragmentation 
studies with a triple quadrupole MS(44). Our findings are in accordance with the 
published results, but due to the additional dimensions of our receptor affinity 
detection system and the utilization of fast polarity switching in full MS mode, we 
were able to identify additional metabolites with biological relevance. Compound 
M02-9 at tr 27.0 min has high affinity for both Estrogen Receptor subtypes and is 
difficult to detect in positive ion mode. Although present in low concentrations, 
this entity is readily detected in negative ion mode and has a [M–H]– with m/z 
295.1714 derived from dehydrogenation of NET or the loss of H2O from a 
hydroxy-product. Based on retention time, affinity to both receptor subtypes and 
HR-MS/MS spectral library matching, we identified this product as EE2. Although 
not frequently described, NET can be metabolized in humans to EE2 via 
hydroxylation of the A ring and a subsequent loss of H2O introducing aromaticity 
in the A ring. This effect was first described by Yamamoto et al.(45, 46), whereas 
Kuhl et al. recently discussed clinical implications of the formation of this potent 
estrogenic active metabolite in humans(47). As described by Ma et al.(36), 
aromatization of the A ring of a steroid, and the inherent loss of the 3-keto,4-ene 
conjugation, changes the ESI significantly. Additionally, the UV absorption 
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maximum shifts from 244 nm to 285 nm indicating the introduction of an aromatic 
moiety. These two properties provide an extra tool in structure characterization of 
steroids. 
Compound M02-08 is produced by the human liver microsomes as well as by the 
mutant P450BM3 M02his and has high affinity towards the hERα subtype. This 
compound is formed in amounts too low to be identified by NMR but is easily 
detected in negative ion mode and has a [M–H]– with m/z 311.1652 (HR-MS 
spectrum in Figure S2.3). Additional experiments were done to identify the 
structure of M02-08. Since M02-08 is a secondary reaction product, the main 
product M02-07 was used as a substrate in analytical scale incubations with the 
mutants M02his and M11his. The data (Figure S2.4) confirms that M02-08 is formed 
from M02-07 via a similar mechanism as norethisterone is converted into 17α-
ethinylestradiol, namely via hydroxylation on the C2 and subsequent loss of H2O. 
Based on these findings as well as on the change of its ionization properties(36) 
and UV absorption profile (Figure S2.5), M02-08 can be identified as 16β-OH 
EE2. Other compounds were found to be secondary products as well, mainly being 
β-hydroxylated products at the C1, C2, C15 and C16 positions.  
2β, 15β-dihydroxy norethisterone (M02-1): 9 µg, ESI: m/z 331.1914 [M+H]+, m/z 329.1770 
[M-H]-, 1H NMR (500 MHz, DMSO-d6) δ ppm: 0.95 – 1.04 (m, 2 H, 9α, 7α) 1.00 (s, 3 H, 
CH3) 1.22 – 1.29 (m, 2 H, 11β, 14α) 1.49 – 1.55 (m, 2 H, 12α, 12β) 1.57 – 1.67 (m, 1 H, 
8β) 1.80 – 1.85 (m, 1 H, 11α )  1.84 – 1.91 (m, 2 H, 1α, 16β)  1.96 – 2.04 (m, 1 H, 1β) 2.17 
– 2.24 (m, 1 H, 10β) 2.28 – 2.34 (m, 1 H, 7β) 2.38 – 2.46 (m, 2 H, 6α, 6β) 2.46 – 2.54 (m, 1 
H, 16α) 3.90 (dd, 1 H, 2α) 3.99 – 4.05 (m, 1 H, 15α) 5.67 (s, 1 H, 4). 
1, 16β-dihydroxy norethisterone (M02-2): 6 µg, ESI : m/z 331.1912 [M+H]+, 1H NMR (500 
MHz, DMSO-d6) δ ppm: 0.81 (s, 3 H, CH3) 0.83 – 0.91 (m, 1 H, 9α) 0.96 – 1.04 (m, 1 H, 
7α) 1.04 – 1.13 (m, 1 H, 15 β) 1.12 – 1.19 (m, 1 H, 14α) 1.30 – 1.39 (m, 1 H, 11β)  1.39 – 
1.47 (m, 1 H, 8β)  1.48 – 1.54 (m, 1 H, 12β) 1.59 – 1.69 (m, 1 H, 12 α) 1.82 – 1.93 (m, 2 H, 
7β, 11α) 2.07 - 2.15 (m, 1 H, 15α) 2.12 – 2.23 (m, 1 H, 10β) 2.20 – 2.26 (m, 1 H, 6β) 2.35 – 
2.41 (m, 1 H, 6α) 2.45 – 2.55 (m, 2 H, 2α, 2β) 3.95 (m, 1 H, 16α) 4.21 (m, 1 H, 1) 4.65 (b, 
1 H, OH17β) 4.83 (b, 1 H, OH1) 5.28 (b, 1 H, OH16β) 5.68 (s, 1 H, 4). 
2β, 16β-dihydroxy norethisterone (M02-3): 44 µg, ESI: m/z 353.1713 [M+Na]+, m/z 
329.1771 [M-H]-, 1H NMR (500 MHz, DMSO-d6) δ ppm 0.82: (s, 3 H, CH3) 0.93 – 1.05 
(m, 2 H, 7α, 9α) 1.08 – 1.16 (m, 1 H, 15β) 1.16 – 1.24 (m, 1 H, 14α) 1.23 – 1.33 (m, 1 H, 
11β) 1.35 – 1.45 (m, 1 H, 8β) 1.50 – 1.57 (m, 1 H, 12β) 1.62 – 1.71 (m, 1 H, 12α) 1.80 – 
1.90 (m, 3 H, 1α, 7β, 11α) 1.95 – 2.03 (m, 1 H, 1β) 2.09 – 2.16 (m, 1 H, 15α) 2.21 – 2.28 
(m, 1 H, 6β) 2.28 – 2.32 (m, 1 H, 10β) 2.38 – 2.44 (m, 1 H, 6α) 3.87 – 3.93 (m, 1 H, 2α) 
3.94 – 3.99 (m, 1 H, 16α) 4.55 – 4.74 (b, 1 H, OH) 5.11 – 5.41 (b, 2 H, 2βOH, 16βOH) 
5.67 (s, 1 H, 4). 13C NMR (500 MHz, DMSO-d6) δ ppm: 12.6 (C18) 25.6 (C11) 31.8 (C7) 
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32.7 (C1) 33.0 (C12) 34.1 (C15) 34.8 (C6) 40.21 (C8) 40.4 (C10) 45.0 (C14) 47.8 (C9) 
68.2 (C2) 76.2 (C16) 120.3 (C4). 
15β-hydroxy norethisterone (M02-4): 393 µg, ESI: m/z 315.1968 [M+H]+, m/z 313.1817 
[M-H]-, 1H NMR (500 MHz, DMSO-d6) δ ppm: 0.73 – 0.85 (m, 1 H, 9α) 0.90 – 0.98 (m, 1 
H, 7α) 1.01 (s, 3 H, CH3) 1.16 – 1.21 (m, 1 H, 11β) 1.22 – 1.28 (m, 1 H, 14α) 1.41 – 1.47 
(m, 1 H, 1α) 1.48 – 1.54 (m, 1 H, 12β) 1.54 – 1.60 (m, 1 H, 12α) 1.61 – 1.70 (m, 1 H, 8β) 
1.76 – 1.84 (m, 1 H, 11α) 1.84 – 1.91 (m, 1 H, 16β) 2.07 – 2.16 (m, 1 H, 7β) 2.17 – 2.26 
(m, 4 H, 1β, 2β, 2α, 10β) 2.26 – 2.33 (m, 1 H, 6β) 2.39 – 2.47 (m, 1 H, 6α) 2.53 – 2.59 (m, 
1 H, 16α) 4.00 – 4.10 (m, 1 H, 15α) 4.45 – 4.57 (d, 1 H, 15βOH) 5.29 – 5.41 (b, 1 H, OH) 
5.69 – 5.78 (s, 1 H, 4). 13C NMR (600 MHz, DMSO-d6) δ ppm: 15.0 (C18), 25.5 (C11), 
26.0 (C1), 29.7 (C7), 33.4 (C12), 34.7 (C6), 36.0 (C2), 36.1(C8), 42.0 (C10), 49.1 (C9), 
51.6 (C16), 53.5 (C14), 66.5 (C15), 123.8 (C4). Previously identified with NMR by 
Ambrus et al. (48). 
16β-hydroxy norethisterone (M02-7): 485 µg, ESI: m/z 315.1965 [M+H]+, m/z 313.1818 
[M-H]-, 1H NMR (500 MHz, DMSO-d6) δ ppm: 0.72 – 0.85 (m, 1 H, 9α) 0.81 (s, 3 H, CH3) 
0.92 – 1.02 (m, 1 H, 7α) 1.08 – 1.15 (m, 1 H, 15β) 1.15 – 1.20 (m, 1 H, 14α) 1.20 – 1.27 
(m, 1 H, 11β) 1.34 – 1.42 (m, 1 H, 8β) 1.43 – 1.49 (m, 1 H, 1α) 1.50 – 1.55 (m, 1 H, 12β) 
1.59 – 1.67 (m, 1 H, 12α) 1.74 – 1.79 (m, 1 H, 7β) 1.79 – 1.84 (m, 1 H, 11α) 2.12 – 2.18 
(m, 1 H, 15α) 2.15 – 2.18 (m, 1 H, 10β) 2.17 – 2.21 (m, 1 H, 1β) 2.20 – 2.24 (m, 2 H, 2α, 
2β) 2.23 – 2.32 (m, 1 H, 6β) 2.36 – 2.45 (m, 1 H, 6α) 3.94 – 4.00 (m, 1 H, 16α) 4.64 (b, 1 
H, OH) 5.26 – 5.27 (d, 1 H, 16βOH) 5.72 (s, 1 H, 4). 13C NMR (600 MHz, DMSO-d6) δ 
ppm: 12.6 (C18), 25.2 (C11), 25.7 (C1), 30.3 (C7), 33.4 (C12), 34.3 (C15), 34.5 (C6), 35.8 
(C2), 39.7 (C8), 41.6 (C10), 45.2 (C14), 48.8 (C9), 76.3 (C16), 124.0 (C4). 
Norethisterone (NET): ESI: m/z 299.2019 [M+H]+, m/z 297.1872 [M-H]-, 1H NMR (600 
MHz, DMSO-d6) δ ppm: 0.72 – 0.78 (m, 1 H, 9α) 0.79 (s, 3 H, CH3) 0.92 – 1.01 (m, 1 H 
7α) 1.17 – 1.25 (m, 1 H, 11β) 1.25 – 1.31 (m, 1 H, 15β) 1.31 – 1.38 (m, 1 H, 8β) 1.38 – 
1.45 (m, 1 H, 14α) 1.45 – 1.52 (m, 1 H, 1α) 1.53 – 1.59 (m, 1 H, 15α) 1.58 – 1.65 (m, 2 H, 
12α, 12β) 1.73 – 1.79 (m, 1 H, 7β) 1.80 – 1.84 (m, 1 H, 11α) 1.83 – 1.88 (m, 1 H, 16β) 2.02 
– 2.18 (m, 1 H, 16α) 2.12 – 2.18 (m, 1 H, 10β) 2.17 – 2.21 (m, 1 H, 1β)  2.20 – 2.24 (m, 2 
H, 2α, 2β) 2.23 – 2.31 (m, 1 H, 6β) 2.39 – 2.45 (m, 1 H, 6α) 5.33 (s, 1 H, OH) 5.69 – 5.78 
(m, 1 H, 4). 13C NMR (600 MHz, DMSO-d6) δ ppm: 12.3 (C18), 22.5 (C15), 25.6 (C11), 
26.0 (C1), 30.4 (C7), 32.3 (C12), 34.6 (C6), 36.1 (C2), 38.7 (C16), 40.3 (C8), 41.8 (C10), 
48.8 (C14), 49.0 (C9), 124.0 (C4). The NMR assignment of NET in chloroform-d1 is 
previously reported by Sedee et al. (49).  
 
2.3.3 Identification approach 
The approach followed in this work is based on two major parts, being the 
analytical scale biosynthesis and analysis utilizing high resolution MS(/MS) (I) and 
preparative biosynthesis followed by isolation and NMR (II). In general, the 
production of novel metabolites is assessed using analytical scale biosynthesis. 
This first part generates information on chemical structure and bioaffinity by 
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utilizing the on-line LC–MS dual receptor affinity detection system. Specific 
profiles are obtained of all metabolites formed and include identifying factors such 
as accurate mass, retention time, relative affinity information, UV-absorption 
profiles and MS/MS fingerprints. When profiles match to the library, the 
identification with HR-MS/MS is sufficient for structure identification. Due to the 
multidimensional data matrix obtained on all compounds, the upscaling for a 
complete structure characterization is only limited to the interesting novel 
compounds generated by specific enzymatic systems. For these novel compounds, 
preparative scale biosynthesis was performed for subsequent preparative LC 
fractionation to determine the structure conformation by NMR while the process is 
monitored with the on-line dual receptor affinity detection system. Insufficient 
product formation disables de-novo structure elucidation by NMR due to the 
detection limits of the NMR employed (magnetic fields up to 600 MHz). By using, 
for example, micro-droplet NMR, NMR on a chip or NMR at higher field (e.g. 800 
MHz equipped with cryo-cooled probes), detection limits may be reduced to ca. 
250 ng(50, 51). We further note that in contrast to de-novo characterization, NMR 
identification of pure stable known library compounds lowers the detection limits. 
However, in our experience, full purity may often not be achieved in practice and 
mixtures with vastly different amounts may occur. Moreover, in steroids, complex 
J-coupling multiplets (doublets up to doublets of doublets of doublets of doublets) 
tend to occur, which leads to higher complexity and lower peak height per proton 
as compared to singlet resonances. These aspects made the given detection limits 
(250 to 1000 ng) approximate but still a practical guideline and can thus be referred 
to as ‘limit of spectroscopic identification’ (LOSI) as discussed recently by Wilson 
et al. for complicated hyphenated systems(52).  
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2.4 Conclusions 
In total, the analytical scale biosynthesis produced over 85 compounds from 6 
different starting templates. As an example, the NET related biotransformation 
products were subjected to full structure characterization. Reaction products of 
NET formed by P450BM3 M02his were identified based on HR-MS(/MS) data, 
drug-target affinity profiles, UV absorption profiles and spectral library matching 
of standards. Of all NET related products generated by the M02his enzymatic 
system, we were able to fully identify ~70% based on the different strategies and to 
obtain final structure confirmation by NMR data. Based on the full structure 
characterization of the M02his produced norethisterone analogues, the majority of 
all products formed by the other enzymatic systems (M11his and HLM) were 
identified by LC-HR-MS(/MS) experiments. In conclusion, by combining 
hyphenated screening assays, HR-MS(/MS) for fast, first line structure 
identification and NMR spectroscopy for full 3D structure confirmation we were 
able to determine, identify and characterize chemical entities produced by 
biosynthetic enzymes. This multidimensional screening approach enabled the 
detection of low abundant biotransformation products which were not suitable for 
detection in either one of its single components. The implementation of this 
approach in early stage drug discovery expands the toolbox of the medicinal 
chemist for the generation and optimization of lead compounds in a quick and 
informative way. A combination of compound library generation, information on 
metabolic soft spots and drug target selectivity is obtained in parallel and thereby 
saving valuable time and manpower. To improve the versatility and throughput of 
our approach, our current research includes the expansion of our mutant enzyme 
library, data stream clustering methods and MS/NMR based drug target affinity 
assays.  
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2.6 Supporting Information 
 
 
 
Figure S2.1 Biological response of the dual receptor affinity detection system, using both 
(A) hERα and (B) hERβ with injections of 17β-E2 (10 µL of 1 nM-100 µM). 
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Figure S2.2 On-line LC–MS dual RAD hERα (solid) and hERβ (dashed) affinity traces of 
reaction mixtures produced by M02his using EE2, 17β-E2 and Org X as scaffolds, (#) 
numbers indicate peaks as depicted in Table S2.1. 
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Figure S2.3 High resolution MS spectrum of 16β-OH EE2 (M02-8), in negative ion mode, 
showing [M–H]–  (0.3 ppm) and [M+ HCOO]– (2.2 ppm). 
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Figure S2.4 hERα (solid) and hERβ (dashed) affinity profiles of biosynthesis products by 
P450BM3 M02his using NET and of 16β-OH NET (M02-7) as scaffolds. (1) M02-6, (2) 
M02-7, (3) M02-8, (4) M02-9. 
Figure S2.5 UV absorption profiles obtained in the screening of NET-products (left) 16β-
OH NET (M02-7) and (right) 16β-OH EE2 (M02-8). 
Table S2.1 Characterization of produced entities. (#) between brackets the peak number as 
indicated in Figure S2.2;  m/z values indicated in bold represent the most abundant ion used 
for identification, all m/z values mentioned for negative ion mode represent the [M–H]–. 
Relative receptor affinity was ranked by relating UV-absorbance and biochemical-assay 
responses; - = no affinity,  + = low affinity, ++ = moderate affinity and +++ = high affinity. 
 Product Identification  Enzymatic System Receptor 
Binding 
    High Resolution - MS           
Tr (min) Modification m/z + ion mode m/z – ion 
mode 
M11his M02his HLM hERα hERβ 
EE2            
11.2 + O   311.1660  √        √ √ − − 
14.1 + O   311.1664  − − √ ++ − 
(1)       15.0 + O   311.1653  √ √ √ ++ − 
16.5 + O [M+K]+ = 351.1362  311.1658  − − √ + − 
(2)      17.3 + O [M+K]+ = 351.1371  311.1660  √ √ √ + − 
(3)      18.7  + O [M+K]+ = 351.1373  311.1666  √ √ √ ++ + 
19.5 + O [M+K]+ = 351.1367 311.1656 − − √ + − 
(4)       20.7 - 2H + O [M+H]+ = 311.1632  309.1499 √ √ √ + − 
21.5 + O   311.1663 − − √ ++ − 
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(5)       22.2 + O [M+Na]+ = 335.1632 311.1656 √ √ √ ++ + 
22.9 - 2H + O   309.1503 √ − √ + + 
24.0 + 2H + O [M+K]+ = 353.1525 313.1813 √ √ − − − 
24.2 + O   311.1661 √ − √ ++ + 
(6)       25.5 - 2H   293.1544 √ √ √ ++ + 
(7)       26.8 Substrate   295.1709 √ √ √ +++ +++ 
            
17β-E2           
6.2 + 2 x O   303.1605 √ √ √ − − 
8.3 - 2H + 2 x O [M+K]+ = 341.1149 301.1445 − √ − − − 
9.6 - 2H + 2 x O [M+K]+ = 341.1150 301.1439 − √ − − − 
9.9 + 2 x O [M+K]+ = 343.1297  303.1594  √ √ − − − 
10.6 + 2 x O [M+K]+ = 343.1304 303.1607 √ √ − − − 
11.6 - 2H + 2 x O   301.1445 − √ − − − 
12.2 + 2 x O   303.1607 − − √ ++ − 
(8)       13.8 + O   287.1652 √ √ − ++ − 
15 + O   287.1662 − − √ − − 
(9)       15.9 + O   287.1652 √ √ √ ++ ++ 
(10)     16.8 + O   287.1664 √ √ √ +++ +++ 
(11)     17.8 - 2H + O [M+K]+ = 325.1195 285.1492 √ √ √ ++ − 
18.8 - 2H + O   285.1505 − − √ ++ − 
(12)     20.2 + O   287.1651  √ √ √ +++ +++ 
(13)     21.5 + O   287.1658  √ √ √ ++ − 
(14)     22.6 + O   287.1663  √ √ √ +++ +++ 
23.3 + O   287.1662  − − √ +++ +++ 
25.1 - 2H   269.1557 − − √ +++ +++ 
(15)     26.4 Substrate   271.1557 √ √ √ +++ +++ 
            
OrgX           
9.4 + 2 x O [M+K]+ = 379.1298  339.1612   − √ √ − − 
10.3 + 2 x O [M+K]+ = 379.1307  339.1615   − √ √ − − 
(16)     14.2 + 2 x O [M+K]+ = 379.1309  339.1598 − √ √ ++ − 
(17)     16.5 + 2 x O [M+K]+ = 379.1299 339.1595   √ √ √ ++ − 
(18)     19.0 + O [M+Na]+ = 363.1354 323.1658   √ √ √ + − 
(19)     20.4 + O [M+Na]+ = 363.1359 323.1650   √ √ √ + − 
(20)     21.5 - 2H + O   321.149 − √ √ + − 
(21)     22.4 - 2H + O   321.1507 − √ √ +++ +++ 
25.0 Substrate [M+Na]+ = 347.1409 307.1699 √ √ √ + + 
(22)     26.1 - 2H   305.1552 − √ √ +++ +++ 
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17α-E2           
8.1 - 2H + 2 x O 301.1445 − √ − − − 
9.2 + 2 x O 
  
303.1601 √ √ − − − 
9.6 - 2H + 2 x O   301.1445 − √ − − − 
12.0 + O   287.1662 √ √ − + − 
14.2 - 2H + O   285.1502 − √ − + − 
15 + 2 x O   303.1612 − − √ + + 
15.2 + O   287.1663 √ √ √ + + 
16.0 - 2H + O   285.1507 √ √ √ + − 
17.1 - 2H + O 285.1507 √ √ √ + + 
17.7 + O 
  
287.1659 − − √ − − 
19.1 - 2H + O   285.1507 √ √ − ++ − 
20.1 + O   287.1652 √ √ √ ++ ++ 
20.7 + O   287.1645 √ √ √ − − 
21.9 - 2H + O   285.1506 √ √ √ − − 
22.4 - 2H + O   285.1507 − − √ ++ − 
24.1 + O   287.1657 − − √ ++ − 
26.1 - 2H   269.1549 √ √ √ ++ ++ 
27.1 Substrate   271.1557 √ √ √ ++ ++ 
            
Org Y           
15.8 + 2 x O [M+K]+ = 397.1777 357.2075 √ − − − − 
17.7 + 2 x O [M+K]+ = 397.1780 357.2088   √ √ √ − − 
19.0 + 2 x O [M+K]+ = 397.1786 357.2072   √ √ √ − − 
19.6 + O [M+K]+ = 381.1830  341.2133 √ √ √ − − 
20.5 + O [M+K]+ = 381.1834 341.2131 − − √ ++ − 
21.3 - 2H + O [M+K]+ = 379.1675 339.1967 − − √ +++ +++ 
22.2 - 2H + O 339.1957 − − √ ++ ++ 
22.4 + O 
 
[M+K]+ = 381.1821 
341.2116 √ √ √ − − 
23.3 - 2H + O [M+K]+ = 379.1679  339.1950 − − √ ++ − 
24.9 - 2H + O [M+K]+ = 379.1683   339.1966 √ √ √ ++ ++   
25.9 + O   341.2123  √ √ √ +++ + 
  27.4 + 2H + O [M+K]+ = 383.1993 343.2274 √ √ − − − 
27.5 + O   341.2134 − − √ ++ + 
29.8 - 2H [M+H]+ = 325.2183  323.2022 − − √ − − 
30 Substrate [M+K]+ = 365.1880 325.2183 √ √ √ ++ ++ 
32.1 - 4H + O   337.1812 − − √ ++ − 
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NMR analysis 
The structures of the M02his produced entities were mainly determined by 
comparing the NMR spectra of the biosynthetic produced entities with the spectra 
of the parent compound (NET). This part of the supplementary explains the NMR 
structure determination of M02-7, as an example. From mass spectrometry data, it 
is already known that the modification of M02-7 is NET+O.  
Figure S2.6 shows the HSQC spectra of NET (black structure and assignments) 
and M02-7 (red structure and assignments). The shift of the C-H correlations 15 
(blue circles/arrows), and 16 (light blue circles/arrows) indicates that the hydroxyl 
of M02-7 is located at position 15 or 16. If the hydroxyl is located at position 15, 
one would expect a chemical shift change of the C14-H14 correlation towards 
lower field, which is not observed. So, by only using the HSQC spectra of NET 
and M02-7, one can easily determine the position of hydroxylation (C16).  
Figure S2.7 shows the DQF-COSY (Double Quantum Filtered Correlation 
SpectroscopY) spectra of NET and M02-7. As can be noticed directly, these two 
spectra are highly comparable with the major difference being the shift of H16 
from ~2.0 ppm to ~3.9 ppm and the shift of both H15α and H15ß frequency. 
Notice that H16 has just two correlations with 15α and 15ß, whereas most other 
protons have a more complex coupling pattern. By analyzing the complete DQF-
COSY spectra, it can be confirmed that the OH modification occurs at C16. 
The 3D structure of M02-7 was determined by measuring a NOESY (Nuclear 
Overhauser Enhancement SpectroscopY) spectrum. According to the presence of a 
NOE correlation between H16α and H14α it allows the conclusion that the 16OH is 
located bèta. The letters a and b used in Figure S2.6 and refer Figure S2.7 to the 
belonging proton located at the alpha (a) or bèta (b) position. Stereochemistry of 
other carbon atoms than the once mentioned above are similar to those in NET.  
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Figure S2.6 HSQC spectra of NET (upper) and M02-07 (lower). Large circles indicating 
the shift of the C15-H15 correlations, smaller circles and arrows indicating the shift of the 
C16-H16 correlation. Note that H4 is not represented in this figure (δH=5.7 ppm, δC=124.0 
ppm). 
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Figure S2.7 DQF-COSY spectra of NET (upper) and M02-07(lower). The different 
coupling pattern of M02-7 confirms that hydroxylation occurs at C16. Note that H4 is not 
represented in this figure (δH=5.7 ppm).  
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Abstract 
Cytochrome P450BM3 from Bacillus megaterium is a monooxygenase with great potential 
for biotechnological applications. In this chapter, we present engineered drug-metabolizing 
P450BM3 mutants as a novel tool for regioselective hydroxylation of steroids at position 
16ß. In particular, we show that by replacing alanine at position 82 with a tryptophan in 
P450BM3 mutants M01 and M11, the selectivity toward 16ß-hydroxylation for both 
testosterone and norethisterone was strongly increased. The A82W mutation led to a ≤ 42-
fold increase in Vmax for 16ß-hydroxylation of these steroids. Moreover, this mutation 
improves the coupling efficiency of the enzyme, which might be explained by a more 
efficient exclusion of water from the active site. The substrate affinity for testosterone 
increased at least 9-fold in M11 with tryptophan at position 82. A change in the orientation 
of testosterone in the M11A82W mutant as compared to the orientation in M11 was 
observed by T1 paramagnetic relaxation nuclear magnetic resonance. Testosterone is 
oriented in M11 with both the A- and D-ring protons closest to the heme iron. Substituting 
alanine at position 82 with tryptophan results in increased A-ring proton-heme iron 
distances and decreased D-ring proton-heme iron distances. This appears to be consistent 
with the relative decrease in the level of A-ring hydroxylation at the 2ß-position and 
increase in the level of D-ring hydroxylation at position 16ß. 
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3.1 Introduction 
Cytochrome P450 (CYPs) constitute a large superfamily of monooxygenases that 
are involved in the oxidation and reduction of a wide variety of primary and 
secondary metabolites and in the biotransformation of xenobiotics(1). Because of 
their broad substrate range and catalytic diversity, there is an increasing interest to 
use P450 enzymes in biotechnology(2-4). Among others, their application in the 
production of pharmaceuticals and the optimization of lead compounds by P450 
enzymes has been explored recently(5). An important class of compounds for 
which P450s play an important role in biosynthesis and catabolism consist of 
steroids, which have a wide range of therapeutic activities, including anti-
inflammatory, immunosuppressive, progestational, diuretic, anabolic and 
contraceptive activities(6). Both chemical and biological approaches are used for 
the production of steroids. Chemical synthesis of steroids requires highly 
complicated, multistep schemes that are expensive and time-consuming. Many 
microorganisms that are able to hydroxylate steroids at specific positions have been 
identified. Therefore, microbial biosynthesis can be an efficient alternative for 
large-scale synthesis of steroid drugs(6). Very often, an early step in these 
biotransformations is a regio- and stereospecific hydroxylation of a steroid core by 
microbial P450s. However, microbial hydroxylation of steroids is often hampered 
by the formation of byproducts because of nonspecific and secondary metabolism.   
Another approach is to clone a genetically engineered steroid hydroxylating P450 
into a suitable expression system that is devoid of secondary steroid catabolism. 
Several mammalian P450s are known to regioselectively hydroxylate steroids(7). 
However, because of their low stability and catalytic activity they are not very 
suitable as biocatalysts for steroid hydroxylations(8, 9). Genetically engineered 
bacterial P450s are often much more stable and exhibit higher catalytic activities, 
which make them more promising candidates for biocatalysis(10). Of the bacterial 
P450s, Cytochrome P450BM3 (P450BM3; CYP102A1) from Bacillus megaterium 
is considered as one of the most promising monooxygenases for biotechnological 
applications because it is the most active P450 so far identified(8). Wild-type 
P450BM3 catalyzes the hydroxylation of long-chain fatty acids at subterminal 
positions (ω-1 to ω-3). By site-directed and random mutagenesis, the substrate 
specificity of P450BM3 has been expanded to include alkanes, indoles, short- and 
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medium-chain fatty acids, polycyclic aromatic hydrocarbons and drugs(4, 11, 12). 
In recent years, several mutants of P450BM3 have been shown to catalyze the 
hydroxylation of steroids. A triple mutant of P450BM3 (R47L/F87V/L188Q) and 
several mutants obtained by random mutagenesis were found to hydroxylate 
testosterone, norethisterone, nandrolone, progesterone and androstendione(13-15). 
However, the regioselectivity of steroid hydroxylation by most P450BM3 mutants 
was still poor, resulting in multiple mono- and dihydroxy metabolites. Testosterone 
hydroxylation by P450BM3 mutants has been shown to occur at positions 2β, 15β 
and 16β (16, 17) and recently other mutants that are highly selective for 2β- and 
15β-hyroxylation were obtained(17). 
Previously, it was shown that increasing the size of the active site residue at 
position 82 in wild-type P450BM3, by mutations A82F and A82W, strongly 
improves binding of fatty acids and indoles, resulting in substantially increased 
catalytic efficiency and binding affinity(18). However, no significant change in 
regioselectivity in metabolism was observed. The aim of this study was to 
investigate whether the introduction the A82W mutation into P450BM3 mutants 
M01 and M11 affects the activity and/or regioselectivity of steroid hydroxylation. 
Two steroid substrates, testosterone and norethisterone, were selected because they 
have been shown to be metabolized to three and two monohydroxy metabolites, 
respectively, by M01 and M11(15, 19).  
The orientation of a substrate in the active site of P450 enzymes can be determined 
by T1 paramagnetic relaxation nuclear magnetic resonance (NMR)(20). T1 
paramagnetic relaxation experiments have been used previously to determine 
proton-heme iron distances in P450 enzymes(21-23), which give information about 
the orientation(s) and mobility of ligands in the active site of P450 enzymes. For 
P450BM3, these experiments have been used to determine the substrate orientation 
of the highly flexible substrates lauric acid and 12-bromolauric acid(17, 21, 24). 
Steroid compounds might be more informative compounds for determining the 
substrate orientation because they are large compounds with a dense network of 
protons; hence, many protons can be used to determine the proton-heme iron 
distances. Because they are rigid structures, the obtained distances give more 
information about the binding and mobility in the active site, rather than the 
conformational flexibility of the steroid. No T1 paramagnetic relaxation NMR 
experiments have been used to study the binding of steroids to P450BM3s. The 
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only T1 paramagnetic relaxation NMR study addressing the binding orientation of 
steroids in P450s involved binding of testosterone to a genetically engineered 
mutant of CYP2D6 (F438I) which had acquired the ability to catalyze testosterone 
hydroxylation(25). In this study, Smith et al. determined the distances from several 
protons of testosterone to the heme iron of the CYP2D6 mutant, including protons 
H2β, H15β and H16β. Recently, we and others have demonstrated that BM3 
mutants catalyze testosterone only at these three positions but with different 
regioselectivities(15-17). In the study presented here, T1 paramagnetic relaxation 
NMR studies were performed to investigate whether the change in regioselectivity 
of testosterone hydroxylation that is observed in the A82W mutants can be 
explained by different binding orientations of testosterone. 
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3.2 Experimental 
3.2.1 Chemicals 
D-Glucose 6-phosphate dipotassium salt hydrate (purity 100%), glucose-6-
phosphate dehydrogenase, dimethylsulfoxide-d6 (purity 100%; 99.9 atom %D), 
carbon monoxide (purity >99%) and sodium dithionite (purity >86%) were 
purchased from Sigma-Aldrich (Schnelldorf, Germany). All other chemicals were 
of analytical grade and obtained from standard suppliers. 
3.2.2 Site-directed mutagenesis 
The A82W mutation was introduced by site-directed mutagenesis in two templates, 
M11 (R47L, E64G, F81I, F87V, E143G, L188Q, E267V and G415S) and M01 
(R47L, F87V, L188Q and E267V)(10). The mutation was introduced into the pBS-
P450BM3 mutant using the QuikChange XL site-directed mutagenesis kit 
(Stratagene). The sequence of the forward primer, for the mutation in M11 was: 
 5’-GT.CAA.GCG.CTT.AAA.TTT.GTT.CGC.GAT.ATT.TGG.GGA.GAC.GGG-
3’, with the altered residue shown in bold italics. The reverse primer for this 
position was 5’-
CCC.GTC.TCC.CCA.AAT.ATC.GCG.AAC.AAA.TTT.AAG.CGC.TTG.AC-3’. 
The sequences of the primers, for the mutation in M01 with, were as follows: 
forward primer: 
5’-GT.CAA.GCG.CTT.AAA.TTT.GTT.CGC.GAT.TTT.TGG.GGA.GAC.GGG-
3’; 
reverse primer:  
5’-CCC.GTC.TCC.CCA.AAA.ATC.GCG.AAC.AAA.TTT.AAG.CGC.TTG.AC-
3’.  
The PCR product was digested with EcoR1 and BamH1 restriction enzymes and 
cloned into a pET28a+ vector, which encodes an N-terminal His-tag to allow facile 
purification. The desired mutations were confirmed by DNA sequencing of the 
heme domain (Baseclear, Leiden, The Netherlands). 
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3.2.3 Expression, isolation and purification of P450BM3 mutants 
Expression of the CYP102A1 mutants was performed by transforming competent 
Escherichia coli BL21 cells with the corresponding pET28+ vectors, as described 
previously(16).  Proteins were purified using Ni-NTA agarose(16), after which 
P450 concentrations were determined according to methods described by Omura 
and Sato(26). The purity of the enzymes was checked by sodium dodecyl sulphate 
– polyacrylamide gel electrophoresis on a 12% gel with Coomassie staining.   
3.2.4 Determination of the kinetic parameters of the biotransformation of 
testosterone and norethisterone by P450BM3 mutants 
Testosterone and norethisterone incubations were performed in 100 mM potassium 
phosphate buffer (pH 7.4), with 200 nM purified P450BM3 mutants(10). The final 
volume of the incubation was 200 μL, with a substrate concentration of 200 µM. 
The reactions were initiated by addition of an NADPH regenerating system (final 
concentrations of 0.2 mM NADPH, 0.3 mM glucose-6-phosphate and 0.4 U/mL 
glucose-6-phosphate dehydrogenase). The reaction was allowed to proceed for 60 
min at 25 °C and terminated by the addition of 200 μL of ice-cold methanol. 
Precipitated protein was removed by centrifugation (15 min, 14000 g), and the 
supernatant was analyzed by UPLC. Metabolites were separated using a C18 
column (Zorbax Eclipse XDB-C18, 4.6x50 mm, 1.8 μm, Agilent Technologies) 
with a flow rate of 1 mL/min, isocratic 60% B (99% MeOH, 0.8% H2O and 0.2% 
formic acid), 40% A (99% H2O, 0.8% MeOH and 0.2% formic acid) and UV 
detection at 254 nm. 
To determine the kinetic parameters, the ranges where the enzyme activity is linear 
with enzyme concentration and incubation time were first determined. On the basis 
of these experiments (data not shown), the most suitable conditions were chosen 
for the determination of the kinetic parameters. The enzyme concentration was 300 
nM and the incubation time was 10 min; 10 substrate concentrations were used in 
the ranges 20-200 μM for testosterone and 10-250 μM for norethisterone. Specific 
activities were calculated and plotted versus substrate concentration. The data were 
fitted with the Michaelis-Menten equation, using OriginPro8. 
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3.2.5 Determination of coupling efficiency 
To measure the NADPH consumption rate, the P450BM3 mutant (final 
concentration of 200nM) was mixed with 870 μL of 100 mM potassium phosphate 
buffer (pH 7.4) containing 200 μM testosterone or norethisterone in DMSO (final 
concentration of 2%). The reaction was started by adding 200 μM NADPH. 
NADPH consumption was monitored at 340 nm with a Libra S12 Biochrom 
spectrophotometer at 25 °C for 10 min. The NADPH concentration was calculated 
using an ε= 6,200 M-1cm-1(27). 
The coupling efficiency, product formation and substrate consumption were 
quantified by HPLC. The percentage of coupling was determined by the ratio of 
the amount of product formed and the amount of NADPH consumed. 
3.2.6 Preparative-scale biotransformation and isolation of testosterone 
metabolites 
The testosterone metabolites were produced on a preparative scale by large-scale 
incubation with M11 as a biocatalyst. A 50 mL reaction volume containing 250 nM 
M11 mutant, 500 µM testosterone and NADPH regenerating system was prepared 
in 100 mM potassium phosphate buffer (pH 7.4). The reaction was allowed to 
continue for 3 h at 25 °C. The reaction products were extracted by using 3 x 100 
mL dichloromethane. The organic layers were combined and evaporated using a 
rotary evaporator. The dried product was redissolved in 0.5 mL of DMSO and 
injected into a Waters preparative LC system, equipped with an HP liquid handler 
for injection and fractionation, a Waters Xbridge Prep C18-MS (10 x 55 mm, 5 µm 
particles) column and a Waters photodiode array detector. At a flow-rate of 5 
mL/min the following gradient was used: from 0 to 1 min, 100% A (99.95% H2O 
and 0.05% TFA); from 1 to 15 min, linear increase to 60 % B (30% MeOH, 60% 
acetonitrile, 10 % H2O and 0.05% TFA), from 15 to 15.5 min, linear increase to 
100% B; constant for 2 min; and finally a column equilibration time of 2 min with 
100% A. Fractions were collected, triggered by UV absorbance at 210 nm. All 
fractions were evaporated to dryness and redissolved in 550 µL of DMSO-d6 with 
tetramethylsilane for internal referencing in the subsequent NMR analysis. 
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3.2.7 Structural characterisation of testosterone metabolites by NMR 
The chemical structures of the testosterone metabolites formed by M11 were 
determined by a combination of 1D-1H, 1H-1H DQF-COSY, 1H-13C HSQC, 1H-13C 
HMQC, 1H-13C HMBC and 1H-1H NOESY NMR experiments. The experiments 
were acquired on a Varian INOVA 500 MHz spectrometer operating at a 1H 
frequency of 499.85 and a Varian INOVA 600 MHz spectrometer operating at a 1H 
frequency of 599.76 both equipped with a 5 mm probe and operating at 298 K. The 
proton and carbon chemical shifts were referenced to the internal reference TMS 
(proton, δ=0.00ppm; carbon, δ=0.00ppm). Data were processed using 
ACDLabs/SpecManager, version 12.01. 
3.2.8 UV-Vis spectroscopy 
UV-visible spectra were recorded using a Varian Cary 300 UV-visible 
spectrophotometer with a temperature controller. All spectra were recorded at 25 
˚C in quartz cuvettes (10 mm path length), containing 100 mM phosphate buffer 
(pH 7.4). UV-vis spectroscopy was used to determine the concentration of enzyme, 
by measuring the concentration of the CO-reduced complex(26), the spectral 
binding constants (Ks) and the spin states of both M11 and M11A82W. 
Experimental details of the latter two will be discussed below. 
3.2.9 Determination of spectral binding constants by UV-Vis difference 
spectroscopy 
Spectral binding constants (Ks) for both M11 and M11A82W with testosterone 
were determined by UV-Vis difference spectroscopy in a fashion similar to that 
described previously(21, 28). Briefly, different enzyme concentrations were used 
(ranging between 0.5 – 10.0 μM). The enzyme was placed in the sample and 
reference cuvettes. The sample cuvette was titrated with 1 μL aliquots of 10 mM 
testosterone dissolved in DMSO. Subsequently, the reference cuvette was titrated 
with an equal amount of DMSO and this was used for background correction. The 
DMSO concentration was always kept below 2%. After the samples had been 
mixed, the contents of the sample cuvette were allowed to equilibrate for 2 min 
prior to analysis. UV-vis difference spectra were recorded between 350 and 600 
nm. The difference in absorption between 390 nm (peak) and 419 nm (trough) was 
plotted versus the testosterone concentration.  
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The spectral binding constants were determined by fitting the difference in 
absorption according to the formula 
nn
s
n
SK
SAA
][
][*
419390 +
Δ=Δ ∞−       3
where ΔA390
.1 
-419 and ΔA∞   represent the difference in absorption between the peak 
3.2.10 Determination of spin states from UV-Vis spectra 
strate-bound form 
3.2.11 Preparation of NMR samples 
ents contained 50, 100, 150 or 200 µM 
and trough at a specific testosterone concentration [S and a saturating testosterone 
concentration, respectively, Ks is the spectral binding constant of the enzyme-
substrate complex and n is the Hill coefficient. Ks and ΔA∞ were estimated by 
nonlinear curve fitting using OriginPro8.  
 
The heme iron spin state of both M11 and M11A82W in the sub
was determined by deconvoluting absolute UV-Vis spectra. Absolute UV-Vis 
spectra were deconvoluted between 350 and 600 nm with an enzyme concentration 
of 500 nM and a testosterone concentration of 200 µM (concentrations were 
identical to those used for NMR experiments). UV-Vis spectra were deconvoluted 
by using the multiple-Gaussian curve-fitting program available in OriginPro8. Both 
enzymes were deconvoluted by using four components: a low-spin Soret band (419 
nm), a high-spin Soret band (390 nm), δ-bands (~360 nm) and an additional “broad 
shoulder” between 440 and 490 nm, caused by the flavin prosthetic groups(29).  
The samples used for NMR experim
testosterone, added from a DMSO stock solution and 500 nM purified enzyme in 
100 mM phosphate buffer (pH 7.4) with 10% D2O for locking. As a diamagnetic 
control, 200 µM testosterone was dissolved in 100 mM phosphate buffer (pH 7.4). 
Prior to analysis, all samples were flushed with nitrogen to remove possible 
dissolved oxygen, which might influence the relaxation rates. The final volume of 
the NMR tube was 550 µL. 
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3.2.12 T1 relaxation experiments 
The relaxation rate (R1 = 1/T1) experiments were conducted on a Varian Unity 
INOVA600 and a Bruker Avance 600 spectrometer operating at a 1H frequency of 
599.76 MHz using a saturation recovery pulse sequence with water flip back and 
Watergate to suppress the water signal(30). Eight spectra were recorded for each 
sample, with an interpulse delay τ ranging from 0.1 to 10 s. For each spectrum 64 
scans were acquired. The data were processed by using ACDLabs/SpecManager, 
Version 12.01; i.e. zero-filling, line-broadening, phasing, baseline correction and 
peak picking. OriginPro8 was used to determine R1 relaxation rates from the peak 
intensities.  
3.2.13 Deriving distances from R1 relaxation data 
Under fast-exchange conditions, the longitudinal relaxation rate is the weighted 
average of the relaxation rates of the free and bound substrate (R1,f and R1,b, 
respectively)(21): 
bbffobs RpRpR ,1,1,1 ⋅+⋅=        3.2 
where  and  are the fractions of the substrate in the free and bound state, 
respectively. Under the conditions of the present experiment, the substrate 
concentration (50 - 200 µM) is much higher than the protein concentration (0.5 
µM), so .  has a contribution of both paramagnetic and diamagnetic 
relaxation rates (
fp
p
bp
1
R1
≈f bR ,1
b, PD RR ,1,1 += ).  As discussed by Luz and Meiboom(31),  
depends on the relaxation rate caused by the paramagnetic ion ( ) and the 
residence time of a ligand in the active site (τM):    
PR ,1
MR ,1
MM
b
Dbfobs T
pRpRR τ++⋅=− ,1,1,1,1      3.3 
Under fast-exchange conditions, MMT τ>>,1 , so that 
M
M T
R
,1
,1
1=  is: 
bp
D1,bf1,obs1,
M1,
RpRR
R
⋅−−=      3.4 
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M1,R  is related to the proton-heme iron distance (rIS) by using the Solomon-
Bloembergen equation(32): 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
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2
0
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15
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μ h
 
 3.5 
Where, μ0 is the permeability of free space, γI and γS are the gyromagnetic ratio of 
the proton and electron, respectively, S is the spin state of the heme iron (obtained 
from deconvoluting UV-Vis spectra), ωΙ and ωS are the nuclear and electronic 
Larmor frequencies, respectively, rIS is the distance from proton nuclei to the heme 
iron and τc is the correlation time that describes the dipolar interaction between the 
ligand and paramagnetic iron in solution. The correlation time τc mainly originates 
from the electron-spin relaxation time τS and has been estimated previously for 
P450 enzymes(21, 23, 25). The average value of τc reported for P450 enzymes is 
3.0e-10 s and this value was used here. Note that even if the used τc value would be 
different by a factor of 2, this error would result in a systematic over- or 
underestimation of the calculated distances by only 10%(23). The validity of fast 
exchange was confirmed from the observation of a positive temperature 
dependence of R1,obs at five temperatures (288, 293, 298, 303 and 308 K)(22, 23).   
Often,  is calculated via equation 3.4  obsR ,1 , by subtracting the 
relaxation rate caused by the CO-reduced diamagnetic form of the enzyme 
( )(21, 28). However, as noted by Smith et al.(25) and Jacobs et 
al.(33), the diamagnetic relaxation rates were similar in the CO-reduced complex 
and enzyme-free buffer, so the diamagnetic relaxation effect caused by the enzyme 
( ) is extremely small and can be neglected (see the Supporting 
Information). Therefore equation 3.6 was used to calculate : 
MR ,1
b Rp ⋅
DR ,1
from
DfR ,1,1 +
bp ⋅
M,1R
b
fobs
M p
RR
R
)( ,1,1
,1
−=        3.6 
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where         
][
]3450[
netestosteroK
BMPp
d
b +=       3.7 
with  being the dissociation constant of the P450BM3-testosterone complex. dK
In case of multiple orientations,  in Equation 3.5 can be rewritten as: MR ,1
...)( 666,1 +++∝
c
c
b
b
a
a
M r
f
r
f
r
fR       3.8 
with , , , etc., the fractions, and , , , etc. the distances of 
orientations a, b, c, etc., respectively, in the active site.  is therefore 
dominated by the term with the shortest distances. If there is one orientation 
present, i.e. 
af bf cf
1
6
ar
6
br
6
cr
MR ,1
=af , the distances determined for all protons are representative for 
that specific orientation. The calculated distance corresponds to the orientation 
with the proton closest to the heme iron. This also implies that the distances should 
be internally consistent with a single orientation. Therefore, when distances are 
internally inconsistent, this indicates the presence of multiple orientations and 
suggests dynamic binding.  
The  values for each proton were calculated using equations 3.2 to 3.7 with 
 and  as input variables (for the other required parameters, see above). 
To obtain robust and reliable error estimates, we used Monte Carlo simulations(34, 
35) given the complexity of equations 3.2 to 3.7.  For each proton, the distance was 
calculated in 10000 iterations with ,  and spectral binding constant Ks 
values varying in a Gaussian distribution around their means with a width 
determined by  the experimental errors that were determined from at least three 
experiments. From the resulting histograms, the average distances and distance 
error (standard deviation) were determined. 
ISr
obsR ,1 fR ,1
obsR ,1 fR ,1
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3.3 Results 
3.3.1 Identification of testosterone and norethisterone metabolites   
The structures of the testosterone and norethisterone metabolites formed by the 
four enzymes are displayed in Figure 3.1. The structures were determined on the 
basis of a combination of 1D-1H, 1H-1H DQF-COSY, 1H-13C HSQC, 1H-13C 
HMQC, 1H-13C HMBC and 1H-1H NOESY NMR and MS experiments. The 
assignments of the NMR spectra and 1H/13C chemical shifts of 15β-
hydroxytestosterone, 16β-hydroxytestosterone and 2β-hydroxytestosterone are 
consistent with previously published data(36, 37). Details of the 1H and 13C NMR 
spectra are tabulated in the Supporting Information.  Interestingly, the NOESY 
spectrum of 2ß-hydroxytestosterone showed that the A-ring is folded into an 
inverted half-chair conformation, as identified by a strong NOE interaction 
between the proton at position 2α and the proton at position 9, which is consistent 
with the observations of Jacobsen et al.(38). The norethisterone metabolites were 
assigned to 15β-hydroxynorethisterone and 16β-hydroxynorethisterone, as recently 
discussed by de Vlieger et al.(15).  
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Figure 3.1 Chemical structures of testosterone, norethisterone and the monohydroxy 
metabolites formed by the P450BM3 mutants M11, M11A82W, M01 and M01A82W. 
 
3.3.2 Effect of mutation A82W on the regioselectivity of steroid hydroxylation 
To evaluate the ability of this set of mutants to oxidize steroids, incubations were 
first measured at a fixed substrate concentration (200 μM). Figure 3.2 shows the 
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relative amounts of monohydroxy metabolites after incubation of 200 µM 
testosterone and norethisterone in the presence of the four studied mutants of 
P450BM3. In the case of testosterone, three metabolites were produced, 
corresponding to 15β-hydroxytestosterone, 16β-hydroxytestosterone and 2β-
hydroxytestosterone. For both M01 and M11, the major metabolite was 15β-
hydroxytestosterone. Addition of mutation A82W to both M01 and M11 resulted in 
a strong increase in the level of 16β-hydroxylation of testosterone. In the case of 
M01, mutation A82W resulted in an increase in the level of 16β-hydroxylation 
from 22 to 85% of total metabolism. In the case of M11, mutation A82W increased 
the selectivity for 16β-hydroxylation from 25 to 75%. In the case of norethisterone, 
two metabolites were produced corresponding to 15β-hydroxynorethisterone and 
16β-hydroxynorethisterone. As was found with testosterone, mutation A82W 
strongly increased selectivity for 16β-hydroxylation. In M01, mutation A82W 
increased selectivity for 16β-hydroxylation from 42 to 88%; in M11 selectivity for 
16β-hydroxylation increased from 58 to 77%. 
 
 
Figure 3.2 Relative amounts of monohydroxy metabolites of testosterone (A) and 
norethisterone (B) metabolism formed by P450BM3 mutants M11, M11A82W, M01 and 
M01A82W. Metabolites were analyzed by UPLC with UV detection at 254 nm and results 
from triplicate experiments are shown. Quantification is based on LC-UV chromatograms 
assuming that the extinction coefficients of the substrate and the metabolites are similar. 
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3.3.3 Enzyme kinetic characterization of the P450BM3 mutants 
To evaluate whether the strong increase in selectivity for 16β-hydroxylation 
was related to an increase in affinity or catalytic efficiency, we determined 
enzyme kinetic parameters KM and Vmax for all mutants with testosterone 
and norethisterone (Table 3.1).  
 
Table 3.1 Enzyme kinetic parameters of metabolism of testosterone and norethisterone by 
P450BM3 mutants M01, M01A82W, M11 and M11A82W 
  Testosterone Norethisterone 
    KMa Vmaxb Vmax/ KM KMa Vmaxb Vmax/ KM 
M01 15β-OH 52.6 ± 5.5 0.4 ± 0.02 7.8 ± 1.2 63.4 ± 5.6 0.7 ± 0.02 10.7 ± 1.3 
 16β-OH 59.5 ± 3.2 0.2 ± 0.005 3.7 ± 0.3 102.8 ± 11.2 0.8 ± 0.04 7.8 ± 0.9 
 2β-OH 52.3 ± 2.5 0.3 ± 0.004 5.5 ± 0.3    
M01  15β-OH 178.2 ± 30.7 0.7 ± 0.05 3.7 ± 0.9 64.5 ± 9.8 1.2 ± 0.02 18.6 ± 3.1 
A82W 16β-OH 248.1 ± 3.9 8.5 ± 0.12 34.5 ± 1 97.4 ± 4.6 12.7 ± 0.6 130.4 ± 12.3 
 2β-OH 256.7 ± 52.1 0.6 ± 0.05 2.2 ± 0.5    
M11 15β-OH 149.6 ± 20.4 18.2 ± 1.2  121.7 ± 24.6 37.5 ± 4.2 1.1 ± 0.05 29.3 ± 4.6 
 16β-OH 145.1 ± 11.8 7.0 ± 0.27  48.5 ± 5.8 39.5 ± 4.6 1.6 ± 0.07 40.5 ± 6.5 
 2β-OH 224.6 ± 34.5 5.8 ± 0.4 24.9 ± 5.5    
M11 15β-OH 106.7 ± 5.5 2.5 ± 0.06 23.4 ± 1.8 85 ± 12.1 1.2 ± 0.08 14.1 ± 3  
A82W 16β-OH 109.9 ± 13.6 10.2 ± 0.6 92.8 ± 16.9 100.8 ± 6.7 4.8 ± 0.3 47.6 ± 6.1 
 2β-OH 99.6 ± 7.5 0.8 ± 0.03 8.1 ± 0.9    
a KM values are in micromolar  
b Vmax values are in nanomoles of product per minute per nanomole of enzyme 
 
For testosterone, mutation A82W in M01 led to a 4.2 ± 0.8-fold increase in the KM 
values. The Vmax for 16β-hydroxylation increased 42.5 times and the catalytic 
efficiency (Vmax/KM) for 16β-hydroxylation increased 9.3 times. In the case of  
M11, mutation A82W led to a 1.7 ± 0.5-fold decrease in the KM value. The Vmax for 
16β-hydroxylation increased 1.5 times, whereas for 15β-hydroxylation and 2β-
hydroxylation it decreased 7.3 times. The Hill coefficient is never significantly 
different from 1; therefore, cooperativity appears not to take place. In contrast to 
the case for testosterone, no A-ring hydroxylation was found in the case of 
norethisterone.  
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In the case of norethisterone, in M01, mutation A82W did not affect KM values 
significantly. Therefore, the different selectivity was due to a change in Vmax 
values. The Vmax for 16β-hydroxylation increased 15.9-fold. In the case of M11, 
mutation A82W led to a 2.4 ± 0.2-fold increase in the KM value. The Vmax for 16β-
hydroxylation increased 3-fold, while the Vmax for 15β-hydroxylation did not 
change significantly. The KM values for norethisterone are always smaller than for 
testosterone. Therefore, it seems that norethisterone has a higher affinity for the 
enzymes, although the level of product formation is higher for testosterone. 
3.3.4 Determination of Coupling efficiency 
To evaluate the effect of the restriction of active site size on the coupling efficiency 
of the enzymes, the rates of NADPH consumption and product formation were 
measured in the presence of 200 μM testosterone and norethisterone (Figure 3.2).  
For testosterone, mutation A82W in M01 led to a 2.1-fold increase in the level of 
NADPH consumption and to a 6.1-fold increase in the level of product formation. 
Thus, this mutation resulted in a 2.8-fold increase in the coupling efficiency of this 
enzyme. In the case of M11, after mutation A82W had been introduced, levels of 
both NADPH consumption and product formation decreased 2-fold, therefore, the 
coupling efficiency did not change significantly. For norethisterone, mutation 
A82W in M01 led to a 3.4-fold increase in the level of NADPH consumption and a 
16-fold increase in the level of product formation resulting in a 4.6-fold increase in 
coupling efficiency. In the case of M11, mutation A82W did not affect NADPH 
consumption significantly and led to a 1.9-fold increase in the level of product 
formation, which corresponds to a 1.9-fold increased coupling efficiency. 
 
Table 3.2 NADPH consumption rates, product formation rates and coupling efficiencies of 
P450BM3 mutants with testosterone (TST) and norethisterone (NET) 
  NADPH consumption ratea Total product formation rateb Coupling efficiency (%) 
  TST NET TST  NET TST  NET 
M11  22.5 ± 2.2 5.4 ± 0.1 17.1 ± 0.4 2.2 ± 0.04 76 ± 9.2 41 ± 1.6 
M11A82W 10.6 ± 2.7 6.2 ± 1.3 9.2 ± 0.2 4.1 ± 0.1 83.5 ± 8.2 66.9 ± 7.2 
M01  5.4 ± 0.6 4.3 ± 0.2 0.7 ± 0.03 0.6 ± 0.03 13.5 ± 2 14.2 ± 1.3 
M01A82W 11.2 ± 0.06 14.8 ± 0.7 4.3 ± 0.2 9.6 ± 0.04 38.5 ± 1.8 64.7 ± 3.5 
a in nanomoles of NADPH per minute per nanomole of P450BM3 
b in nanomoles per minute per nanomole of BM3 
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3.3.5 Binding affinity and spin state from UV-Vis spectroscopy  
As mentioned above, the A82W mutants of both M11 and M01 produced 
significantly larger amounts of 16β-hydroxytestosterone as well as of 16β-
hydroxynorethisterone. For a more in-depth analysis of the metabolism in terms of 
binding affinity, spin-state determination and orientation of ligand in the heme 
active site, optical binding studies and T1 paramagnetic relaxation NMR studies 
were performed. Testosterone was chosen over norethisterone because it also 
showed changes in 15ß-hydroxylation to 16ß-hydroxylation ratio as well as in D-
ring to A-ring hydroxylation ratio. Its higher solubility also allows for more 
sensitivity in the optical and NMR experiments. In addition, the NMR spectrum of 
testosterone displays a smaller degree of proton resonance overlap than that of 
norethisterone, so that T1 relaxation times can be measured more accurately. 
Although the increase in D-ring selectivity caused by the A82W mutation was 
greater for M01 than for M11, the NMR studies were performed with M11 and 
M11A82W because of their higher coupling efficiency, which suggests a more 
productive mode of binding.  
 
Table 3.3 Characteristics of binding of testosterone to P450BM3 mutants M11 and 
M11A82W 
  Ks (µM)a Hill coefficient High Spin (%)b 
M11 > 450  0.8 ± 0.3 27 
M11A82W 51 ± 4 1.01 ± 0.04 16 
a Spectral binding constant obtained by optical titration experiments (see 3.2 Experimental)  
b In the presence of 500nM enzyme and 200 μM testosterone  
 
Binding of testosterone to both M11 and M11A82Wenzymes resulted in a Type I 
binding spectrum (Figure 3.3) corresponding to a substrate induced low-spin to 
high-spin conversion. The spectral binding constants of testosterone binding to 
M11 and M11A82W and the percentage of high-spin state in the bound form are 
summarized in Table 3.3. For M11A82W a dissociation constant of 51 ± 4 µM 
(Table 3.3) was determined for testosterone with good accuracy thanks to the 
saturation of substrate binding being almost reached. In contrast, when testosterone 
was titrated into M11 no complete enzyme saturation was reached, which is 
indicative of a much higher dissociation constant compared to that of M11A82W. 
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Nevertheless, via a fit of the nonlinear curve, the spectral dissociation constant of 
testosterone binding to M11 was estimated to be > 450 μM. This value lies outside 
the range of testosterone concentrations used in the titration. The highest 
concentration employed was 200 µM and was limited by the solubility of 
testosterone under our conditions. Smith et al.(25) were able to record binding 
spectra for a CYP2D6-mutant with testosterone concentrations ≤ 1.5 mM by 
including 13% DMSO in the medium. However, DMSO concentrations of > 2% 
induced strong spectral changes with our P450BM3 mutants (data not shown), 
consistent with previous observations(39). The percentage of low-spin and high-
spin of the heme iron were determined by deconvolution of the absolute spectra at 
a protein concentration of 500 nM in the presence of 200 µM testosterone. For 
M11A82W, the percentage of the high-spin form was estimated to be 16% (Table 
3.3 and Figure S3.2 of the Supporting Information), while for M11 the high-spin 
content of substrate-bound M11 was estimated to be 27%. In the absence of 
testosterone, the high-spin content was estimated to be around 10% in both 
enzymes.  
 
Figure 3.3 UV-VIS difference spectra of testosterone binding to M11 (A) and M11A82W 
(B) 
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3.3.6 Determination of fast exchange 
Equation 3.4 assumes that MMT τ>>,1
MT ,1
, which means that testosterone should be in 
fast-exchange with M11 and M11A82W. The fact that fast exchange conditions 
hold follows from the following observations.   of the testosterone protons 
increases linearly with an increasing reciprocal temperature in both M11 and 
M11A82W (see 
obsR ,1
Figure S3.1 of the Supporting Information)(22, 23). Titration of 
testosterone into a constant concentration of M11 and M11A82W shows chemical 
shift changes of the methyl resonances (data not shown), which indicates fast-
exchange(40). We further note that the ratio of unbound to bound substrate is 
around 400:1 in our case. Under these conditions, binding affects T1 only if τM is 
not significantly smaller than . As mentioned by Myers et al.(41), a τM value 
of 10-4 s or larger seems unlikely for a substrate under these circumstances. 
 
3.3.7 T1 relaxation and proton-heme iron distances 
The spin-lattice (R1) relaxation rates of testosterone protons were measured in the 
presence and absence of M11 and M11A82W to obtain information about the 
individual proton-heme iron distances in each mutant. Only for the protons for 
which the chemical shift does not overlap with those of other protons can 
relaxation rates be measured. Figure 3.4 shows the assignment of the signals in the 
1D-1H NMR spectrum of testosterone that do not overlap with other signals. For 11 
protons, spread over the rigid testosterone structure, the relaxation rate and thus 
proton-heme iron distances could be determined. Unfortunately, the signals of 
protons H2β and H16β, the sites of 2β- and 16β-hydroxylation, respectively, 
overlapped with those of protons H6β and H11β, respectively, according to the 1H-
13C HSQC-spectrum of testosterone (Figure S3.5 of the Supporting Information). 
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Figure 3.4 1D-1H NMR spectrum of testosterone in aqueous buffer. The resonances used 
for the T1 NMR relaxation experiments are indicated 
 
Table 3.4 shows the relaxation rates for each proton of testosterone in the absence 
and presence of mutants M11 and M11A82W, and the calculated proton-heme iron 
distances. The values presented are averages and standard deviations of at least 
three independent experiments with 200 µM testosterone and 500 nM P450BM3 
mutant. Proton-heme iron distances and their corresponding standard deviations 
were determined by Monte Carlo simulations, in which the experimental errors 
originating from the relaxation rates and binding constants were simulated in a 
Gaussian distribution around their means. 
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Table 3.4. R1 relaxation rates of testosteronea protons in the presence and absence of M11 
and M11A82W and calculated proton-heme iron distances (Å) 
  Ring buffer M11 M11A82W M11 M11A82W 
   R1,f (s-1) b R1,obs (s-1) b R1,obs (s-1) b r (Å) c r (Å) c 
H1α A 1.88 ± 0.04 2.20 ± 0.07 2.19 ± 0.06 6.0 ± 0.2 6.7 ± 0.2 # 
H1ß A 2.11 ± 0.05 2.21± 0.08 2.19 ± 0.05 7.1 ± 0.5 8.2 ± 0.5 # 
H4 A 0.53 ± 0.01 1.26 ± 0.03 1.54 ± 0.02 5.26 ± 0.04 5.53 ± 0.02 # 
H19 A/B 1.27 ± 0.01 1.49 ± 0.01 1.76 ± 0.01 6.4 ± 0.1 6.3 ± 0.1 
H7ß B 1.93 ± 0.05 2.04 ± 0.09 2.26 ± 0.07 6.9 ± 0.5 6.6 ± 0.2 
H12α C 1.90 ± 0.04 2.07 ± 0.09 2.24 ± 0.08 6.5 ± 0.2 6.5 ± 0.2 
H12ß C 1.74 ± 0.03 1.86 ± 0.08 2.22 ± 0.04 6.9 ± 0.4 6.2 ± 0.1 # 
H18 C/D 1.14 ± 0.01 1.37 ± 0.02 1.72 ± 0.01 6.4 ± 0.1 6.1 ± 0.1 # 
H15ß D 1.73 ± 0.04 1.84 ± 0.09 2.11 ± 0.16 7.1 ± 0.5 6.4 ± 0.3 # 
H16α D 1.44 ± 0.05 1.89 ± 0.12 2.23 ± 0.09 5.6 ± 0.3 5.7 ± 0.1 
H17α D 1.11 ± 0.02 1.38 ± 0.05 1.72 ± 0.03 6.2 ± 0.2 6.0 ± 0.1 
a R1 relaxation rates at 200 μM testosterone are shown 
b averages and standard deviations of R1 relaxation rates were determined from three to five 
independent R1 measurements  
c distances and standard deviations were estimated on the basis of Monte Carlo simulations 
considering the standard deviations of R1,obs, R1,f and Kd 
# statistically significant difference in proton-heme iron distances between M11 and 
M11A82W.  
 
As one can see in Figure 3.4, the shortest proton-heme iron distances in M11 are 
for the protons in the A-ring and for protons in the D-ring, while longer distances 
are found for the B- and C-rings. Because it is not possible to derive one specific 
orientation for testosterone that is consistent with all measured distances, the 
binding must be dynamic; i.e. testosterone must bind in multiple orientations in 
M11. In the case of multiple orientations, there is a possibility that each binding 
orientation has a different binding constant(42). The spectral binding constant that 
was obtained by UV-Vis difference spectroscopy does not provide information 
about the affinity of different orientations. By measuring  as a function of 
ligand concentration for each individual proton and by fitting the obtained data 
with equation 3.5, previously independent estimates of the binding constant were 
determined by NMR(42). However, because of the limited solubility of 
obsR ,1
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testosterone and the low signal-to-noise ratios at low testosterone concentrations, 
we could measure the concentration dependence of  only over a small 
concentration range (100 - 200 µM) in the present study. Although this small range 
and small number of data points did not permit the assessment of accurate Kd 
values for each proton, for each mutant no significant differences in the slope of 
the plot  versus testosterone concentration were found for each proton 
(
obsR ,1
obsR ,1
Figure S3.7 of the Supporting Information). This might point to comparable 
binding constants for each orientation. From the significantly different slopes of 
the versus testosterone concentration curves between M11 and M11A82W 
(see 
obsR ,1
Figure S3.7 of the Supporting Information), we can conclude that the affinity 
of testosterone for M11 is much lower than that for M11A82W, consistent with the 
difference in the spectral binding constants. 
Upon comparison of the proton-heme iron distances of testosterone bound to 
M11A82W with those of M11, it is observed that the A-ring protons H1α, H1β and 
H4 show small but significantly increased proton-heme iron distances in the 
M11A82W mutant. In contrast, the distances from D-ring protons H18 and H15β 
to the heme iron were decreased by the A82W mutation. The results of the 
relaxation experiments at the lower testosterone concentrations were consistent to 
those obtained at 200 µM testosterone. Again, the introduction of the A82W 
mutation was shown to cause an increase in the proton-heme iron distances of A-
ring protons and a decrease in the proton-heme iron distances of some D-ring 
protons (data not shown). Because of the better signal-to-noise ratios, Table 3.4 
shows only the results obtained at 200 µM testosterone. 
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3.4 Discussion 
Because hydroxysteroids have important pharmaceutical applications, there is a 
great need for biocatalysts with high activity and regioselectivity in steroid 
hydroxylation. Recently, by laboratory evolution starting from P450BM3 (F87A) 
mutants were obtained with high selectivity for 2β- and 15β-hydroxylation(17). In 
the work presented here, we present two novel P450BM3 enzymes, M01A82W 
and M11A82W, which can catalyze regioselective hydroxylation of steroids at 
position 16β. The importance for modification of steroids at this position has been 
discussed previously by Laplante et al.(43) and Vicker et al.(44).  
Huang et al.(18) previously showed that substitution of alanine 82 in wild-type 
P450BM3 with the larger and more hydrophobic amino acids, tryptophan and 
phenylalanine, improves binding affinity and KM for long-chain fatty acids by 
orders of magnitude. In this study, we demonstrate that substitution of alanine 82 
with tryptophan in P450BM3 mutants M01 and M11 results in improved 
regioselectivity and catalytic efficiency of testosterone hydroxylation. The binding 
affinity of testosterone for M11A82W is significantly higher than its binding 
affinity for M11 (Table 3.3), which might be explained by the addition of a 
hydrophobic interaction between testosterone and the tryptophan at position 82. A 
more efficient exclusion of water from the active site by the stronger substrate-
enzyme interaction might also explain the increased coupling efficiency of the 
A82W mutants (Table 3.2). Uncoupling of the catalytic cycle of P450s can occur 
when mutations are introduced into the active site of P450 or in the presence of 
non-native substrates(45), leading to the formation of reactive oxygen species and 
rapid enzyme inactivation(8). Interestingly, the recently published P450BM3 
mutants with high selectivity for 2ß- and 15ß-hydroxylation of testosterone also 
contained substitutions at position 82, including the A82F(17). However, only 
small amounts of 16ß-hydroxytestosterone were found. In this study, mutations at 
position 82 were always combined with mutations at position 78, because this 
combination was expected to act synergistically. Therefore, the simultaneous 
mutation at position 78 might explain the preference for 15ß-hydroxylation. 
T1 NMR relaxation experiments were performed to investigate whether mutation 
A82W leads to changes in proton-heme iron distances that might reflect differences 
in the orientation and dynamics of testosterone in the active sites of M11 and 
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M11A82W. Using the same approach, Smith et al.(25) previously studied the 
orientation of binding of testosterone to a CYP2D6 mutant that had acquired the 
ability to catalyze testosterone hydroxylation by an F483I mutation. In this study, 
first the proton resonances of testosterone were assigned on the basis of DQF-
COSY, 1H-13C HSQC, 1H-1H NOESY and 1D-1H NMR spectra.  All assignments 
were consistent with those of Kirk et al. (37).  On the basis of our assignments, we 
conclude that a number of resonances were incorrectly assigned by Smith et al. 
(25), as detailed in the Supporting Information. In particular, the signals of the 
protons at positions 2β and 16β which are two of the sites of hydroxylation by 
BM3 mutants, appeared to overlap with the resonances of other protons, excluding 
the possibility of determining relaxation rates for these protons. 
As shown in Table 3.4, for M11 the shortest proton-heme iron distances are 
obtained for protons located in the A- and D-rings (H1α, H4 and H16α). The fact 
that it is not possible to assign a specific orientation of testosterone in M11 that is 
consistent with all measured distances implies that the binding must be dynamic; 
i.e., testosterone is able to bind in multiple orientations. The distance data, which 
are well spread over the rigid testosterone, appear to be consistent with two classes 
of orientations of testosterone in the M11 active site, namely a group of 
orientations with the A-ring closest to the heme iron and a group of orientations 
with the D-ring closest to the heme iron. Also, in the case of M11A82W, the 
distances imply the presence of multiple orientations and dynamics involved in 
binding. Significant differences in testosterone orientation were found upon 
comparison of M11A82W with M11, as visualized in Figure 3.5. In M11A82W, 
protons H1α, H1ß and H4 moved farther from the heme iron, whereas H12ß, H15ß 
and H18ß moved closer to the heme iron.  
Although the change in substrate orientation is mainly deduced by changes in 
distances of protons that are not hydroxylated, the changes are consistent with the 
increased selectivity for D-ring hydroxylation and reduced selectivity for A-ring 
hydroxylation by M11A82W. The decrease in 15ß-hydroxylation in the M11A82W 
mutant relative to that in M11 (Figure 3.2) might be explained by an orientation of 
the D-ring in which H16ß is able to approach the heme iron significantly closer 
than H15ß. Alternatively, the C-H16ß bond might orient in a more favorable 
position for abstraction of hydrogen by the reactive FeO species: a linear 
arrangement of C-H-O is considered a typical feature in the C-H-bond activation 
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by FeO species which precedes aliphatic hydroxylation(46). In both cases, H16β 
will be the preferred site of hydroxylation at the expense of H15β hydroxylation. 
Unfortunately, it was not possible to determine the difference in distances between 
the heme iron and the H15ß and H16ß protons, because the signal of the latter 
proton overlaps with that of proton H11ß. 
 
Figure 3.5 Differences in distances for binding of testosterone binding to M11 and 
M11A82W. The protons for which proton-heme iron distances were derived are colored 
according to the difference in distance (see the legend). The directly attached carbon and C-
H bond are colored like the proton. Protons for which no proton-heme iron distance could 
be derived are colored white. A negative difference in distance (reddish) means a shorter 
proton-heme iron distance in M11A82W than in M11. A positive difference in distance 
(blueish) means a longer proton-heme iron distance in M11A82W than in M11.  
  
From the distance data, it can be seen that the average proton-heme iron distances 
of testosterone in M11 and M11A82W are 6.3Å, while the shortest distances are 
~5.3Å. A distance of <4Å is considered to be necessary to allow hydrogen 
abstraction(47). However, it should be realized that the proton-heme iron distances 
in Table 3.4 represent binding of testosterone to the initial ferric enzyme-substrate 
complexes that do not necessarily represent the orientation of testosterone in the 
oxygenated ferrous form of P450BM3. It has been shown previously that fatty 
acids bind P450BM3 enzymes via a two-step binding process, with initial binding 
to a site distant from the heme iron and movement closer to the heme iron upon 
iron reduction(47). Nonflexible compounds like codeine and testosterone were 
considered to bind via a one-step binding mechanism to CYP2D6 (class I 
P450)(22, 50). The question of whether non-flexible ligands, like steroids, bind in 
P450BM3 enzymes via a two-step binding mechanism or directly to the proximal 
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position then arises. The average distances and shortest distances for binding of 
testosterone to M11 and M11A82W indicate that testosterone binds distant in the 
nonreduced form in both enzymes, similar to fatty acids binding to nonreduced 
P450BM3(21). Thus, it is most likely that steroids bind to P450BM3 enzymes via a 
two-step binding mechanism.  
In summary, we showed that applying substitution A82W to P450BM3 mutants 
M01 and M11 improves regioselective hydroxylation of norethisterone and 
testosterone at position 16ß. This mutation improved both binding affinity and 
coupling efficiency, thereby strongly improving the catalytic activity. As shown by 
T1 paramagnetic relaxation NMR, this single mutation appears to change the 
orientation of testosterone in the M11A82W mutant as compared to the orientation 
in M11. Testosterone is oriented in M11 with both the A- and D-rings closest to the 
heme iron, whereas testosterone is mainly oriented with its D-ring closest to the 
heme iron in the M11A82W mutant which might explain its increased selectivity 
for D-ring hydroxylation. 
 
Ard Kolkman 125
Chapter 3   
3.5 References 
 
1. Guengerich, F. P. (2001) Common and uncommon cytochrome P450 reactions 
related to metabolism and chemical toxicity, Chem Res Toxicol 14, 611-650. 
2. Guengerich, F. P. (2002) Cytochrome P450 enzymes in the generation of 
commercial products, Nat Rev Drug Discov 1, 359-366. 
3. Bernhardt, R. (2006) Cytochromes P450 as versatile biocatalysts, J Biotechnol 
124, 128-145. 
4. Urlacher, V., and Schmid, R. D. (2002) Biotransformations using prokaryotic 
P450 monooxygenases, Curr Opin Biotechnol 13, 557-564. 
5. Sawayama, A. M., Chen, M. M., Kulanthaivel, P., Kuo, M. S., Hemmerle, H., and 
Arnold, F. H. (2009) A panel of cytochrome P450 BM3 variants to produce drug 
metabolites and diversify lead compounds, Chemistry 15, 11723-11729. 
6. Fernandes, P., Cruz, A., Angelova, B., Pinheiro, H. M., and Cabral, J. M. S. 
(2003) Microbial conversion of steroid compounds: recent developments, Enzyme 
Microb Tech 32, 688-705. 
7. Agematu, H., Matsumoto, N., Fujii, Y., Kabumoto, H., Doi, S., Machida, K., 
Ishikawa, J., and Arisawa, A. (2006) Hydroxylation of testosterone by bacterial 
cytochromes P450 using the Escherichia coli expression system, Biosci Biotechnol 
Biochem 70, 307-311. 
8. Munro, A. W., Leys, D. G., McLean, K. J., Marshall, K. R., Ost, T. W., Daff, S., 
Miles, C. S., Chapman, S. K., Lysek, D. A., Moser, C. C., Page, C. C., and Dutton, 
P. L. (2002) P450 BM3: the very model of a modern flavocytochrome, Trends 
Biochem Sci 27, 250-257. 
9. Peters, M. W., Meinhold, P., Glieder, A., and Arnold, F. H. (2003) Regio- and 
enantioselective alkane hydroxylation with engineered cytochromes P450 BM-3, J 
Am Chem Soc 125, 13442-13450. 
10. Lussenburg, B. M. A., Babel, L., Vermeulen, N. P. E., and Commandeur, J. N. M. 
(2005) Evaluation of alkoxyresorufins as fluorescent substrates for high-
throughput screening of cytochrome P450BM3 and site-directed mutants, Drug 
Metab Rev 37, 20-21. 
11. Lewis, J. C., Mantovani, S. M., Fu, Y., Snow, C. D., Komor, R. S., Wong, C. H., 
and Arnold, F. H. (2010) Combinatorial Alanine Substitution Enables Rapid 
Optimization of Cytochrome P450(BM3) for Selective Hydroxylation of Large 
Substrates, Chembiochem 11, 2502-2505. 
12. Lewis, J. C., Bastian, S., Bennett, C. S., Fu, Y., Mitsuda, Y., Chen, M. M., 
Greenberg, W. A., Wong, C. H., and Arnold, F. H. (2009) Chemoenzymatic 
elaboration of monosaccharides using engineered cytochrome P450BM3 
demethylases, Proc Natl Acad Sci U S A 106, 16550-16555. 
13. van Vugt-Lussenburg, B. M., Damsten, M. C., Maasdijk, D. M., Vermeulen, N. P., 
and Commandeur, J. N. (2006) Heterotropic and homotropic cooperativity by a 
drug-metabolising mutant of cytochrome P450 BM3, Biochem Biophys Res 
Commun 346, 810-818. 
14. van Vugt-Lussenburg, B. M., Stjernschantz, E., Lastdrager, J., Oostenbrink, C., 
Vermeulen, N. P., and Commandeur, J. N. (2007) Identification of critical residues 
in novel drug metabolizing mutants of cytochrome P450 BM3 using random 
mutagenesis, J Med Chem 50, 455-461. 
Ard Kolkman 126 
                                                                  Regioselectivity of steroid hydroxylation 
15. de Vlieger, J. S., Kolkman, A. J., Ampt, K. A., Commandeur, J. N., Vermeulen, N. 
P., Kool, J., Wijmenga, S. S., Niessen, W. M., Irth, H., and Honing, M. (2010) 
Determination and identification of estrogenic compounds generated with 
biosynthetic enzymes using hyphenated screening assays, high resolution mass 
spectrometry and off-line NMR, J Chromatogr B Analyt Technol Biomed Life Sci 
878, 667-674. 
16. Damsten, M. C., van Vugt-Lussenburg, B. M. A., Zeldenthuis, T., de Vlieger, J. S. 
B., Commandeur, J. N. M., and Vermeulen, N. P. E. (2008) Application of drug 
metabolising mutants of cytochrome P450BM3 (CYP102A1) as biocatalysts for 
the generation of reactive metabolites, Chem-Biol Interact 171, 96-107. 
17. Oliver, C. F., Modi, S., Primrose, W. U., Lian, L. Y., and Roberts, G. C. K. (1997) 
Engineering the substrate specificity of Bacillus megaterium cytochrome P-450 
BM3: hydroxylation of alkyl trimethylammonium compounds, Biochem J 327, 
537-544. 
18. Huang, W. C., Westlake, A. C., Marechal, J. D., Joyce, M. G., Moody, P. C., and 
Roberts, G. C. (2007) Filling a hole in cytochrome P450 BM3 improves substrate 
binding and catalytic efficiency, J Mol Biol 373, 633-651. 
19. Vottero, E., Rea, V., Lastdrager, J., Vermeulen, N.P.E., Commandeur J.N.M. Role 
Of Residue 87 In Substrate- And Regioselectivity Of Drug Metabolizing 
Cytochrome P450 CYP102A1 M11. Unpublished experiments. 
20. Yao, H., McCullough, C. R., Costache, A. D., Pullela, P. K., and Sem, D. S. 
(2007) Structural evidence for a functionally relevant second camphor binding site 
in P450cam: Model for substrate entry into a P450 active site, Proteins 69, 125-
138. 
21. Modi, S., Primrose, W. U., Boyle, J. M. B., Gibson, C. F., Lian, L. Y., and 
Roberts, G. C. K. (1995) Nmr-Studies of Substrate-Binding to Cytochrome-P-450 
(Bm3) - Comparisons to Cytochrome-P-450 (Cam), Biochemistry-Us 34, 8982-
8988. 
22. Regal, K. A., and Nelson, S. D. (2000) Orientation of caffeine within the active 
site of human cytochrome P450 1A2 based on NMR longitudinal (T-1) relaxation 
measurements, Arch Biochem Biophys 384, 47-58. 
23. Cameron, M. D., Wen, B., Allen, K. E., Roberts, A. G., Schuman, J. T., Campbell, 
A. P., Kunze, K. L., and Nelson, S. D. (2005) Cooperative binding of midazolam 
with testosterone and alpha-naphthoflavone within the CYP3A4 active site: A 
NMR T-1 paramagnetic relaxation study, Biochemistry-Us 44, 14143-14151. 
24. Oliver, C. F., Modi, S., Sutcliffe, M. J., Primrose, W. U., Lian, L. Y., and Roberts, 
G. C. K. (1997) A single mutation in cytochrome P450 BM3 changes substrate 
orientation in a catalytic intermediate and the regiospecificity of hydroxylation, 
Biochemistry-Us 36, 1567-1572. 
25. Smith, G., Modi, S., Pillai, I., Lian, L. Y., Sutcliffe, M. J., Pritchard, M. P., 
Friedberg, T., Roberts, G. C., and Wolf, C. R. (1998) Determinants of the 
substrate specificity of human cytochrome P-450 CYP2D6: design and 
construction of a mutant with testosterone hydroxylase activity, Biochem J 331 ( 
Pt 3), 783-792. 
26. Omura, T., and Sato, R. (1964) Carbon Monoxide-Binding Pigment of Liver 
Microsomes .I. Evidence for Its Hemoprotein Nature, J Biol Chem 239, 2370-
2378. 
27. Truan, G., and Peterson, J. A. (1998) Thr268 in substrate binding and catalysis in 
P450BM-3, Arch Biochem Biophys 349, 53-64. 
Ard Kolkman 127
Chapter 3   
28. Hummel, M. A., Gannett, P. M., Aguilar, J., and Tracy, T. S. (2008) Substrate 
proton to heme distances in CYP2C9 allelic variants and alterations by the 
heterotropic activator, dapsone, Arch Biochem Biophys 475, 175-183. 
29. Li, H. Y., Darwish, K., and Poulos, T. L. (1991) Characterization of Recombinant 
Bacillus-Megaterium Cytochrome-P-450bm-3 and Its 2 Functional Domains, J 
Biol Chem 266, 11909-11914. 
30. Liu, M. L., Mao, X. A., Ye, C. H., Huang, H., Nicholson, J. K., and Lindon, J. C. 
(1998) Improved WATERGATE pulse sequences for solvent suppression in NMR 
spectroscopy, J Magn Reson 132, 125-129. 
31. Luz, Z., and Meiboom, S. (1964) Proton Relaxation in Dilute Solutions of 
Cobalt(2) + Nickel)2) Ions in Methanol + Rate of Methanol Exchange of 
Solvation Sphere, J Chem Phys 40, 2686-&2692. 
32. Solomon, I., and Bloembergen, N. (1956) Nuclear Magnetic Interactions in the Hf 
Molecule, J Chem Phys 25, 261-266. 
33. Jacobs, R. E., Singh, J., and Vickery, L. E. (1987) Nmr-Studies of Cytochrome-P-
450scc - Effects of Steroid Binding on Water Proton Access to the Active-Site of 
the Ferric Enzyme, Biochemistry-Us 26, 4541-4545. 
34. Bevington (1992) Data reduction and error analysis for the pysical sciences, 
McGraw-Hill, London. 
35. Press, W. H. (2007) Numerical Recipes: The Art of Scientific Computing, 
Cambridge University Press Chapter 7 Random numbers. 
36. Mahato, S. B., and Mukherjee, A. (1984) Microbial Transformation of 
Testosterone by Aspergillus-Fumigatus, J Steroid Biochem 21, 341-342. 
37. Kirk, D. N., Toms, H. C., Douglas, C., White, K. A., Smith, K. E., Latif, S., and 
Hubbard, R. W. P. (1990) A Survey of the High-Field H-1-Nmr Spectra of the 
Steroid-Hormones, Their Hydroxylated Derivatives, and Related-Compounds, J 
Chem Soc Perk T 2, 1567-1594. 
38. Jacobsen, N. E., Kover, K. E., Murataliev, M. B., Feyereisen, R., and Walker, F. 
A. (2006) Structure and stereochemistry of products of hydroxylation of human 
steroid hormones by a housefly cytochrome P450 (CYP6A1), Magn Reson Chem 
44, 467-474. 
39. Roccatano, D., Wong, T. S., Schwaneberg, U., and Zacharias, M. (2005) 
Structural and dynamic properties of cytochrome P450BM-3 in pure water and in 
a dimethylsulfoxide/water mixture, Biopolymers 78, 259-267. 
40. Jardetzky, O., and Roberts, G. C. K. (1981) NMR in Molecular Biology, Academic 
Press New York. 
41. Myers, T. G., Thummel, K. E., Kalhorn, T. F., and Nelson, S. D. (1994) Preferred 
Orientations in the Binding of 4'-Hydroxyacetanilide (Acetaminophen) to 
Cytochrome-P450 1a1 and 2b1 Isoforms as Determined by C-13-Nmr and N-15-
Nmr Relaxation Studies, J Med Chem 37, 860-867. 
42. Modi, S., Gilham, D. E., Sutcliffe, M. J., Lian, L. Y., Primrose, W. U., Wolf, C. 
R., and Roberts, G. C. K. (1997) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as 
a substrate of cytochrome P450 2D6: Allosteric effects of NADPH-cytochrome 
P450 reductase, Biochemistry-Us 36, 4461-4470. 
43. Laplante, Y., Cadot, C., Fournier, M. A., and Poirier, D. (2008) Estradiol and 
estrone C-16 derivatives as inhibitors of type 1 17 beta-hydroxysteroid 
dehydrogenase: Blocking of ER+ breast cancer cell proliferation induced by 
estrone, Bioorgan Med Chem 16, 1849-1860. 
Ard Kolkman 128 
                                                                  Regioselectivity of steroid hydroxylation 
44. Vicker, N., Lawrence, H. R., Allan, G. M., Bubert, C., Smith, A., Tutill, H. J., 
Purohit, A., Day, J. M., Mahon, M. F., Reed, M. J., and Potter, B. V. L. (2006) 
Focused libraries of 16-substituted estrone derivatives and modified E-ring 
steroids: Inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1, 
Chemmedchem 1, 464-481. 
45. Loida, P. J., and Sligar, S. G. (1993) Engineering Cytochrome-P-450 (Cam) to 
Increase the Stereospecificity and Coupling of Aliphatic Hydroxylation, Protein 
Eng 6, 207-212. 
46. Kamachi, T., and Yoshizawa, K. (2003) A theoretical study on the mechanism of 
camphor hydroxylation by compound I of cytochrome P450, J Am Chem Soc 125, 
4652-4661. 
47. Modi, S., Sutcliffe, M. J., Primrose, W. U., Lian, L. Y., and Roberts, G. C. K. 
(1996) The catalytic mechanism of cytochrome P450 BM3 involves a 6 angstrom 
movement of the bound substrate on reduction, Nat Struct Biol 3, 414-417. 
48. Cavanagh, J., Fairbrother, W. J., Palmer III, A. G., Rance, M., and Skelton, N. J. 
(2007) Protein NMR spectroscopy - Principles and practice, London, England. 
49. Lide, D. R. (1995) Handbook of Chemistry and Physics, 75th edition, London, 
England. 
 
 
 
 
 
Ard Kolkman 129
Chapter 3   
3.6 Supporting Information 
 
3.6.1 1H and 13C chemical shift of testosterone metabolites of P450BM3 
mutants 
15β-hydroxy testosterone: 1H NMR (500 MHz, DMSO-d6) δ ppm: 0.62 – 0.70 (m, 1H, 14α) 
0.84 – 0.96 (m, 6H, 9α, 18β, 7α, 12α) 1.16 (s, 1H, 19β) 1.29 – 1.40 (m, 1H, 11β) 1.39 – 
1.45 (m, 1H, 16β) 1.45 – 1.53 (m, 1H, 11α) 1.55 – 1.65 (m, 1H, 1α) 1.65 – 1.73 (m, 1H, 
12β) 1.81 – 1.90 (m, 1H, 8β) 1.94 – 2.01 (m, 1H, 1β) 2.08 – 2.13 (m, 1H, 7β) 2.12 – 2.20 
(m, 1H, 2α) 2.20 – 2.28 (m, 1H, 6α) 2.27 – 2.34 (m, 1H, 16α) 2.34 – 2.40 (m, 1H, 6β) 2.39 
– 2.46 (m, 1H, 2β) 3.27 – 3.34 (m, 1H, 17α) 3.93 – 3.99 (m, 1H, 15α) 5.61 – 5.65 (m, 1H, 
4) 13C NMR (125 MHz, DMSO-d6) δ ppm: 13.5 (C18) 16.8 (C19) 20.1 (C11) 30.5 (C7) 
31.0 (C8) 32.0 (C6) 33.5 (C2) 35.2 (C1) 37.5 (C12) 42.9 (C16) 53.8 (C9) 54.8 (C14) 67.0 
(C15) 79.5 (C17) 123.0 (C4) 
 
16β-hydroxy testosterone: 1H NMR (500 MHz, DMSO-d6) δ ppm: 0.69 – 0.76 (m, 1H, 14α) 
0.75 (s, 3H, 18β) 0.84 – 0.92 (m, 1H, 9α) 0.89 – 0.97 (m, 1H, 7α) 0.98 – 1.05 (m, 1H, 12α) 
1.08 – 1.15 (m, 1H, 15β) 1.15 (s, 3H, 19β) 1.32 – 1.41 (m, 1H, 11β) 1.46 – 1.53 (m, 1H, 
11α) 1.54 – 1.63 (m, 2H, 1α, 8β) 1.69 – 1.74 (m, 1H, 12β) 1.76 – 1.82 (m, 1H, 7β) 1.93 – 
1.99 (m, 1H, 1β) 2.03 – 2.09 (m, 1H, 15α) 2.11 – 2.18 (m, 1H, 2α) 2.21 – 2.27 (m, 1H, 6α) 
2.34 – 2.42 (m, 1H, 2β) 2.38 – 2.44 (m, 1H, 6β) 3.13 – 3.19 (d, 1H, 17α) 3.88 – 3.96 (m, 
1H, 16α) 5.60 – 5.66 (m, 1H, 4) 13C NMR (125 MHz, DMSO-d6) δ ppm: 12.0 (C18) 16.7 
(C19) 19.9 (C11) 31.2 (C7) 31.8 (C6) 33.5 (C2) 34.4 (C8) 34.8 (C15) 34.9 (C1) 36.7 (C12) 
46.3 (C14) 53.4 (C9) 68.4 (C16) 79.7 (C17) 123.0 (C4) 
 
2β-hydroxy testosterone: 1H NMR (500 MHz, DMSO-d6) δ ppm: 0.67 (s, 3H, 18β) 0.86 – 
0.95 (m, 2H, 7α, 14α) 0.99 – 1.08 (m, 1H, 12α) 1.14 (s, 3H, 19β) 1.15 – 1.21 (m, 1H, 15β) 
1.19 – 1.26 (m, 1H, 9β) 1.29 – 1.38 (m, 1H, 16β) 1.36 – 1.45 (m, 1H, 11β) 1.43 – 1.51 (m, 
1H, 15α) 1.55 – 1.67 (m, 3H, 8β, 11α, 1α) 1.72 – 1.79 (m, 1H, 12β) 1.79 – 1.86 (m, 1H, 
16α) 1.81 – 1.90 (m, 1H, 7β) 2.02 – 2.10 (m, 1H, 1β) 2.16 – 2.25 (m, 1H, 6α) 2.39 – 2.45 
(m, 1H, 6β) 3.40 – 3.48 (m, 1H, 17α) 3.94 – 4.02 (m, 1H, 2α) 5.62 – 5.67 (m, 1H, 4) 13C 
NMR (125 MHz, DMSO-d6) δ ppm: 11.3 (C18) 21.6 (C11) 21.9 (C19) 22.9 (C15) 29.8 
(C16) 31.9 (C6) 33.5 (C7) 35.1 (C8) 36.0 (C12) 40.8 (C1) 49.9 (C14) 50.7 (C9) 68.0 (C2) 
79.6 (C17) 119.8 (C4) 
 
3.6.2 Rationalization of the low contribution of diamagnetic relaxation times 
In the experimental section,  is said to be much smaller than  and is 
therefore negligible. In this paragraph, the proton longitudinal relaxation rate of 
testosterone bound to diamagnetic P450BM3 will be calculated theoretically to 
confirm the estimation p
DbRp ,1
DR ,1
fR ,1
fb R ,1<< . The longitudinal relaxation rate R1 
depends, amongst others, on the rotational correlation time ( Rτ ) of a molecule. A 
small molecule (testosterone) that binds towards a large molecule (P450BM3) will 
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obtain approximately the same rotational correlation time as the large molecule and 
hence there is a change in its R1 relaxation rate. The main relaxation mechanism for 
protons bound to carbon is the dipolar relaxation mechanism. A theoretical 
derivation of the longitudinal R1 dipolar relaxation rate, based on Cavanaugh(48), 
is given below. First, the effects of 1H-13C dipolar relaxation on the proton 
relaxation rates will be calculated, after which the effects 1H-1H dipolar relaxation 
will be shown. 
))(6)()(6)(3)((*
4
00
1 CHCHCHCCH JJJJJ
dR ωωωωωωωωω ++−−+++−=   S3.1 
Where, 6222
2
0
00 4
−⎟⎠
⎞⎜⎝
⎛= CHCH rd γγπ
μ h  and 
)(15
2)( 22
R
RJ τω
τω +=  
0μ  is the permeability of free space, h  is the reduced plank constant,  and  
are the gyromagnetic ratios of the 1H and 13C spin respectively,  is the C-H 
bond length, 
Hγ Cγ
CHr
Hω  and Cω  are the 1H and 13C Larmor frequencies respectively and 
 is the rotational correlation time of the molecule which can be estimated 
theoretically for approximately spherical globular proteins:  
Rτ
Tk
r
B
Hw
R 3
4 3πητ =         S3.2 
Where, wη is the viscosity of the solvent (0.89mPa·s(49)), kB is the Boltzmann 
constant, T is the temperature (K) and  is the effective hydrodynamic radius of a 
protein which can be estimated from the formula: 
Hr
w
A
r
H rN
MVr += 3/1)
4
3( π        S3.3 
Where V is the specific volume of the protein (0.73 cm3/g), NA is Avogadro’s 
number, Mr is the molecular mass of the protein and rw is the hydration layer. 
Filling these numbers gives an  of 35.2 Å and a rotational correlation time Hr Rτ  
of 41 ns. 
R1 can be calculated by using Equation S3.1: R1 = 0.039 s-1. Since testosterone is in 
fast exchange with M11A82W, the observed proton R1 relaxation rate in the 
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diamagnetic form is the weighted average of the R1 relaxation rate of testosterone 
free in solution and bound to M11A82W: 
bbffD RpRpR ,1,1,1 +=        S3.4 
fp
fR ,1
 = fraction free in solution,  = fraction bound to protein,  is the R1 
relaxation rate of testosterone protons free in solution and  is the R1 relaxation 
time of testosterone protons bound to the protein, as calculated above. The average 
 is 1.78s-1 (see Table 3.4),  = 0.039 s-1, 
bp fR ,1
.0
bR ,1
bR ,1 99796=fp  and 
. 00204.0=bp
039.0*00204.078.1*99796.0,1 +=DR  
The second term is much smaller than the first term. Therefore,  is much 
smaller than  and the contribution of the 1H-13C dipole relaxation of 
testosterone protons bound to M11A82W can be neglected. In addition, the 1H-1H 
dipolar relaxation contributes as well; a similar calculation can be performed as 
shown above. With the difference that the dipole relaxation mechanism is 1H-1H 
and not 1H-13C. Therefore, , 
bbRp ,1
ff Rp ,1
Cγ Cω  and  are replaced in the equations by , CHr Hγ
Hω  and , respectively. In a CH2 group the protons are closest to each other: 
1.82Å. Equations S3.1 to S3.3 can be used to calculate  caused by the 1H-1H 
dipolar relaxation mechanism, yielding an  of 0. 016s-1. This relaxation rate is 
of course also a weighted average of the free and bound testosterone, so the 1H-1H 
dipolar relaxation mechanism is also negligible compared to . 
HHr
bR ,1
p
b,R1
ff R ,1
In conclusion, the diamagnetic relaxation rate of testosterone can be obtained by 
measuring its relaxation time in buffer. The diamagnetic relaxation time caused by 
testosterone bound to M11A82W is extremely small and can be neglected. 
 
3.6.3 Demonstration of fast exchange 
The validity of fast exchange was confirmed from the observation of a positive 
temperature dependence of R1,obs at five temperatures (288, 293, 298, 303 and 308 
K)(22, 23), see Figure S3.1. 
Ard Kolkman 132 
                                                                  Regioselectivity of steroid hydroxylation 
 
Figure S3.1 Temperature dependence of R1,obs of individual protons of testosterone in M11 
(right graph) and M11A82W (left graph). Concentration of the P450BM3 mutants was 0.5 
μM; concentration of testosterone was 200 μM. 
 
3.6.4 Deconvolution of absolute UV-Vis spectra 
Figure S3.2 shows deconvoluted UV-Vis spectra of M11 and M11A82W in the 
presence of 200 μM testosterone. Deconvolution is used to estimate the 
percentages low- and high-spin heme iron.  
 
Figure S3.2 Absolute absorbance spectra of M11 and M11A82W with testosterone and 
deconvolution. Concentration of the P450BM3 mutants was 0.5 μM; concentration of 
testosterone was 200 μM. 
 
3.6.5 Correction of the assignment of 1H-NMR spectra of testosterone as 
published by Smith et al.(25) 
In the present study some differences were observed when comparing our 
experimental NMR spectra with those published by Smith et al.(25). After trying to 
reproduce the 1D-1H NMR spectrum of smith et al. with exactly the same buffer 
conditions, testosterone concentration, temperature and spectrometer frequency 
(600MHz), the spectrum shown in Figure S3.3 was produced.  
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Figure S3.3 Reproduction of the 1D-1H NMR spectrum of testosterone, as measured under 
exactly the same conditions as the 1D-1H NMR spectrum published by Smith et al.  
 
There are some clear differences when comparing this spectrum with the spectrum 
published by Smith et al. Several multiplets appeared to have significantly different 
chemical shifts. After repeated measurements in different solvents, we concluded 
that the spectrum shown by Smith et al. most probably was acquired in pure 
DMSO-d6 (Figure S3.4). 
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Figure S3.4 1D-1H NMR spectrum of testosterone in DMSO-d6 
 
Based on our 1H-13C HSQC spectrum (Figure S3.5), we also conclude that some of 
the assignments given by Smith et al. are incorrect. It can be seen that the multiplet 
at ~2.4 ppm, assigned by Smith et al. to 2α and 2β, consists of 2 proton nuclei 
which are not attached to the same carbon. The assignment of these protons to 2α 
and 2β is therefore not correct. The same holds for the two resonances at ~2.2 ppm. 
Smith et al. assigned these multiplets to 6α and 6β, whereas these protons are not 
attached to the same carbon, as can be seen in the HSQC spectrum. Moreover, the 
multiplet at ~1.95ppm is assigned by Smith et al. to 16β and 1β. The HSQC 
spectrum in Figure S3.5 shows that this multiplet consists of one single proton and 
not 2 protons, as suggested by Smith et al. The assignment of each correlation to 
individual protons in Figure S3.5 is based on the combined 1H-13C HMBC, 1H-1H 
DQF-COSY, 1H-1H NOESY, 1H-13C HSQC and 1D-1H NMR experiments.  
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Figure S3.5 Assigned 1H-13C HSQC spectrum of testosterone in DMSO. The region 
between 0.6 and 2.45 ppm (proton chemical shift) is shown. 
 
3.6.6 Monte Carlo simulations 
Monte Carlo simulations were used to estimate proton-heme iron distances and 
their corresponding standard deviations, in which the experimental errors 
originating from the relaxation rates and binding constants were simulated in a 
Gaussian distribution around their means. As an example, Monte Carlo simulations 
for H18, H1α and H16α are shown in Figure S3.6. 
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Figure S3.6 Examples of the Monte Carlo simulations used to estimate proton-heme iron 
distances and standard deviations for individual testosterone protons (H18, H16α and H1α). 
Results are shown for M11 (A) and M11A82W (B). 
 
3.6.7 Concentration dependence of R1,obs of testosterone in M11 and 
M11A82W  
The relaxation rates of testosterone in presence of 0.5 μM M11 and M11A82W 
(R1,obs) were measured at three ligand concentrations (100, 150 and 200 μM). 
Higher concentrations could not be reached due to the limited solubility of 
testosterone. Lower concentrations (50 μM) were tried, but the S/N-ratio was too 
poor to obtain reliable R1 values. The plots of R1,obs vs testosterone concentration 
are shown in the Figure S3.7.  
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Figure S3.7 Concentration dependence of R1,obs of testosterone in M11 and M11A82W. 
Left graph represents the effect of M11A82W on the concentration dependence of R1,obs on 
the protons of testosterone. Right graph represents the effect of M11 on the protons of 
testosterone.  
 
Because of the limited number of concentrations, no exponential curves could be 
obtained as previously(42) was used to determine Kd values for individual protons. 
Nevertheless, it can be clearly seen that for each proton the slope is significantly 
steeper in case of M11A82W than in case of M11. To understand these differences 
in slopes, simulations were performed with different Kd values. For proton 19 of 
testosterone (binding to M11A82W), the concentration dependence of R1,obs is 
simulated by using  equation 3.5 (Figure S3.8, blue graph). The graph is obtained 
by using a Kd of 51 μM. As can be seen, the blue line crosses the experimental data 
points rather good. This indicates that the estimated Kd of 51 μM obtained by UV-
Vis difference spectroscopy seems to be seems to be consistent with the NMR 
experiments. With a Kd of 500 uM, the red curve in Figure S3.8 was obtained. The 
slope of this graph is less steep than the one obtained using a Kd of 51 μM. So, by 
analyzing the slope of the experimental R1,obs data as a function of testosterone 
concentration (Figure S3.7) indicates that the Kd of testosterone for M11 is much 
higher than the Kd of testosterone for M11A82W. 
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Simulated data of H19 of testosterone (binding to M11 A82W), Kd of 51uM
Experimental data of H19 of testosterone (binding to M11A82W) 
Simulated data of H19 of testosterone (binding to M11 A82W), Kd of 500uM
 
Figure S3.8 Simulated (blue and red graphs) and experimental (green circles) data of the 
concentration dependence of R1,obs. The blue and red curves were obtained by using 
different Kd’s (51μM and 500μM, resp.). The experimental data points match well with the 
simulated data corresponding to a Kd of 51μM 
 
By using a single binding model, equation 3.5, the concentration dependence of 
R1,obs for all protons of testosterone binding to M11A82W could be fitted. The 
binding constants for all protons are estimated to be 45 ± 20 μM. This is in good 
agreement with the binding constant obtained by UV-VIS difference spectroscopy 
(51 ± 4 μM). The fact that the Kd for all protons appear to be similar suggests that 
the two binding orientations (one with the A-ring and one with the D-ring closest 
to the heme iron) have the same binding constant. For M11, the fitting of the 
concentration dependence of R1,obs was not as straightforward as for M11A82W, 
due to the small difference in R1,obs in the concentration range which could be 
measured. Nevertheless, the binding constant for all protons was estimated to be 
560 ± 350 μM. This is also in good agreement with the binding constant obtained 
by UV-VIS difference spectroscopy (>450 μM). The Kd could not be seperately 
calculated for each proton of testosterone due to the limited solubility of 
testosteorne (limited concentration range) in combination with the high Kd (higher 
than 450 µM), which  leads to a very shallow concentration dependence of R1,obs. 
Consequently, one single value for the Kd (~450μM) in both orienations has to be 
assumed for M11 ligand binding. 
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Abstract 
A microfluidic high-resolution NMR flow probe based on a novel stripline detector 
chip is demonstrated. This tool is invaluable for the in-situ monitoring of reactions 
performed in microreactors. As an example, the acetylation of benzyl alcohol with 
acetyl chloride was monitored. Because of the uncompromised (sub-Hz) resolution, 
this probe holds great promise for metabolomics studies, as shown by an analysis 
of 600 nL of human cerebrospinal fluid. 
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4.1 Introduction 
NMR spectroscopy is an indispensable technique in chemistry, biology, and 
medicine. Despite its extreme site electivity, which makes it by far the most 
information-rich analysis technique for molecular structure determination, NMR is 
seldom the method of choice for analysis of mass-limited samples because of the 
intrinsically low sensitivity. Since the absolute sensitivity of an NMR instrument 
for small sample volumes can be improved by decreasing the diameter of the 
detection coil, this miniaturization has been studied for more than a decade(1-4). 
An improvement in terms of sensitivity and resolution using microcoil technology 
is very well possible, but the trade-off in terms of reduced resolution has impeded 
its fast incorporation into mainstream NMR analysis. Besides spectroscopic 
problems, micro- or nanoliter sample handling becomes difficult in a standard 
NMR setup. Small samples are ideally handled in microfluidic systems, which are 
available nowadays at a very high integration level. The implementation of 
microcoils in such a microfluidic system would offer the possibility of studying 
reaction kinetics(5, 6). Currently, NMR on small liquid samples at room 
temperature is performed using small solenoids wrapped around a capillary(3) or 
planar coils on glass chips containing microfluidic channels(2, 7). Solenoid coils 
are limited in scalability, as they can hardly be produced with diameters less than 
300 μm(8), whereas planar coils are scalable but show lower signal sensitivity 
because of the inefficient contribution of the outermost windings to the radio 
frequency (rf) field(8). More importantly, these approaches suffer from spectral 
resolution problems, mainly induced by the nearby windings of the microcoil that 
distort the static magnetic field(7). To overcome these problems, we introduced a 
new NMR “coil”, the stripline. This stripline design has an intrinsically higher 
sensitivity than solenoid and planar coils, as was demonstrated for both liquids and 
solid samples(9). A microfluidic chip based on this resonator showed superior 
spectral resolution (line width of <1 Hz) in pure ethanol without the use of 
additional susceptibility matching(10). Here we describe a flow probe (Figure 4.1) 
based on this resonator that allows in-situ monitoring of the kinetics of reactions 
performed in microreactors at full NMR resolution.  
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4.2 Results and Discussion  
The chip is positioned vertically in an aluminum tube and connected capacitively to 
the rf circuit. A fused silica capillary (length 200 mm, ID 100 μm) is used to 
fluidically connect the NMR chip to the microreactor. Glass microreactors 
(Micronit)(11) can be placed in a custom-built chip holder, which is mounted on 
top of the probe. Syringe pumps are connected to the reactor through FEP tubing to 
control the flow in the reactor. A detailed analysis of a 1H ethanol spectrum yielded 
a line width of 0.7 Hz. The line width at 0.55% is ~30 Hz, which is larger than that 
of commercial 5 mm probes but significantly smaller than those reported for other 
μNMR probe heads, including microslot-based probes(1, 12). The rf homogeneity 
is a further critical factor in pulse sequences that are more complex than a single 
pulse. In this design, the A180°/A90° ratio amounts to 76%. To show the typical 
resolution, Figure 4.2 displays a spectrum recorded in flow (25 μL/min) during 
carbamate formation from toluene diisocyanate (TDI) (0.5 M in toluene) and pure 
ethanol. Since the high resolution is maintained, typical reactant or product 
multiplets can easily be identified.  
 
 
Figure 4.1 (a) The custom-made microfluidic probe. The dashed line indicates the position 
of the NMR chip. (b) Close-up view of the microreactor holder mounted on top of the 
probe. (c) Close-up view of the stripline chip holder. (d) Schematic representation of the 
mechanical arrangement of the microfluidic chip in the holder. 
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Figure 4.2 Spectrum recorded during carbamate formation at flow rates of 24.46 and 0.54 
μl/min for TDI and ethanol, respectively. Only resonances of solvents and reactants are 
visible because of the short reaction time (9 sec) and the low TDI concentration. Inset: 
toluene aromatic peaks with all of the J-couplings resolved, indicating the high-resolution 
performance. 
 
The probe allows the study of reactions in a time range from several seconds to 30 
min, depending on the flow rate; the lower limit is determined by the volume of the 
tubing connecting the microreactor with the NMR detector chip, which is 4.5 μL in 
the current implementation. Figure 4.3 shows two spectra obtained during real-time 
monitoring of the acetylation of benzyl alcohol with acetyl chloride in the presence 
of N,N-diisopropylethylamine (DIPEA) at different reaction times.  
 
 
Figure 4.3 In-situ NMR monitoring of the acetylation of benzyl alcohol in the presence of 
DIPEA. Spectra at reaction times of (a) 9 s and (b) 3 min are shown. Stoichiometry: benzyl 
alcohol/DIPEA/acetyl chloride - 1:1:1.2. 
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These experiments allowed monitoring of the conversion over time, which was 
shown to accumulate to 70% in 3 min. Because of the inherently high resolution, 
line broadenings can be interpreted as meaningful information about the sample. In 
the current experiments, peak broadenings and shifts of the DIPEA resonances 
were observed and attributed to partial protonation of DIPEA at short reaction 
times (<15 min). Moreover, the microreactor experiments showed a resonance at 
2.40 ppm that was not observed in experiments performed in a 5 mm NMR tube. 
These results demonstrate the possibility of tracking intermediates using fast in-situ 
analysis. An in-depth study of this reaction is underway. Although it was not 
specifically built for this purpose, we tested the microfluidic stripline resonator to 
establish its suitability for metabolomics studies. Figure 4.4 shows 1H NMR 
spectra of human cerebrospinal fluid (CSF) as measured in a conventional 5 mm 
probe for reference and in the stripline chip.  
 
 
Figure 4.4 NMR spectra of human CSF as recorded in (a) a 5 mm probe and (b) the 
microchip, containing 450 μL and 600 nL, respectively. Conditions: (5 mm probe) 256 
scans, 90° pulse width (PW) of 6 μs, pH 9.89; (microchip probe) 4608 scans. 90° PW of 7 
μs. pH 9.41. 
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The composition of CSF, which surrounds the spine and brain, reflects the 
cytological and biochemical basis of central nervous system diseases, inborn 
metabolic errors, and metabolism of different diseases(13). A 5 μL sample 
prepared from the reference CSF sample (concentrated 9 times in D2O; see 
Supporting Information) was injected into the chip with a 600 nL detectable 
volume, thus containing 1.2% of the metabolites in the reference sample. In both 
1D spectra, all of the main metabolite resonances in the aliphatic region could be 
identified successfully. Small chemical shift changes between the two spectra are 
due to pH differences. The stripline spectrum is slightly broader, as a lock channel 
has yet to be implemented. The lowest intensity peak that could be identified was 
for alanine (1.45 ppm). The concentration of this metabolite was 1.21 mM, 
corresponding to 0.7 nmol in 600 nL. The sensitivity enhancement of the stripline 
probe relative to the reference probe was a factor of 3.4 (Table S4.1, Supporting 
Information). This enhancement is rather moderate considering the sensitivity 
reported previously for the stripline. However, the sensitivity can be improved 
considerably by the use of substrates with lower losses and optimization of the 
filling factor. Furthermore, an optimized stripline for metabolomics studies should 
have an appropriate volume that takes into account both the overall amount of 
material available and the solubility of the various compounds. Finally, preparatory 
sample handling should preferably be integrated into the microfluidic device along 
with methods to maximize the “observe factor”, which could be achieved by 
introducing plug flow. Currently we are contemplating such a design. On the basis 
of the experience with our prototype stripline probe(9), we anticipate measurement 
times of a few minutes for the analysis of mouse CSF, where ~ 7 μL is available 
ante mortem(14). In conclusion, we have demonstrated an integrated microfluidic 
NMR flow probe for the study of reaction kinetics. Furthermore, we have 
demonstrated the possibility of using the stripline design for screening of mass-
limited biological samples. With the microfabrication toolbox available nowadays, 
a completely integrated platform in one chip that can handle and detect raw 
samples without preparative laboratory work is within reach. 
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4.4 Supporting Information 
4.4.1 Experimental details 
General 
The NMR chip design consists of a flat strip confined between two metal shielding 
planes, resulting in a λ/2 stripline resonator. To obtain a high rf field strength, 
which is necessary for high sensitivity, the strip is constricted in the center. Due to 
this constriction, the current density is increased locally, and with that the rf field 
strength. Because of the symmetric copper geometry and the in-line positioning of 
the stripline parallel to the B0 field, minimal static field distortions are induced, 
ensuring high spectral resolution. The rf field is homogeneous because the 
boundary conditions at the metal planes dictate that the field lines run parallel to 
these surfaces. High resistivity silicon is used as a substrate material. A 
microfluidic channel containing 5 μL of sample is fabricated in the substrate on top 
of the strip. The NMR detection volume is 600 nL under the constriction. The 
spectral resolution was assessed using ethanol (96% pro analysi), see Figure S4.1. 
The 1D 1H-NMR experiments on the stripline probe were carried out on a 
Chemagnetics CMX-Infinity 600 solid-state NMR spectrometer (600 MHz) 
operated by Spinsight software. All spectra were recorded at 300K and processed 
by using the MatNMR processing package(15). 
 
Resolution 
The ultimate resolution offered by the current probe design was established by 
analyzing a single scan spectrum of pure ethanol (Figure S4.1). A Lorentzian fit of 
the methyl resonances gave a full width at half maximum of 0.7 Hz comparable to 
commercial high-resolution probeheads. The linewidth at 0.55% is ~30Hz which is 
larger than commercial 5mm probes but significantly better than numbers reported 
for other microNMR probeheads.  Although being of minor concern, this is 
attributed to fractions of the sample outside of the area of interest contributing to 
the signal, which can e.g. be remedied by implementing plug flow.  
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Figure S4.1 NMR spectrum of 600 nl pure ethanol. Conditions: single scan, spectral width 
5 kHz, 90° pulse width of 4.5 μs, transmitter frequency 600 MHz, transmitter power 5W, 
no apodization. Inset: Lorentzian fit of the methyl peak. The dots represent the data points, 
whereas the line shows the fit. Linewidths at different heights: 50%: 0.73Hz, 0.55%: 
30.13Hz, 0.11%: 93.72Hz. 
 
CSF measurements 
NMR analysis of human CSF is a standardized technique, and the corresponding 
spectra provide unique information, which cannot be obtained by NMR 
spectroscopy on other body fluids, such as urine or blood(16). CSF samples were 
provided by the Dutch Top Institute Pharma, project D4-102. The CSF samples 
were collected by lumbar puncture and immediately frozen to -80°C. Before 
analysis, 500 μL CSF was centrifuged at 650g for 5 minutes to remove cells. To 
400 μL supernatant 44.3 μL D2O and 5.7 μL 40.4 mM 3-(trimethylsilyl)-2,2-3,3-
tetradeuteropropionic acid (TSP-d4) in D2O was added for locking and chemical-
shift referencing. The final concentration of TSP-d4 in the CSF was 0.513 mM. 
After obtaining the reference spectrum, the sample was concentrated 9 times in 
D2O. Subsequently, 5 μL was injected into the chip by syringe injection through a 
capillary from which 600 nL was detected. Conditions 5 mm probe: 256 scans, 
spectral width 10 kHz, acquisition time 5 sec, delay time 12 sec, 90° PW of 6 μs, 
transmitter power 24W, pH 9.89, presaturation 12 seconds at 0.00015 % of 90° 
pulse power, zerofilling factor 2. Conditions microchip probe: 4608 scans (36x128 
scans, unlocked), spectral width 8 kHz, acquisition time 2 sec, delay time 12 sec, 
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90° PW of 7 μs, transmitter power 5W, pH 9.41, presaturation 2 seconds at 0.13% 
of 90° pulse power, zerofilling factor 2. 
The 1D 1H-NMR reference spectra were acquired on a Bruker AMX-500 NMR 
spectrometer (500 MHz) operated by Bruker Topspin software. Equal processing 
parameters for both data: 0.3 Hz line broadening; baseline correction. 
4.4.2 Sensitivity comparison 
 
Table S4.1 Comparison of CSF measurement results with respect to the sensitivity. 
  5mm stripline 
Detected volume 300 μL  600 nL 
Number of scans 256 4608 
Field strength B0 500 MHz 600 MHz 
Concentration 1 9 
SNR of Lactate (1.33ppm) 1175 200 
 
Since the detected sample volume is 500 times smaller, and the initial sample is 9 
times concentrated, there are 55.5 times less spins detected which means that in the 
same NMR system one should average 3080 (55.52) times more to obtain the same 
SNR.  
The SNR of the 5mm system was 5.88 times higher than the SNR obtained with the 
stripline probe. To obtain the same SNR in the stripline chip as we had in the 5mm 
probe, we should have averaged 4608*5.882/256=623 times more. From this we 
can conclude that the sensitivity is enhanced by a factor of 4.9. Taking the different 
field strengths into account, (factor (600/500)2), the final enhancement is 3.4. 
 
Reaction monitoring experiments 
Independently controlled syringe pumps (New Era NE-1000) and syringes (SGE 10 
ml gastight luer-lock) were used to control the flow in the microreactor. The 
microreactor was mounted in a custom-made chip-holder(17). 
DIPEA and benzyl alcohol were mixed together prior to loading into the syringe, at 
0.5 M : 0.5 M. Acetyl chloride molarity: 1.2M. Deuterated chloroform was used as 
a solvent. The reference spectrum was acquired on a Bruker AMX-400 in a 5mm 
tube. 
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Figure S4.2 Reference NMR spectrum of the benzyl acetate formation from benzyl alcohol 
and acetyl chloride. Stoichiometry: Benzyl alcohol:DIPEA:AcCl=5:5:1.2; 8 scans. 
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Abstract 
A high sensitivity, pure shift NMR experiment for mass-limited samples is 
presented to acquire simplified 1D-1H NMR spectra where only chemical shift 
information is present. The experiment proves to be quantitative and can therefore 
be used to determine solutes concentrations. Because of its high sensitivity, our 
experiment might provide a valuable support in the investigation of complex, low 
concentrated mixtures, such as body fluids, food extracts and natural products. 
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5.1 Introduction 
Resolution is a crucial element for the successful application of analytical NMR 
techniques to complex systems. One of the spectral features that can limit NMR 
resolution in liquids is the fine structure of signals, which is determined by scalar 
coupling interactions (J-couplings). The splitting of NMR resonances in multiplets 
due to J-couplings can cause significant signal overlap even in the spectra of 
relatively simple molecules, hampering interpretation, assignment and quantitative 
analysis of NMR spectra. Several approaches(1-14) have been proposed to enhance 
the resolution and simplify NMR spectra by acquiring so-called pure shift NMR 
experiments, in which only chemical shift information and no homonuclear J-
coupling is present. Such pure shift spectra can aid NMR analysis by providing a 
straightforward picture of the number of signals, their chemical shifts and their 
relative intensities. These methods have however found a limited application due to 
a variety of reasons, the most important one being probably low sensitivity. At 
present, the concentration requirements of pure shift techniques (typically > mM 
range) preclude their employment for routine analysis of mass-limited samples, 
such as metabolic mixtures, body fluids or natural products.  
Here, we present an experiment specifically designed for mass-limited samples to 
acquire high resolution one-dimensional 1H pure shift spectra at concentrations as 
low as 50 μM. The proposed pure shift experiment proves to be quantitative and 
can therefore be used to determine solutes concentrations.  
 
5.2 Results and Discussion 
Figure 5.1A displays the conventional 1H NMR spectrum of testosterone: the 
network of homonuclear scalar couplings generates complex multiplet patterns 
with a width (20-50 Hz) that largely exceeds the natural linewidth of the proton 
resonances and causes extensive signal overlap. Figure 5.1B shows a pure shift 1H 
spectrum of 250 μM testosterone acquired at 500 MHz in 27 minutes using the 
pulse scheme of Figure 5.2. The spectrum is greatly simplified and the broad 
multiplets collapsed to pure shift signals with a width at half height of ~1 Hz. The 
quality of the spectrum and the signal-to-noise ratio (~40:1) allow to easily 
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distinguish each individual proton signal in the aliphatic region and to accurately 
determine its chemical shift. By applying our method at higher field strengths and 
using cryo-cooled probes for detection it is possible to further reduce the 
concentration requirements to acquire pure shift spectra. 
 
 
Figure 5.1 (A) 1H NMR spectrum of 250 μM testosterone in DMSO-d6 recorded at 500 
MHz 1H resonance frequency. The spectrum was measured in ca. 5 minutes with 64 
transients and an acquisition time of 0.9 s. (B) Pure shift spectrum of the same sample 
recorded at 500 MHz 1H resonance frequency. (C) Pure shift spectrum of 50 μM 
testosterone in DMSO-d6 recorded at 800 MHz 1H resonance frequency. A signal-to-noise 
ratio of ca. 40:1 and 35:1 was estimated for the spectra in (B) and (C), respectively. Four 
blocks per scan (i.e. n=3, Figure 5.2) were acquired and the combinations of the four 
reconstructed spectra is displayed. The peaks marked with an asterisk originate from 
impurities. 
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Figure 5.1C shows a pure shift spectrum of 50 μM testosterone acquired at 800 
MHz in 40 minutes. A sensitivity increase of almost one order of magnitude is 
estimated compared to previous reported pure shift experiments.(6, 12) This opens 
the possibility to acquire pure shift, simplified 1H NMR spectra of mass-limited 
samples for analytical purposes. Note, however, that despite the sensitivity 
enhancement here achieved, the pure shift scheme is still approximately 10-15 
times less sensitive than the conventional 1D experiment (see discussion in 
Supporting Information).   
 
 
Figure 5.2 Pure shift experiment optimized for low concentrated samples. Rectangular 
boxes and black triangles denote non-selective 180º pulses and acquisition periods (15 – 20 
ms), respectively. A pure shift 1H spectrum is reconstructed from several selective 2D 
datasets recorded by shifting the frequency of the shaped pulses in regular steps to sample 
the region of interest. The elements inside the square brackets allow for the acquisition of 
additional blocks per scan. 
 
The pulse scheme employed to record the pure shift spectra of testosterone is 
sketched in Figure 5.2. Analogous to the experiment first introduced by Zangger 
and Sterk(6) and recently optimized by Aguilar et al.,(12) the evolution of 1H 
single quantum coherence between time-points a and c is determined by chemical 
shifts only, being the effect of homonuclear J-couplings exactly refocused at time-
point c. The experiment is performed in 2D fashion by incrementing the duration of 
t1 and acquiring the proton signal for a short time period (typically 15-20 ms) 
around the echo point c. A 1D FID free from the modulation due to homonuclear J-
couplings is then reconstructed from the 2D dataset by concatenating data points 
acquired at different t1 increments. 
Our strategy to acquire pure shift spectra at low concentrations is based on the 
introduction of three elements that can enhance the sensitivity of the conventional 
pure shift experiment(6, 12) up to almost one order of magnitude (see Supporting 
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Information). Firstly, our method proceeds via the interleaved acquisition of 
several selective 2D datasets to reconstruct the spectral region of interest, rather 
than measuring the complete spectrum at once in a single 2D experiment. In 
addition, by carefully designing the pulse scheme, fast pulsing can be employed, 
which substantially reduces the experiment time. Finally, because of the relatively 
long T2 relaxation time in small molecules, extra refocusing rsnob pulses can be 
applied after the first detection period (~15-20 ms) to acquire additional blocks 
within the same scan; in this way multiple independent pure shift spectra are 
obtained and combined to further increase the signal-to-noise ratio. For the steroid 
samples employed in the present work, the highest sensitivity was obtained by 
acquiring four blocks per scan, which provided ca. 50% increase in S/N ratio. Since 
only signals within the bandwidth of the esnob pulse(15) (30 Hz) are excited, the 
experiment in Figure 5.2 must be performed several times to record the complete 
region of interest, each time acquiring a different frequency window. In the 
proposed scheme, excitation is followed by a hard 180º pulse which compensates 
for the second inversion pulse. This allows to preserve the longitudinal 
magnetization of protons outside the esnob bandwidth. Consequently, recovery 
delays of only a few hundred milliseconds (typically 250 – 350 ms) suffice before 
shifting the transmitter frequency to measure a different portion of the spectrum. 
This was confirmed with simulations as well as experiments by comparing pure 
shift spectra obtained with recovery delays of 350 ms (fast pulsing) and 5 s 
(equilibrium conditions). On average, the relative decrease of the signal integrals in 
the case of fast pulsing did not exceed 10%.  
The values of the normalized signal integrals for pure shift 1H spectra of 
testosterone recorded with one acquisition block per scan (n=0, Figure 5.2) at 500 
MHz and 800 MHz are listed in Figure 5.1. 
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Table 5.1 Normalized signal integrals of the pure shift spectra of 250 μM Testosterone 
recorded at 500 MHz and 800 MHz. The first acquisition block was considered (n=0, 
Figure 5.2). 
  H6α H2α H1ß H16α H12ß 
H7ß 
H1α H8ß 
H11α 
H15α 
(ppm) 2.29 2.20 2.02 1.89 ~1.81 1.64 ~1.57 
500 MHz 0.84[b] 0.93 1.00 1.03 2.10[a] 1.01 2.97[a] 
800 MHz 1.01 0.98 1.00 1.01 2.02[a] 0.97 3.00[a] 
        
  H16ß 
H11ß 
H15ß 19-CH3 H12α H7α 
H9α 
H14α 
18-CH3 
 
(ppm) ~1.40 1.26 1.20 1.03 ~0.94 0.74  
500 MHz 1.66[a,b] 0.83[b] 3.18 1.00 3.03[a] 3.03  
800 MHz 1.80[a] 0.93 3.03 0.96 2.97[a] 3.09  
[a] sum integral of the (partially) overlapping pure shift signals given.  
[b] normalized integral displays a deviation larger than 10%. 
 
From this table it can be seen that most integral values correspond well with the 
expected value of 1.00 per proton and can be used for a quantitative analysis. Only 
for three integral values, at 500 MHz, deviations larger than 10% were observed. 
These deviations originate from non-negligible strong coupling effects for the 
corresponding protons; a much better agreement is found for the same signals at 
800 MHz where strong coupling is attenuated. Furthermore, if multiple blocks per 
scan are acquired, not only signals affected by strong coupling, but also sharp 
resonances (e.g. methyl signal at 0.72 ppm in Figure 5.1A) should be considered 
with care for a quantitative analysis.  
The resolution increase resulting from pure shift techniques can be of particular 
interest for the analysis of complex 1H NMR spectra of low concentrated mixtures. 
As an example, we recorded the pure shift 1H spectrum of a mixture of two steroids 
(250 μM testosterone and 850 μM cortisone). Figure 5.3A shows the conventional 
1H spectrum recorded at 800 MHz, which suffers from extensive signal overlap and 
has therefore little practical utility for the analysis of the sample composition. 
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Figure 5.3 (A) Conventional 1H NMR spectrum of a mixture of 250 μM testosterone and 
850 μM cortisone in DMSO-d6 recorded at 800 MHz 1H resonance frequency. The 
conventional spectrum was measured in 4 minutes with 32 transients. (B) Pure shift 
spectrum of the same sample recorded at 800 MHz. Proton signals from testosterone and 
cortisone are colored in red and blue, respectively. The signals enclosed in the rectangular 
box originate from an AB proton spin system. 
 
The impressive resolution increase of the pure shift spectrum (see Figure 5.3B) 
allows the identification of most individual proton signals and a good estimate of 
the concentration ratio between the two species in solution (see Supporting 
Information). 
In summary, we have presented a method that considerably lowers the 
concentration requirements for the acquisition of pure shift proton spectra by 
increasing the sensitivity 5-10 times relative to the previously proposed 
schemes.(6, 12) Our method extends the spectral simplification of pure shift 
techniques to samples at sub-millimolar concentrations with a modest investment 
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in experimental time. 2D homonuclear correlation experiments offer a different 
approach to spectral simplification and resolution enhancement. When compared to 
these 2D techniques, our pure shift experiment is more sensitive and, therefore, 
more efficient at low concentrations (see discussion in Supporting Information). 
However, pure shift should not be viewed as an alternative to standard 2D 1H 
COSY-type experiments, as it can not provide any information about protons 
correlations. It should rather be considered a complementary tool to obtain an 
overview of the proton signals, providing a quick and straightforward way to 
accurately determine their integrals and chemical shifts, even for low concentrated 
samples. An added value of the proposed scheme is its application in quantitative 
analysis, provided the effects of strong coupling are considered. This experiment 
therefore can represent a valid support in the study by 1H NMR of cases where 
interpretation is limited by overlap of broad multiplets. Particularly, the proposed 
scheme might find broad application as a valuable tool for the analysis of complex 
mixtures, such as body fluids, food extracts, natural products and pharmaceuticals. 
We believe that our pure shift experiment will be of interest for the large number of 
chemists who use proton NMR spectra in their daily work. 
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5.3 Experimental Section 
All NMR experiments were performed at 298K on Varian UnityInova 
spectrometers operating at 500 MHz or 800 MHz (1H resonance frequency), the 
latter equipped with a cryo-cooled probe. The pulse sequence shown in Figure 5.2 
made use of esnob (bandwidth = 30 Hz) and rsnob (bandwidth = 50 Hz) shaped 
pulses with a duration and RF strength of 47.3 ms at 38.6 Hz and 37.0 ms at 68.6 
Hz, respectively. 
The main reason to use a somewhat larger bandwidth for the refocusing pulses 
relates to the performance of rsnob pulses when multiple blocks per scan are 
acquired. In our experience, when applying several rsnob pulses, the signal 
decrease at the edge of the pulse bandwidth becomes more severe as the number of 
refocusing pulses increases. We found that for our steroid samples we could 
enhance the S/N ratio by 10-15% by increasing the rsnob bandwidth to 50 Hz 
without affecting the quality of homonuclear decoupling. 
The recovery delay was 250 ms at 500 MHz and 350 ms at 800 MHz. The duration 
of all gradients was 1 ms and the strength of gradients G1, G2 and G3 were 2.05 
G/cm, -2.05 G/cm and -4.1 G/cm, respectively, while the strength of gradients G4 
was varied within one scan between 3.9 G/cm and 5.9 G/cm for different acquired 
blocks. 
All spectra shown in the present work were obtained by acquiring four blocks per 
scan. Please note that because of the additional refocusing rsnob pulses, chemical 
shift evolution during the even blocks (i.e. 2nd and 4th block) is exactly time-
reversed compared to the odd blocks (i.e. 1st and 3rd block). Therefore, the different 
blocks were not directly summed up but stored separately and used to reconstruct 
four independent pure shift FIDs. After correcting for the time reversal of the even 
FIDs, and performing a standard Fourier transformation, the four individual pure 
shift spectra were combined.  
Pure shift spectra recorded at 500 MHz were reconstructed using 48 2D datasets 
recorded at 48 regularly spaced offsets (Δ = 20 Hz) for the esnob/rsnob pulses, 
whereas pure shift spectra recorded at 800 MHz were reconstructed using 75 2D 
datasets. Each 2D dataset consisted of 40x78 complex points, corresponding to a 
final t1 evolution time of ca. 0.6 s and an acquisition time t2 of 15.2 ms. All pure 
shift spectra acquired at 500 and 800 MHz were recorded in 27 minutes and 40 
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minutes, respectively. The offset step used to span the spectral region of interest 
can also influence the value of the signal integrals. Both simulations and 
experimental data indicate that an offset step of 20 Hz, as used in the present work, 
can cause an underestimation of the peak integrals of 10% at most. A smaller 
sampling step can reduce this systematic error (3% for offset jumps of 10 Hz) at 
the cost of a longer measuring time. 
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5.5 Supporting Information 
5.5.1 Chemicals 
Testosterone (purity ≥ 98.0%), cortisone (purity ≥ 99.0%) and DMSO-d6 (99.96 
atom% D) were purchased from Sigma-Aldrich, Schnelldorf.  
 
5.5.2 Chemical structure, 1H NMR assignment and 1H-1H scalar coupling 
constants for testosterone in DMSO-d6 
Figure S5.1 shows the chemical structure of testosterone and the numbering of the 
carbon atoms. Figure S5.1 shows the proton chemical shifts and J-couplings of 
testosterone in DMSO-d6 as solvent. The J-couplings were obtained from 
Hayamizu et al.(16) with the addition of JH17α/17OH (4.9 Hz) that could be 
determined in DMSO as a solvent. 
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Figure S5.1 Chemical structure of testosterone with the carbon atoms numbered. 
 
5.5.3 Integrals of the pure shift spectrum of the mixture containing 
testosterone and cortisone 
Table S5.2 lists the values of the normalized integral (a value of 1.00 
corresponding to one proton of testosterone) of the non-overlapping signals in the 
spectrum of the mixture shown in Figure 5.3 (250 μM testosterone and 850 μM 
cortisone). The average integral value of testosterone is 1.00±0.03 and the average 
integral value of cortisone is 3.39±0.08. This ratio corresponds well with the ratio 
found in the conventional 1D-1H NMR spectrum of 1:3.45.  
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Table S5.1 1H Chemical shifts (ppm) and J-coupling constants (Hz) for testosterone. 
DMSO-d6 was used as solvent and internal reference. 
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Table S5.2 Integrals of the non-overlapping signals of a mixture containing 250μM 
testosterone and 850μM cortisone.  
Ch
em
ica
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hif
t (p
pm
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Int
eg
ral
Co
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nd
0.74 3.06 Testosterone (CH3)
0.92 1.00 Testosterone (1H)
1.04 0.95 Testosterone (1H)
1.21 3.15 Testosterone (CH3)
1.65 0.98 Testosterone (1H)
1.68 3.38 Cortisone (1H)
1.72 3.27 Cortisone (1H)
1.85 3.29 Cortisone (1H)
1.90 1.01 Testosterone (1H)
2.01 3.47 Cortisone (1H)
2.03 1.00 Testosterone (1H)
2.18 3.46 Cortisone (1H)
2.29 1.00 Testosterone (1H)
2.32 3.46 Cortisone (1H)  
 
5.5.4 Sensitivity pure shift experiments and conventional 1D-1H experiment 
The sensitivity of the proposed pure shift experiment (Kolkman et al.) is compared 
with the sensitivity of the conventional pure shift experiment (Aguilar et al.(12)) 
and of a standard 1D-1H experiment.  
The acquisition time (AT) of the proposed pure shift experiment (Kolkman et al.) 
can be approximated with the following expression: 
=++⋅++++++⋅= ]4...4[ 1111 rsnobesnobincrrsnobesnoboffKolkman pwpwtNdpwpwtdNAT
   4...4[ 11 rsnobesnobincrrsnobesnoboff pwpwatNdpwpwatdN + ]+Δ⋅+++++Δ+⋅    
where indicates the duration of the recovery delay; 1d  atΔ  is the acquisition time 
in the 2D experiment (usually ~15 ms);  and  are the pulse widths 
of the esnob and rsnob pulses, respectively;  denotes the number of frequency 
jumps that must be performed to scan the region of interest (spectral width, sw): 
esnobpw
offN
rsnobpw
⎟⎟⎠
⎞
⎜⎜⎝
⎛
Δ= offsetoff
swN  
where  is the distance between two adjacent frequency offsets 
(typically 20 Hz). 
offsetΔ
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The expression for the acquisition time can then be rearranged as: 
~
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                  )
2
4( 1
atpwpwdNsw rsnobesnobincr
offset
+++⋅⋅⎟⎟⎠
⎞
⎜⎜⎝
⎛
Δ  
where  is the total acquisition time of the reconstructed FID and  is the 
number of increments, which can be determined by: 
at incrN
40
015.0
6.0 =≈Δ= at
atNincr  
Assuming a region of interest of 1000 Hz: 
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The signal-to-noise ratio of a one-scan reconstructed pure shift spectrum is: 
0
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where  is a factor defining the increase in signal intensity due to the 
collapse of a multiplet in a singlet (typically ~2-3),  defines the increase in 
k  and k  indicate the efficiency of the selective pulses with respect to  
pulses (here taken 0.9 for both esnob and rsnob). 
S0 indicates the signal intensity for a conve
collapsek
signal-to-noise
rsnob
echomultk _
u ratio due to the acquisition of m ltiple blocks per scan (~1.5), 
 hard
ntional one-scan 1D spectrum acquired 
esnob
with a total recovery delay of 3·T1 and a 90 degree pulse, N0 is the RMSD noise in 
the conventional one-scan 1D spectrum. The parameter offn  indicates the number 
of selective 1D spectra that contribute to a given signal (typically 43~ −n ). 
 
off
Ard Kolkman 170 
                                                            Quantitative pure shift 1H NMR at low concentrations 
The acquisition time for the conventional pure shift (Aguilar et al.(12)) experiment 
is: 
⎟⎠
⎞⎜⎝
⎛ ++⋅⎟⎠
⎞⎜⎝
⎛ Δ+⋅++⋅=
2
~
2
)1()( 11
atpwdNatNNpwdNAT rsnobincrincrincrrsnobincrAguilar  
Assuming a recovery delay of 3·T1 (i.e. ~2.0 s): 
min5.1~)3.0037.02(40
2
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The signal-to-noise ratio of a one-scan reconstructed pure shift spectrum is: 
0
0
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G
bwkk
noise
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rsnobcollapse ×××≈  
where all the symbols retain their previous meaning. In addition, bw represents the 
bandwidth of the rsnob pulse (50 Hz) and GSL denotes the strength (in Hz) of the 
slice selection gradient; it is here assumed that GSL exceeds by 30% the width of 
the region of interest to avoid distortions of the signals at the edges. In this case: 
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If the conventional pure shift experiment is acquired with more than one scan to 
obtain the same experiment duration as the new experiment the signal-to-noise 
ratio becomes: 
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With the settings here employed, the proposed experiment provides a 5 – fold 
increase in signal-to-noise ratio compared to the conventional experiment. Note 
that this factor will increase even further for a larger spectral region.  
 
In the case of a conventional 1D 1H experiment, acquired with a 90 degree pulse 
and a total recovery delay (i.e. including the acquisition time) of 3·T1, the signal-
to-noise ratio is: 
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The conventional 1D 1H experiment is therefore expected to be ca. 10-15 times 
more sensitive than the proposed pureshift experiment. 
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Abstract 
NMR spectroscopy is an extremely powerful analytical technique for the identifi-
cation and quantification of compounds present in (biological) mixtures. One of the 
most important limitations which hamper the identification and quantification is 
the large spectral overlap in 1D-1H NMR spectra. We show here that a 1D-1H 
NMR spectrum of a complex mixture, consisting of testosterone and its three me-
tabolites produced by a Cytochrome P450BM3 enzyme, can be simplified by using 
the pure shift NMR experiment as shown in Chapter 5 of this thesis. In particular 
we show that the spectral simplification allows the identification and quantification 
of the metabolites based on pure shift fingerprint profiles of the individual com-
pounds. In addition, an automated screening procedure is proposed where com-
pounds present in our pure shift NMR library are screened for their presence or 
absence in the mixture.  
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6.1 Introduction 
The identification and quantification of metabolites in complex (biological) mix-
tures has already led to the discovery of numerous novel metabolites, metabolic 
diseases, metabolic pathways and biomarkers(1, 2). The two most common used 
analytical methods to determine the content of complex mixtures are liquid chro-
matography (LC) coupled to mass spectrometry (MS) and nuclear magnetic reso-
nance spectroscopy (NMR). Both LC-MS and NMR are powerful techniques for 
metabolic analysis and give mainly complementary information(3). NMR spectros-
copy is a non-destructive, quantitative method to provide structural information of 
a wide range of structurally different metabolites simultaneously. Mainly because 
of this and its high reproducibility makes that NMR spectroscopy is a robust and 
reliable technique for the analysis of complex mixtures. The most common used 
NMR experiment to study mixtures is undoubtedly the simple ‘pulse-acquire’ ex-
periment. This experiment results in one dimensional proton NMR spectra contain-
ing structural information in the form of both chemical shift and J-coupling. Al-
though J-couplings are crucial parameters to identify spin systems, the broad mul-
tiplets originating from these couplings (e.g. Figure 6.1A) cause severe spectral 
overlap resulting in overcrowded spectra.  
 
Figure 6.1 (A) Collapse of the broad multiplet corresponding to proton 16α of testosterone 
to a pure shift signal by removing the J-coupling. (B) Pure shift experiment optimized for 
low-concentrated samples. Rectangular boxes denote non-selective 180˚ pulses and the 
gradients were given to remove unwanted coherences and pulse imperfections. The ex-
periment is described in more detail in Chapter 5 and 7 of this thesis. In short, a pure shift 
spectrum is reconstructed from several selective 2D datasets recorded by shifting the fre-
quency of the shaped pulses in regular steps of 20 Hz to sample the region of interest. 
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In order to improve the resolution and simplify 1D-1H NMR spectra, several meth-
ods(4-13) have been proposed to obtain so-called pure shift spectra in which only 
chemical shift information is present and no J-coupling (Figure 6.1A). These meth-
ods have only found limited use in the analysis of complex mixtures due to a vari-
ety of reasons, from which a poor sensitivity is probably the most important one. 
Figure 6.1B shows the pulse sequence, as introduced in Chapter 5 of this thesis and 
described in more detail in Chapter 7, which is specifically designed for the acqui-
sition of quantitative correct pure shift spectra for samples with concentrations as 
low as 50μM. This experiment makes it possible to simplify 1D-1H NMR spectra 
of mixtures with analytes present at sub-mM concentrations and extend the infor-
mation content which can be obtained from these spectra. Here we show a novel 
approach in which pure shift NMR can straightforwardly be applied to simplify the 
extremely crowded region between 0.6 and 2.4 ppm of a moderately complex mix-
ture containing testosterone and its three metabolites produced by a Cytochrome 
P450 enzyme. The spectral simplification allows the identification and quantifica-
tion of the metabolites based on pure shift fingerprint profiles of the individual 
compounds. Identification can be performed in an automated fashion, where the 
pure shift NMR mixture is analyzed for the existence of metabolites which are pre-
sent in our pure shift NMR library.  
 
6.2 Results and Discussion 
Cytochrome P450s (CYPs) are monooxygenase enzymes primarily present in the 
liver and responsible for the metabolization of most drugs and xenobiotics(14). 
Cytochrome P450BM3 from Bacillus megaterium is a bacterial P450 and its ge-
netically engineered mutants are capable of metabolizing drugs and other non-
native compounds with a high regio- and stereoselectivity(15). P450BM3 enzymes 
are commonly used as biocatalysts and are well-known for their predictive role for 
drug metabolism in humans(16). P450BM3M11 is such a genetically engineered 
mutant and capable of metabolizing testosterone into three reaction products (as it 
was shown in Chapter 3 of this thesis): 2ß-, 15ß- and 16ß-hydroxyl testosterone 
(Figure 6.2), from which the first two are formed by CYPs in human liver micro-
somes as well(17).  
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Figure 6.2 Chemical structure of testosterone. The carbons atoms are numbered and the 
positions of the hydroxyl of the three metabolites produced by P450BM3M11 are indicated 
with an arrow. 
Testosterone was metabolized by P450BM3M11 and the reaction mixture was, after 
extraction with dichloromethane, re-dissolved in DMSO-d6 (see Supporting Infor-
mation for experimental details). Figure 6.3A shows the 1D-1H NMR spectrum of 
the reaction mixture containing testosterone and its three metabolites between ~0.6 
and ~2.4 ppm. This region of the NMR spectrum has the highest proton density 
and thus resonance density in the NMR spectrum, i.e. ~90 proton signals are ex-
pected to resonate in this small spectral region given the four steroids present in the 
mixture. Moreover, the broad multiplets, caused by complex J-coupling patterns, 
and subsequent large spectral overlap makes it fairly impossible to identify, quan-
tify or derive structural information of the compounds present in the mixture. Sev-
eral computational methods have been developed to extract most information from 
these kind of complex spectra, e.g. rNMR(18), Chenomx NMR suite software(19) 
and Principal Component Analysis (PCA). However, these methods still suffer 
from the strong spectral overlap and one of the most significant challenges facing 
modern metabolomics is therefore the translation of this complex data into the 
identification and quantification of compounds(18). 
A completely new approach to identify and quantify compounds in complex mix-
tures is presented here. It is based on the pure shift experiment shown in Figure 
6.1B. The pure shift NMR spectrum of the mixture containing testosterone and its 
three P450BM3M11 metabolites is shown in Figure 6.3B. The spectacular increase 
in resolution simplifies the 1D-1H NMR spectrum significantly. All broad multi-
plets, with a width ranging between approximately 20 and 50 Hz, collapsed into 
singlets with line widths of approximately 1 Hz, which allows to clearly distin-
guish most individual proton signals in the spectrum. The resolving power (resolu-
tion) of pure shift NMR experiments is one to two orders of magnitude higher than 
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the conventional ‘pulse-acquire’ experiment. In order to improve the resolution of 
pure shift NMR spectra even further, the most obvious strategy would be to acquire 
pure shift NMR spectra at a spectrometer with a magnetic field strength as high as 
possible. 
 
Figure 6.3 (A) 1H NMR spectrum of the mixture containing testosterone and the three me-
tabolites produced by P450BM3M11: 2ß, 15ß and 16ß-hydroxyl testosterone in DMSO-d6. 
This spectrum was acquired at an 800MHz (1H frequency) spectrometer with a cryogenic 
cooled probe with 32 transients. The large truncated signals at ~1.1ppm and ~1.3ppm origi-
nate from impurities, whereas the truncated signals at ~0.95ppm and ~1.2ppm correspond 
to methyl signals of the compounds. (B) Pure shift spectrum of the mixture acquired at an 
800MHz (1H frequency) spectrometer in 40 minutes. Four blocks per scan (n=3, Figure 
6.1B) were acquired and the combination of the four reconstructed spectra is displayed. 
Pure shift signals marked with an asterisk originate from the most abundant metabolite: 
15ß-hydroxyl testosterone. 
 
The pure shift signals corresponding to metabolite 15ß-hydroxyl testosterone, indi-
cated with an asterisk in Figure 6.3B, can be identified based on their higher inten-
sity, since this is the most abundant metabolite (see Supporting Information). As-
signment of the signals of the other three compounds, 2ß-hydroxyl testosterone, 
16ß-hydroxyl testosterone and testosterone, which each are present at approxi-
mately the same concentration (~150μM), is best performed by comparison with 
the pure shift spectrum of each individual compound. This comparison is named 
fingerprint profiling. A fingerprint of a compound by means of pure shift NMR can 
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best be described as a set of pure shift signals (no J-coupling) which unambigu-
ously identifies the compound. Testosterone has, for example, 21 pure shift signals 
resonating between 0.6 and 2.5 ppm. The position (chemical shift) of these pure 
shift signals is well defined by the electronic environment of the proton nuclei as 
well as solvent effects. When the structure of a compound is modified, by the in-
sertion of a hydroxyl for example, the position of (most of) the pure shift signals 
will change. Because of the resolution increase and spectral simplification attained 
with the pure shift experiment, chemical shift changes of only a few hertz can be 
appreciated and used to discriminate signals from different compounds. Therefore, 
a set of pure shift proton signals can effectively be used as a fingerprint profile to 
uniquely identify a compound in a mixture. 
This is exemplified in Figure 6.4: two highly crowded regions of the 1D-1H NMR 
spectrum and of the pure shift 1D-1H NMR spectrum of the reaction mixture are 
shown in Figure 6.4A and Figure 6.4B, respectively. No signal identification is 
possible in the conventional spectrum due to the overlap of complex multiplets 
from different compounds. Conversely, most individual proton signals can be rec-
ognized by simple inspection of the pure shift 1H NMR spectrum of the mixture 
(Figure 6.4), due to the spectral simplification. The two regions of the pure shift 
spectrum of the mixture can be reconstructed from the combination of the finger-
print profiles of each individual compounds (Figure 6.4C-F). As a result, the com-
position of the mixture can be determined by using pure shift NMR. 
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Figure 6.4 (A) Two of the most crowded regions of the 1D-1H NMR spectrum of the mix-
ture containing testosterone and its three P450BM3M11 metabolites. (B) Pure shift spectrum 
of these two crowded regions. (C – F) Pure shift spectra of the individual compounds: tes-
tosterone, 15ß-, 16ß- and 2ß-hydroxyl testosterone, respectively. These pure shift spectra 
can straightforwardly be used as fingerprints to screen for the presence of these compounds 
in the pure shift spectrum of the mixture (A), see color coding. Dashed peaks correspond to 
impurities. 
 
In order to improve the reliability of the metabolite identification process based on 
pure shift NMR, not only small spectral regions should be used (Figure 6.4), but 
the complete pure shift NMR spectrum (Figure 6.3B). When doing so, approxi-
mately 70% of the pure shift signals can unambiguously be assigned to one of the 
compounds by using their characteristic pure shift fingerprint profile.  
The identification of metabolites in complex mixtures based on fingerprint profil-
ing by pure shift NMR can also be performed in an automated fashion. We will 
exemplify this using the same mixture as discussed above. First, a database con-
taining pure shift NMR spectra (i.e. fingerprint profiles) of nine hydroxyl forms of 
testosterone was generated, see Supporting Information. The pure shift NMR spec-
trum of the mixture was subsequently screened for the presence or absence of the 
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compounds present in the library using an automated procedure. Note that hte pro-
posed simple automated profiling procedure uses only peak positions (i.e. chemical 
shifts) and no peak intensities, which thus leaves space for improvements.  
The automated identification procedure can roughly be divided into three stages. 
(1) The pair-wise distances between the pure shift signals observed in the mixture 
and each signal of each compound in the pure shift database are calculated. For 
each compound, the shortest pair-wise distances for all pure shift signals are used 
in the next stage. (2) The overall quality of the matching of a pure shift spectrum in 
the database with the pure shift spectrum of the mixture is evaluated by the largest 
pair-wise distance obtained from stage 1. For this a new parameter named Maximal 
Individual Frequency Shift (MIFS) is introduced. The MIFS describes the largest 
frequency difference between a pure shift signal of a compound in the database and 
the mixture, see Supporting Information for a more detailed explanation. (3) The 
presence or absence of compounds, present in the pure shift library, in the mixture 
is based on the MIFS. Compounds which have a small MIFS (hence, large similar-
ity between the signals of the compound and a mixture) are most likely present in 
the mixture, whereas compounds which have a large MIFS are most likely absent 
in the mixture. The easiest way to display the output of this automated screening 
procedure is shown in Figure 6.5. Here, the compounds which are present in the 
library are plotted as a function of the MIFS.  
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Figure 6.5 Maximal Individual Frequency Shift of the compounds present in the pure shift 
NMR library as screened towards the pure shift NMR mixture containing testosterone at its 
three P450BM3M11 metabolites. 
 
The four compounds which are present in this mixture have the smallest MIFS and 
can clearly be distinguished from the other hydroxy-testosterone derivatives pre-
sent in the pure shift database. Note that ideally the MIFS is close to 0 Hz, which 
corresponds to an exact match between the pure shift signals in the mixture and the 
compound in the database. This is however not observed. The relative large values 
of MIFS of the compounds present in the mixture are most-likely caused by small 
deviations in solvent composition. Trace amounts of adducts from the extraction 
procedure and deviating amounts of residual water most likely explains the relative 
large values of MIFS. It is therefore of utmost importance to keep the solvent com-
positions for compounds present in the database and mixture identical.  
Quantification of pure shift spectra is best performed by integrating non-
overlapping pure shift signals. In case of (partially) overlapping pure shift signals, 
deconvolution is the method of choice. Deconvolution is a widely applied algo-
rithm-based method to determine surface areas of partially overlapping signals. 
Approximately ten pure shift signals per compound were deconvoluted in the pure 
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shift spectrum shown in Figure 6.3B. From this analysis, the concentration ratios 
were found to be 4.15 (±3%), 1.08 (±13%), 0.97 (±14%), and 1.00 (±13%) for 15ß-
OH, testosterone, 16ß-OH and 2ß-OH, respectively. These values correspond well 
with the ratios found by LC chromatography (4:1:1:1; see Supplementary informa-
tion). It is finally noted that signals affected by strong coupling or sharp singlet 
resonances should be avoided for a reliable quantitative analysis (see Chapter 5 and 
7 of this thesis). 
In summary, 1D-1H NMR spectra of complex (biological) mixtures can be greatly 
simplified by acquiring pure shift NMR spectra, as shown here for a mixture con-
taining testosterone and its three metabolites produced by a Cytochrome P450 en-
zyme. This new generation of pure shift experiments has a high sensitivity and is 
quantitative and allows therefore the acquisition and quantitative analysis of pure 
shift spectra of metabolic mixtures, in which the concentrations are in the sub-mM 
range. The results presented in this Chapter give new possibilities to identify and 
quantify compounds present in moderately complex (biological) mixtures based on 
pure shift fingerprint profiling. This approach is not only applicable to P450 meta-
bolic mixtures, but can easily be extended to other complex mixtures, like blood 
plasma, cerebrospinal fluid, urine, food extracts, pharmaceuticals and many others. 
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6.4 Supporting Information 
6.4.1 Chemicals 
Testosterone (purity ≥ 98.0%), D-glucose-6-phosphate dipotassium salt hydrate 
(purity 98 - 100%), glucose-6-phosphate dehydrogenase, NADPH (purity 95%) 
and DMSO-d6 (99.96 atom% D) were purchased from Sigma-Aldrich, Schnelldorf. 
6β-, 7α-, 11α, 11β and 16α-hydroxyl testosterone were obtained from Steraloids, 
Inc., USA. 2β-, 15β- and 16β-hydroxyl testosterone were obtained from a large 
scale biotransformation of testosterone with M11, as described in detail in Chapter 
2 (Experimental details) of this thesis. 
 
6.4.2 Experimental details 
Biotransformation of testosterone by P450BM3M11 
A 10mL reaction was performed in 100mM potassium phosphate buffer pH 7.4 
with 500nM purified P450BM3M11 and 200μM testosterone. The reaction was initi-
ated by the addition of an NADPH regenerating system (final concentrations of 0.3 
mM NADPH, 4.5 mM glucose-6-phosphate and 0.5 U/mL glucose-6-phosphate 
dehydrogenase). The reaction was allowed to proceed for 80 minutes at 25˚C. The 
reaction products were extracted by using 3 x 20mL dichloromethane. The organic 
layers were combined and evaporated using a rotary evaporator. The dried product 
was redissolved in 1.0mL DMSO-d6, from which 600μL was transferred to an 
NMR tube and 100μL to an LC vial for further analysis. 
HPLC analysis 
The reaction mixture was analyzed using a Shimadzu HPLC system, equipped with 
a Reprosil 100 C18 3μm (150 x 3 mm) column. Elutes were detected using a UV-
VIS detector at 210nm. At a flow-rate of 0.4 mL/min the following gradient was 
used: 0-1 minute isocratic at 95% A (99.9% mQ + 0.1% (v/v) TFA); 1-31 minutes 
linear increase to 100% B (99.9% acetonitrile + 0.1% TFA); 31-36 minutes 
isocratic at 100% B; 36-41 minutes linear decrease to 95%B; 41-50 minutes 
isocratic at 95% B. 
Acquisition NMR experiments 
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All NMR experiments were performed at 298K on a Varian UnityInova spectrome-
ter, equipped with a cryogenic cooled probe, operating at 800 MHz (1H resonance 
frequency). Pure shift NMR spectra were acquired and processed as described in 
short in Chapter 5 (experimental section) and into more detail in Chapter 7 of this 
thesis. 1D-1H NMR spectra were acquired using 128 transients and an acquisition 
period of 0.6 s.  
Automated compound identification 
The automated comparison of the pure shift NMR spectrum of the mixture with the 
pure shift NMR spectra of individual compounds present in the pure shift database 
allows fast identification of the compounds present in the mixture. In the first step, 
the pair-wise distance between each pure shift signal of the mixture and each signal 
in the database is calculated. The procedure is schematically illustrated in Figure 
S6.1; one spectrum corresponds to the pure shift NMR spectrum of the mixture and 
the other two spectra correspond to the pure shift NMR spectra of compounds A 
and B. The three signals of compounds A have a pair-wise distance of 1, 0.9 and 
1.1 Hz, respectively. The overall quality of the match is evaluated by using the 
largest pair-wise distance. This measure is called Maximal Individual Frequency 
Shift (MIFS) and for compound A, MIFS is found to be 1.1 Hz. The pure shift 
spectrum of compounds B illustrates a second scenario. Two signals match exactly 
with two signals of the mixture; however the third signal is shifted 3.5 Hz. The 
MIFS for compound B is therefore equal to 3.5 Hz which means that it is consid-
ered as a worse match than compound A.  
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Figure S6.1 Screening procedure of the pure shift spectra. The pair-wise distance between 
each signal are evaluated, the largest one define the Maximal Individual Frequency Shift 
i.e. the quality of the matching. 
 
Deconvolution pure shift NMR spectra 
The pure shift NMR spectrum of the mixture was deconvoluted by using the multi-
ple-Gaussian curve-fitting program available in OriginPro8. Pure shift signals were 
deconvoluted using a Lorentzian lineshape from which the chemical shift, peak 
width and peak area were estimated in an iterative procedure. In total, 8 pure shift 
signals of testosterone, 8 pure shift signals of 15ß-OH, 7 of 16ß-OH and 10 of 2ß-
OH were deconvoluted in order to derive quantitative information. 
 
6.4.3 LC chromatogram 
Figure S6.2 shows the LC chromatogram of the reaction mixture containing testos-
terone and its three mono-hydroxy metabolites. The conversion of testosterone is 
approximately 85% and the most abundant metabolite is 15ß-hydroxyl testoster-
one. The concentration ratio of the compounds is approximately 4:1:1:1 as is evi-
dent from UV- absorbance, assuming no differences in extinction coefficient be-
tween the different compounds.  
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Figure S6.2 LC chromatogram of the reaction mixture containing testosterone and its three 
mono-hydroxy metabolites. 
 
6.4.4 Results deconvolution pure shift NMR spectra 
The concentration (ratio) of the compounds can be determined by deconvoluting 
(partially) overlapping pure shift signals, a small region of the deconvoluted pure 
shift spectrum is shown in Figure S6.3. The pure shift spectrum was deconvoluted 
using the Origin Pro 8 SR2 software. In total, 8 pure shift signals of testosterone, 8 
pure shift signals of 15ß-OH, 7 of 16ß-OH and 10 of 2ß-OH were deconvoluted. 
The concentration ratio was found to be 4.15 (±3%) : 1.08 (±13%) : 0.97 (±14%) : 
1.00 (±13%) for 15ß-OH, testosterone, 16ß-OH and 2ß-OH, respectively. These 
values correspond well with the ratios found by LC chromatography, whereas it 
was not possible to extract this information from the conventional 1D-1H NMR 
spectrum.  
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Figure S6.3 Deconvolution of (partially) overlapping pure shift signals.   
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6.4.5 Pure shift spectra database 
Figure S6.4 shows pure shift NMR spectra of the nine hydroxyl forms of testoster-
one present in our library, whereas Figure S6.5 shows the conventional 1D-1H 
NMR spectra of the testosterone derivatives.  
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Figure S6.4 Pure shift spectra of the testosterone derivatives present in our pure shift li-
brary. The pure shift NMR spectrum of the testosterone-P450BM3M11 reaction mixture is 
shown at the top.  
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Figure S6.5 Conventional 1D-1H NMR spectra of the testosterone derivatives. The con-
ventional NMR spectrum of the testosterone-P450BM3M11 reaction mixture is shown at the 
top.  
Chapter 7   
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Abstract 
The pure shift NMR experiment described in Chapter 5 and 6 of this thesis allows 
the acquisition of broadband homonuclear decoupled 1D-1H NMR spectra. In 
particular it was shown that this experiment has a high sensitivity, high resolution 
and the obtained spectra can be used for a quantitative analysis. In this Chapter, a 
detailed explanation of the pure shift NMR experiment is given. First, the way this 
experiment is acquired will be discussed and compared to the original pure shift 
NMR experiments. Secondly, the reconstruction and processing of the FIDs will be 
explained and the effect of multiple block acquisition on the S/N ratio as well as on 
the integral will be discussed. Finally, the parameters which can interfere with the 
signal integral will be summarized.  
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7.1 Introduction 
High spectral resolution in liquid state 1H NMR spectroscopy is crucial for the 
identification, quantification and extraction of structural information of the 
analytes present. The most common way to obtain high resolution 1D-1H NMR 
spectra is by using spectrometers operating at strong magnetic fields. Although 1 
GHz spectrometers exist now-a-days, the resolution increase compared to a more 
common 500 MHz spectrometer is only a factor of two. A different approach to 
significantly improve the resolution of 1D-1H NMR spectra is by removal of 
homonuclear scalar couplings. Scalar couplings (J-coupling) split proton 
resonances in broad multiplets. These broad multiplets can cause severe spectral 
overlap, which hampers the extraction of information from spectra. By recording 
homonuclear decoupled 1D-1H NMR spectra, broad multiplets collapse to singlets, 
which strongly improves the resolving power (resolution). For instance, multiplets 
with a 50 Hz width are not uncommon and the collapse to a singlet of 1 Hz 
corresponds to a resolution enhancement of 50. Where hetereonuclear decoupling 
can simply be performed by applying a proper RF pulse scheme during 
acquisition(1-3), removal of homonuclear splittings is a more complex problem.  
Pell et al.(4) showed for example that the 45˚ projection of the diagonal multiplets 
of an anti z-COSY gives a homonuclear decoupled 1D-1H NMR spectrum with 
absorption mode lineshapes. The poor sensitivity of this experiment is clearly a 
disadvantage when one wants to measure low concentrated samples. Giraud et 
al.(5) applied a 1H δ-resolved 2D NMR experiment, which has a sensitivity 
comparable to the anti z-COSY experiment(4), in order to obtain homonuclear 
decoupled spectra by projecting the indirect dimension. The results allowed 
discrimination of enantiomers which were dissolved in a chiral liquid crystal. 
Constant time COSY experiments(6-8) can also be used to obtain homonuclear 
decoupled 1D-1H NMR spectra. A serious restriction of this experiment, however, 
is the limited range of J-couplings which can be suppressed. Two-dimensional J-
resolved spectroscopy, as first described by Aue et al.(9), is mainly used for the 
accurate determination of coupling constants, but can also be used to obtain 
broadband homonuclear decoupled 1D-1H NMR spectra. One of the major 
drawbacks of the conventional 2D J-resolved experiment are the dispersive 
antiphase components present, which results in spectra that can not be phased to 
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absorptive lineshapes. Although several methods(10-18) exist to compensate for 
these phase-twisted lineshapes, they still suffer from a poor linewidth, sensitivity 
and/or not being quantitative. Most likely because of these drawbacks they have 
not found a widespread use. 
One of the most promising class of experiments for the acquisition of high 
resolution homonuclear decoupled 1D-1H NMR spectra are the so-called pure shift 
NMR experiments(19, 20). Pure shift NMR experiments can be recorded fast and 
have absorption mode lineshapes with a high resolution (peak width at half height 
being ~1 Hz). The main disadvantage of the pure shift NMR techniques has until 
now been their poor sensitivity. We have shown in Chapter 5 of this thesis that by 
modifying the original pure shift NMR experiment, the sensitivity is improved by 
almost one order of magnitude and that correct integrals are obtained. Solute 
concentrations as low as 250 μM were assessed, using a conventional 500 MHz 
spectrometer equipped with a room temperature probe, in 27 minutes. Moreover, 
concentrations as low as 50 μM were acquired, with a signal-to-noise ratio of ~25, 
in 40 minutes using an 800 MHz spectrometer equipped with a cryogenic cooled 
probe.  
In this work, the acquisition, processing and analysis of the pure shift NMR 
experiment with a high sensitivity is explained in detail, focusing in addition on its 
practical applications. The NMR spectrum of the steroid testosterone will be used 
as a reference, since testosterone proves to be a good example of the spectral 
simplification obtained by pure shift NMR. Most multiplets are relatively broad 
(up to 50 Hz), resonate in a small spectral region (between ~0.6 and ~2.5 ppm) and 
display extensive resonance overlap. First, the acquisition will be discussed and 
compared to the original pure shift NMR experiments(19, 20). Secondly, 
reconstruction and processing of the FIDs will be discussed, after which the effect 
of multiple block acquisition on the S/N-ratio as well as on the integral will be 
addressed. 
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7.2 Experimental 
7.2.1 Chemicals 
Testosterone (purity ≥ 98.0%) and DMSO-d6 (99.96 atom% D) were purchased 
from Sigma-Aldrich, Schnelldorf.  
 
7.2.2. Experimental details 
All NMR experiments were recorded at 298 K on Varian UnityInova spectrometers 
operating at 500 MHz or 800 MHz (1H resonance frequency), the latter equipped 
with a cryo-cooled probe. Pulse duration and RF strength (in Hz) for the esnob 
pulse (bandwidth = 30 Hz) were 47.3 ms and 38.6 Hz, respectively. Pulse duration 
and RF strength (in Hz) for the rsnob pulse (bandwidth = 50 Hz) were 37.0 ms and 
68.6 Hz, respectively. The duration of all gradients was 1 ms. The strength of 
gradients G1, G2 and G3 were 2.05, -2.05 and -4.1 G/cm, respectively, while the 
strength of gradients G2 was varied within one scan between 3.9 G/cm and 5.9 
G/cm for different acquired blocks. The t1-evolution period was incremented in 
steps of 15.2 ms and the acquisition period had a duration of 15.6 ms 
corresponding to 78 complex data points. 
Reconstruction of the FIDs is performed using an in-house developed Matlab 
script. Processing of the reconstructed FIDs is performed using the NMRPipe 
software(21). The Agilent pulse sequence, as well as the reconstruction and 
processing scripts will be made available upon request. 
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7.3 Results and Discussion 
The quantitative pure shift NMR experiment with high sensitivity we proposed is 
displayed in Figure 7.1A. It shows in its overall appearance large similarities with 
the original pure shift NMR experiment first introduced by Zangger and Sterk(20) 
and recently optimized by Aguilar et al.(19) (Figure 7.1B). However, several 
features are implemented that lead to the enhanced sensitivity and essential correct 
integrals.  
 
 
Figure 7.1 (A) Pure shift experiment optimized for low-concentrated samples. Excitation is 
performed by a selective esnob pulse with a bandwidth of 30 Hz. A pure shift spectrum is 
reconstructed from several selective 2D datasets recorded by shifting the frequency of the 
shaped pulses in regular steps of 20 Hz to sample the region of interest. The elements inside 
the square brackets allow for the acquisition of additional blocks per scan. The delay δ 
(2/SW) is inserted for acquisition periods 3 and higher to obtain correct timing in the 
reconstructed FIDs (see main text) (B) Pulse scheme of the conventional pure shift 
experiment.(19) Narrow and wide rectangular boxes denote non-selective 90º and 180º 
pulses, respectively. An rsnob shaped pulse with a bandwidth of 30 Hz or 50 Hz is used as 
a refocusing element. The gradient shadowed in grey makes the rsnob pulse slice selective 
thus allowing the detection of signals of different chemical shifts from different regions of 
the sample. 
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In the quantitative pure shift experiment we propose (Figure 7.1A), the 
longitudinal magnetization is transferred to single quantum coherence via a 
selective excitation pulse (esnob selective pulse with a bandwidth of 30 Hz) 
followed by a non-selective 180° pulse. In contrast, in the conventional pure shift 
experiment (Figure 7.1B) a non-selective excitation pulse is employed. In both 
experiments, the evolution of 1H single quantum coherence between time-points a 
and c (Figure 7.1A and B) is determined by chemical shifts only, because the effect 
of homonuclear J-couplings is exactly refocused at time-point c. This holds true, 
provided the rsnob 180° pulse is sufficiently selective to affect only one of a 
network of coupled spins. The experiment is performed in 2D fashion by 
incrementing the duration of t1 and acquiring the proton signal at the echo point c. 
A 1D FID free from the modulation due to homonuclear J-couplings can be 
reconstructed from the 2D dataset by concatenating individual points acquired at 
different t1 increments. In practice, because of the small values of homonuclear J-
couplings, acquisition can be extended to a time interval of ca. 15-20 ms duration 
around the echo point(19). This considerably reduces the number of t1 increments 
and the total experiment duration without introducing appreciable artifacts on the 
reconstructed FID. In the conventional pure shift experiment (Figure 7.1B), the 
weak magnetic field gradient shadowed in Figure 7.1B extends the width of the 
detected spectral region beyond the bandwidth (typically 30-50 Hz) of the selective 
rsnob pulse. This gradient makes the rsnob pulse slice-selective, allowing signals 
of different chemical shifts to be generated in different horizontal slices of the 
NMR sample. This elegant approach to access a large spectral region has, however, 
the drawback of a reduction of the effective solutes concentration, causing a severe 
drop (20- to 40-fold) in sensitivity. Our approach to acquire pure shift NMR 
spectra (Figure 7.1A) with high sensitivity does make use of a slice-selective 
gradient. Instead, a large spectral width is accessed by the interleaved acquisition 
of multiple 2D datasets each with different frequency settings for the selective 
excitation pulse (esnob) and refocusing pulse (rsnob) and in this way 
reconstructing the spectral region of interest. That is, for each t1 increment the 
transmitter frequency for the selective pulses (esnob and rsnob) is shifted several 
times to scan the spectrum. Figure 7.2 shows the 1D-1H NMR spectrum of 
testosterone with the sequence of the frequency jumps for the selective pulses 
indicated as recorded at a 500 MHz spectrometer.  
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Figure 7.2 Sequence of the frequency jumps performed to acquire the signals in the 
spectral region of interest. The sine-bell shapes in grey indicate the bandwidth as well as 
the offset of the esnob/rsnob selective pulses.  The index i on the grey shapes indicate the 
order at which every portion is acquired. Starting from the right hand side of the spectrum 
with fixed frequency jumps of 120 Hz, when the left side of the NMR spectrum is reached 
(for the 8th segment, i=8), the frequency of the esnob/rsnob pulses is shifted back to the 
right hand side of the spectrum, with an offset of 20 Hz with respect to the first segment. 
Again, eight segments are sequentially acquired shifting the frequency of the shaped pulses 
from right to left. This procedure is repeated until the complete NMR region of interest is 
scanned. 
 
The first segment (1 in Figure 7.2) is acquired at ~0.6 ppm, the second (2 in Figure 
7.2) at ~0.85 ppm, the third at ~1.09 ppm, and so on with regular spaced frequency 
jumps of 120 Hz. This procedure is repeated until the left part of the NMR 
spectrum is reached (8 steps at 500 MHz). In the next set of experiments, the 
transmitter frequency of the shaped pulses was shifted 20 Hz with respect to the 
first set of experiments, leading to the segments 9, 10, etc. This procedure is 
repeated until the complete NMR spectrum is scanned in regular steps of 20 Hz. To 
scan a spectral region between ~0.6 and ~2.4 ppm at a 500MHz spectrometer, as in 
Figure 7.2, 48 offset steps are required. Obviously, the number of offset steps 
changes when pure shift experiments are acquired at a stronger or weaker magnetic 
field. After the complete spectral region is scanned in steps of 20 Hz, the value of 
t1 is incremented; the transmitter frequency is then set back to its original start 
value at the right hand side of the spectrum and the whole procedure is repeated. In 
this way a selective 2D dataset is acquired for each frequency, with a maximum t1 
evolution period of ca. 600 ms, corresponding to 40 t1-increments. Since excitation 
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is performed with an esnob pulse with a bandwidth of 30 Hz, the ordering of the 
frequency jumps, as it is shown in Figure 7.2, minimizes perturbation of proton 
magnetization in segments that have not yet been excited. This therefore means 
that fast pulsing can be employed, i.e. the recovery delay between two successive 
acquisitions can be shortened to 250 – 350 ms, which greatly reduces the 
experimental time. The total experimental time of the pure shift NMR experiment 
described here is determined by the number of frequency steps as well as the 
number of t1 increments. For the pure shift spectrum of testosterone recorded at 
500MHz, using 48 frequency steps and 40 t1-increments, the experimental time is 
approximately 27 minutes. In contrast, the experimental time of the pure shift 
experiments as proposed by Zangger et al.(20) and Aguilar et al.(19) are only 
determined by the number of t1 increments, and can therefore be performed in a 
few minutes. Although this experiment can be performed relatively fast, it was 
shown that it is still at least five times less sensitive than our approach, taking the 
difference in experimental time into account (Chapter 5 of this thesis, supporting 
information). Another element which enhances the sensitivity of the pure shift 
NMR experiment even further (a factor of ~1.5) are the extra refocusing rsnob 
pulses which can be applied after the first detection period (Figure 7.1A). These 
extra refocusing pulses allow the acquisition of additional echo points within the 
same scan, hence additional acquisition blocks of 15-20 ms. These refocusing 
pulses make use of the relatively long T2 relaxation time in small molecules and in 
this way multiple independent pure shift spectra are obtained and combined to 
further increase the signal-to-noise ratio, see paragraph “Effect of multiple block 
acquisition on the S/N-ratio and integral” for more information. It is further noted 
that it should be relatively straightforward to implement this element to other pure 
shift methodologies in order to improve their sensitivity(19, 20).  
 
7.3.1 FID reconstruction 
For each selectively recorded 2D dataset a 1D FID has to be reconstructed. Table 
7.1 shows the data points as they were acquired in this study and the way they are 
reshuffled for 1D FID reconstruction. Here, each acquisition period consists of 78 
complex points with a total duration of 15.6 ms. Table 7.1 shows both the 
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reconstruction of 1D FIDs corresponding to acquisition blocks 1 and 2 (n=1, 
Figure 7.1A).  
First, the data points acquired in block 1 and the way these data points were 
reshuffled to obtain a 1D FID with correct timing (Table 7.1) will be discussed. In 
each acquisition period a number of data points surrounding the echo points are 
retained before J-modulation becomes visible (typically ± ~7.5 ms). However, in 
the first acquisition period, corresponding to t1 = 0 ms, the echo point lies at the 
beginning rather than in the centre of the acquisition period. So the acquisition 
starts by necessity from the echo point. Therefore only a number of data points 
after the echo point can be recorded. We took here the first 41 data points, with a 
total duration of 8.2 ms, for FID reconstruction (data points which have to be 
removed from the recorded dataset are striped in Table 7.1). In the second 
acquisition period, corresponding to the first t1-incrementation (t1 = 15.2 ms) the 
echo point lies in the centre of the acquisition period and the first three data points 
need to be removed to make the timing equally spaced in the reconstructed FID. In 
the third column of Table 7.1, the evolution time of the spins is given for each data 
point. Note that in the reconstructed FID, the evolution time should form an 
uninterrupted array of equally spaced time points. Apart from the first three data 
points, also the final two data points were removed, in order to obtain correct 
timing with respect to the next t1 increment. From the third increment on (t1 ≥ 30.4 
ms), the first two data points of each acquisition period are removed (striped in 
Table 7.1). This is done because the first two data points of each acquisition period 
are slightly distorted and would cause discontinuity in the reconstructed FIDs. In 
order to compensate for these removals, the second t1/2 evolution period which 
follows the rsnob pulse is shortened by 2/SW. Note that in Table 7.1 for 
acquisition period 3 and higher two additional data points are displayed at the end 
of each period (data points 79 and 80, coloured gray). These data points are 
inserted as a delay in the pulse sequence to obtain correct timing between blocks 1, 
2 and further; they will be discussed below for block 2.  
Ard Kolkman 206 
                                                                                    Pure shift NMR: a detailed explanation 
 
Table 7.1 Schematic representation of the sequence of data points recorded in each 
acquisition period (first column), ordering of these data points in the reconstructed 1D FID 
(second column) and the corresponding time in the reconstructed FID (third column). In the 
example here given, two blocks of data points are acquired per scan (i.e. n=1 in Figure 
7.1A); block 1 (at the left hand side) and block 2 refer to the reconstruction of two 
independent FIDs from these two blocks. The data points in gray indicate delays introduced 
in the pulse sequence to preserve correct timing. 
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The data points recorded in block 1 are echoed by a selective rsnob pulse to obtain 
block 2. Also for block 2, 78 complex data points are recorded for each acquisition 
period with a total length of 15.6 ms. The reconstruction to obtain an FID for block 
2 follows the same pattern as described for block 1. The most important aspect to 
notice is that in block 2 the order of the recorded data points in each acquisition 
period has to be inverted. This is because the rsnob pulse inverts the chemical shift 
evolution direction of the spins. Hence, the first point of acquisition period 1 in 
block 2 corresponds to the final point of the corresponding acquisition period in 
block 1, the second point of acquisition period 1 in block 2 corresponds to the 
second last point of acquisition period 1 in block 1, and so on. As for block 1, for 
the first acquisition period of block 2 (t1 = 0), only the first 41 data points were 
retained; in the second acquisition period of block 2 the first three data points and 
the final two data points were removed. A delay δ corresponding to two data points 
(0.4 ms) was added in the pulse sequence (Figure 7.1A) after each acquisition 
period, starting from acquisition period 3. These data points are indicated in gray in 
Table 7.1. Absence of this delay in block 1 after acquisition period 3 and further, 
leads to time points 38.0 and 27.8 ms to be the last time points in block 1 and the 
first two points to be acquired in block 2. These first two points need to be 
removed and consequently the timing between block 1 and 2 would be incorrect. 
However, introduction of this delay δ after block 1 (points 38.2 and 38.4) allows 
recording time points 38.2 and 38.4 in block 2 as the first two data points. Their 
removal restores the correct timing between block 1 and block 2.  In case more 
than two blocks within one scan are acquired (n > 1, Figure 7.1A), reshuffling of 
data points in even recorded blocks is identical to those discussed for block 2 and 
those of odd acquired blocks are identical to those discussed for block 1. 
 
7.3.2 Data processing 
The reconstructed FIDs are processed with an NMRPipe(21) script using a cosine-
bell apodization function, zero filling to 32k complex points, Fourier 
transformation and phase correction. Figure 7.3 shows for four FIDs the resulting 
pure shift spectra in the region between ~0.7 and ~1.1 ppm. For each spectrum, the 
pure shift signals are only present within a small spectral region centered around 
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the transmitter frequency offset of the shaped pulses. The width of this spectral 
region is determined by the bandwidth of the selective excitation pulse and the 
width of a multiplet, which is maximal 80 Hz in case of testosterone when using a 
30 Hz excitation pulse. The intensity of each pure shift spectrum outside this 80 Hz 
region is set to zero in order to prevent unnecessary summation of noise or residual 
solvent signals. Subsequently, the selectively recorded pure shift spectra, 48 for 
testosterone at 500 MHz, are summed to obtain a high resolution broadband 
homonuclear decoupled spectrum.  
 
Figure 7.3 Four selectively recorded pure shift spectra of testosterone in the region 
between ~0.7 and ~1.1 ppm are summed to obtain a pure shift spectrum. The spectra were 
recorded on a 500 MHz spectrometer, in order to obtain a pure shift spectrum of 
testosterone between ~0.6 and ~2.5 ppm, 48 selectively recorded pure shift spectra have to 
be summed. Note that in each spectrum, a region of 80 Hz around the transmitter frequency 
offset of the shaped pulses is retained, whereas the rest of the spectrum is set to zero in 
order to prevent unnecessary summation of noise or residual solvent signals. 
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7.3.3 Effect of multiple block acquisition on the S/N-ratio and integral 
The effect of multiple-block acquisition (i.e. n ≥ 1 in Figure 7.1A) on the signal-to-
noise ratio as well as on the peaks integral is demonstrated for a 50 μM sample of 
testosterone. The spectra displayed in Figure 7.4 were acquired at 800 MHz and 
correspond to the first four reconstructed FIDs. The sum of the four pure shift 
spectra provides an increase in signal-to-noise ratio of ca. 50% relative to the first 
reconstructed spectrum (FID 1 in Figure 7.4).  
 
Figure 7.4 Pure shift spectra of a 50 μM solution of testosterone in DMSO-d6 from four 
reconstructed FIDs corresponding to four acquired blocks per scan (i.e. n=3 in Figure 
7.1A). The sum of the four spectra is plotted at the same noise level as the others. The 
signal-to-noise increase in the sum amounts to ca. 50% (25:1 in FID 1 to 35:1 in the sum). 
The experiment was performed at 800 MHz (1H resonance frequency) in 40 minutes using 
a cryo-cooled probe. Signals marked with an asterisk originate from impurities. The 
normalized value of the peak integrals is reported in red for FID 1 and for the sum. 
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The drop in signal intensity for successive acquisition blocks (FID 1 to 4 in Figure 
7.4) is due to T2 relaxation as well as the progressive narrowing of the selected 
bandwidth as additional rsnob pulses are applied. This effect is more evident on 
broad multiplets while it is negligible in the case of sharp lines (e.g. methyl 
signals). As a consequence, the integral ratios in the sum spectrum present strong 
systematic deviations (as large as 50%) for sharp singlet signals. On the other 
hand, if such sharp signals are excluded, similar values of the normalized integrals 
are found in the sum spectrum and in the first reconstructed spectrum. Protons for 
which strong coupling effects are present, show a more rapid signal decay for 
successive echoes and a quantitative analysis of their integral in the sum spectrum 
should be performed with care.  
 
7.3.4 Quantification 
The parameters which can interfere with correct integrals are: T2 relaxation, T1 
relaxation, non-uniform excitation, strong coupling effects and multiple block 
acquisition within one scan. The former one was already discussed in paragraph 
7.3.3. A large difference in T2 relaxation time can cause errors on the integral. For 
example, proton nuclei of testosterone have a T2 relaxation time of ~200-300 ms 
and TSP has a T2 relaxation time larger than 1 s. Due to the relaxation effects 
during the selective pulses and evolution periods, the signal intensity of the faster 
relaxing nuclei (testosterone) are expected to attenuate faster than the signal 
intensity of the slower relaxing nuclei (TSP). This results in distorted integral 
ratios between nuclei which have large differences in T2 relaxation time. T1 
relaxation time is the third parameter which can interfere with correct integrals. 
The recovery delay between consecutive experiments is only ~250 – 350 ms. Due 
to the ordering of the frequency jumps of the esnob and rsnob pulses (Figure 7.2), 
segments that have been acquired can relax back to thermal equilibrium before 
they are excited again. Table 7.2 shows the effect of a short and long recovery 
delay (fast pulsing and slow pulsing, respectively) on the integrals of testosterone 
protons. On average the integral is 10 ± 1% lower in the case of fast pulsing. Most 
important, this decrease is uniform and not sensitive to differences in 1H T1 
relaxation time that for testosterone can be larger than 50%. Considering that a 
pure shift experiment with a recovery delay of 5 seconds would take approximately 
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6 times longer than a pure shift experiment with a recovery delay of 250 ms, makes 
that only a 10% loss in sensitivity is more than acceptable.  
 
Table 7.2 The effect of a short and long recovery delay (d1) on the integrals of testosterone 
protons as acquired at an 800MHz spectrometer (n = 0, Figure 7.1A). The first column 
shows the chemical shift, the second column the integral and the third column the 
normalized integral, where a value of 1.00 corresponds to one proton. The column labeled 
with ‘Delta’ represents the difference in normalized integral between fast and slow pulsing. 
fast pulsing d1 =  350ms slow pulsing d1 = 5s
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0.74 314.2 1.05 0.74 352.0 1.17 0.13
0.92 100.9 1.01 0.92 110.6 1.11 0.10
0.95 192.0 0.96 0.95 214.4 1.07 0.11
1.03 100.5 1.00 1.03 109.0 1.09 0.09
1.2 306.6 1.02 1.2 338.6 1.13 0.11
1.26 93.0 0.93 1.26 101.6 1.02 0.09
1.4 183.2 0.92 1.4 201.2 1.01 0.09
1.56 301.2 1.00 1.56 325.2 1.08 0.08
1.64 97.4 0.97 1.64 108.7 1.09 0.11
1.81 202.2 1.01 1.81 223.5 1.12 0.11
1.89 100.9 1.01 1.89 n.d.
2.02 100.9 1.01 2.02 108.8 1.09 0.08
2.19 100.6 1.01 2.19 111.2 1.11 0.11
2.29 100.0 1.00 2.29 109.4 1.09 0.09
0.99 Average 1.09 Average 0.10
0.04 Standard deviation 0.04 Standard deviation 0.01  
* Delta = difference between normalized integrals of fast and slow pulsing 
 
In the pure shift NMR experiment proposed here, an offset step of 20 Hz is used to 
scan (excite) the spectral region of interest. Both simulations and experimental data 
indicate that an offset step of 20 Hz can cause an underestimation of the peak 
integrals of 10% at most (Figure 7.5). A smaller sampling step can reduce this 
systematic error (1% for offset jumps of 10 Hz) at the cost of measurement time 
which will be twice as long.  
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Figure 7.5 (A) The effect of the pureshift experiment on the signal integral is simulated 
using one block acquisition and offset jumps of 20 Hz and 10 Hz. A proton signal with 4 
coupling partners was used: 12.3 Hz, 11.9 Hz, 6.9 Hz and -12.6 Hz. The J-couplings were 
scaled down to zero in steps of 10% in order to observe the effect of the width of the 
multiplets on the signal integrals. (B) Simulated reference (with J-couplings) and pure shift 
signals of the multiplet with different scaling factors. Offset jumps of 20 Hz were used.  
 
Strong coupling is the most important parameter which can hamper the quality of a 
pure shift spectrum. Two situations were observed while performing the research 
described in this thesis; 1) when two coupling partners have approximately the 
same chemical shift (e.g. rectangular box in Figure 5.3) irregular peak shapes are 
present; 2) non-negligible strong coupling effects reduce the integral of pure shift 
signals as shown in Table 5.1. The easiest way to reduce the effects caused by 
strong coupling is by acquiring pure shift spectra at spectrometers with higher 
magnetic field strengths. Recently, Thrippleton et al.(22) and Aguilar et al.(23) 
proposed methodologies to circumvent the problems associated with strong 
coupling artefacts. This comes however at the cost of a large reduction in 
sensitivity. The next hurdle to overcome is most likely the combination of 
suppressing the effects of strong coupling artefacts, while retaining correct 
integrals and a high sensitivity.  
 
7.4 Conclusions 
In summary, we have given a detailed explanation of the acquisition and 
processing of the pure shift NMR experiment with high sensitivity as it was 
introduced in Chapter 5 and 6 of this thesis. The pure shift experiment can easily 
Ard Kolkman 213
Chapter 7   
be implemented on most spectrometers and reconstruction and processing of the 
data is best performed using a Matlab and NMRPipe script. The Agilent pulse 
sequence as well as the Matlab and NMRPipe script will be provided upon request.  
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8.1 Summary 
The research described in this thesis is mainly devoted to the application of liquid 
state Nuclear Magnetic Resonance (NMR) spectroscopy into a variety of 
disciplines particularly related to the pharmaceutical industry. NMR spectroscopy 
is an extremely information-rich analytical technique. It allows for the non-
invasive determination of the structure and dynamics of molecules and the 
quantification of their amounts in complex mixtures. More specifically, this thesis 
describes the application and further development of NMR based methodologies 
for a better understanding of Cytochrome P450BM3 drug metabolism, metabolite 
identification and mixture analysis. 
Cytochrome P450s are monooxygenase enzymes catalyzing a variety of reactions. 
Although P450s are present in most tissues, the liver is the main organ for drug 
metabolism and approximately 75% of all drugs are metabolized by Cytochrome 
P450s. This, together with other aspects, has led to a considerable interest into 
Cytochrome P450 enzymes in the pharmaceutical industry. Nevertheless, several 
aspects of the metabolization of (drug) compounds by P450 enzymes are not well 
understood yet. Also the application of P450 enzymes in the pharmaceutical 
industry for (I) elimination or systematic clearance of drugs, (II) bioavailability of 
drugs, (III) (de-) toxification of drug compounds, (IV) determining metabolic weak 
points in lead compounds, (V) introducing new functional groups into drugs which 
would be difficult to introduce chemically, (VI) drug-drug interactions and many 
others aspects, need to be further discovered. There is thus a great demand for 
analytical platforms / methods that can unravel the mechanism of metabolization of 
drug and drug-like compounds by Cytochrome P450s.  
This thesis can roughly be divided into two parts (i) application of already existing 
NMR methodologies into new application fields (Chapters 2 and 3) and (ii) 
development of novel NMR based methodologies (Chapters 4, 5, 6 and 7). 
In chapter 1 a review and general introduction is given of the pharmaceutical 
industry, Cytochrome P450 enzymes and NMR spectroscopy. In particular, there is 
a focus on the role of analytical sciences in drug discovery. Also, the basic 
principles of NMR spectroscopy are described and in light of the development of 
pure-shift NMR methods (Chapters 5, 6, and 7) aspects of homonuclear decoupling 
in 1D-1H NMR spectroscopy are specifically described.  
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Chapter 2 describes the formation and identification of estrogenic compounds 
generated by P450BM3 enzymes. A hyphenated screening assay is described 
where, in parallel, the bioactivity of the generated compounds towards the human 
Estrogen receptors α and β is determined and HR-MS is used as quick tool for fast 
first line structure identification. NMR spectroscopy is subsequently used to obtain 
full structural information of the set of generated drug metabolites.  
Cytochrome P450BM3 enzymes can be designed in such a way to suite a particular 
application. In Chapter 3 it is shown that a single mutation (A82W) in the active 
site of P450BM3 mutants M01 and M11 results in a strong increase in the 
regioselectivity of steroid hydroxylation at position 16β. The A82W mutation 
further improved both binding affinity and coupling efficiency, thereby strongly 
improving the catalytic activity. As shown by T1 paramagnetic relaxation NMR, 
this single mutation changes the orientation of testosterone in the active site in the 
M11A82W mutant as compared to its orientation in the active site in M11. The 
preferred active-site orientation of testosterone in the A82W mutant might explain 
its increased selectivity for hydroxylation in the D-ring (position 16β). 
In Chapter 4 a microfluidic high-resolution NMR flow probe is demonstrated. 
This flow probe has a detection volume of only 600nL and a sensitivity which is 
~3.4 times larger than that of a conventional 5mm NMR probe. The excellent  
spectral resolution (line width of < 1 Hz) is demonstrated on a sample of pure 
ethanol. Two application fields of this microfluidic NMR flow probe are 
demonstrated (i) in-situ monitoring of the kinetics of reactions performed in 
microreactors at full NMR resolution; (ii) the analysis of mass-limited samples. 
Application field (i) is exemplified by following the acetylation of benzyl alcohol 
in the presence of DIPEA over time and application field (ii) is exemplified by 
analyzing 600nL of human cerebrospinal fluid.  
Resolution is a crucial element for the successful application of analytical NMR 
techniques to complex systems (e.g. complex molecules or mixtures). One of the 
spectral features that can limit NMR resolution in liquids is the fine structure on the 
NMR resonance of a particular spin, which is determined by scalar coupling 
interactions (J-couplings). The splitting of NMR resonances in multiplets due to J-
couplings can cause significant signal overlap even in the spectra of relatively 
simple molecules, hampering interpretation, assignment and quantitative analysis 
of the NMR spectra. Chapter 5 shows a novel pure shift NMR experiment in 
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which broad multiplets collapse to singlets. In particular the acquisition of 
broadband homonuclear decoupled 1D-1H NMR spectra of mass-limited samples 
(e.g. 50μM testosterone in 40 minutes) is demonstrated. The experiment proves to 
be quantitative and can therefore be used to determine solute concentrations. The 
sensitivity of this experiment is found to be approximately one order of magnitude 
more sensitive than previously reported pure shift experiments. Finally, the 
resolution increase resulting from this pure shift NMR experiment is demonstrated 
using a mixture of the steroid hormones cortisone and testosterone.  
Chapter 6 shows an application of the pure shift NMR experiment described in 
Chapter 5. The complex 1D-1H NMR spectrum of a mixture containing 
testosterone and its three metabolites produced by a Cytochrome P450BM3 
enzyme is greatly simplified by acquiring the pure shift NMR experiment. In 
particular we show that the spectral simplification allows the identification and 
quantification of the metabolites based on pure shift fingerprint profiles of the 
individual compounds without a physical separation of the components present in 
the mixture. It is also shown that this identification can be performed in an 
automated fashion. 
In Chapter 7, gives a detailed explanation of the pure shift NMR experiment 
introduced in Chapter 5 and 6. First, the acquisition of this experiment is discussed 
and compared to the original pure shift NMR experiments. Secondly, the 
reconstruction and processing of the FIDs is explained and the parameters affecting 
the signal integral are discussed. 
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8.2 Samenvatting 
In dit proefschrift wordt hoofdzakelijk de toepassing van kernspinresonantie 
(NMR) in verschillende takken van de farmaceutische industrie beschreven. NMR 
spectroscopie is een analytisch chemische techniek die erg veel informatie geeft 
over de structuur en dynamica/beweging van moleculen. Tevens kan NMR 
gebruikt worden om exact te kwantificeren. In dit proefschrift wordt de toepassing 
en verdere ontwikkeling van methodes die gebaseerd zijn op NMR beschreven. Dit 
wordt met name gedaan om het metabolisme van medicijnen door cytochroom 
P450BM3 enzymen beter te begrijpen alsmede om metabolieten te identificeren en 
mengsels te karakteriseren.  
Cytochroom P450 enzymen zijn eiwitten die onder andere aanwezig zijn in het 
menselijk lichaam. De functie van deze enzymen bestaat onder meer uit het 
metaboliseren van medicijnen. De reacties die Cytochroom P450 eiwitten 
katalyseren is erg verschillend en ligt aan het type enzym en ligand/medicijn. 
Cytochroom P450 enzymen zijn in bijna alle weefsels aanwezig, maar het grootste 
percentage van de medicijnen (~75%) wordt gemetaboliseerd in de lever. De 
hierboven beschreven functies van P450 enzymen heeft er mede toe geleid dat er 
vanuit de farmaceutische industrie een grote belangstelling is voor deze enzymen. 
Desalniettemin zijn er verschillende aspecten van het metabolisme van medicijnen 
door P450 enzymen nog onbegrepen. Ook de toepassing van P450 enzymen in de 
farmaceutische industrie voor bijvoorbeeld (I) eliminatie van medicijnen uit het 
lichaam; (II) bio-beschikbaarheid van  medicijnen; (III) vergifiting / ontgiftiging 
van medicijnen; (IV) bepaling van metabolisch zwakke plekken op een molecuul; 
(V) introduceren van functionele groepen in medicijnen / chemicaliën; (VI) 
medicijn-medicijn interacties en vele anderen moet verder ontwikkeld worden. Er 
is dus een grote vraag voor analytische platforms en methodes voor het ophelderen 
van het metabolisme van medicijnen en andere chemicaliën door P450 enzymen.  
Dit proefschrift kan het beste onderverdeeld worden in twee gedeelten (i) 
toepassing van al bestaande NMR methodologieën binnen nieuwe 
toepassingsgebieden (Hoofdstuk 2 en 3) en (ii) ontwikkeling van nieuwe 
methodologieën die gebaseerd zijn op NMR (Hoofdstuk 4, 5, 6 en 7).  
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In hoofdstuk 1 wordt een algemene introductie gegeven over de farmaceutische 
industry, Cytochroom P450 enzymen en NMR spectroscopie. Er wordt in het 
bijzonder aandacht gegeven aan de rol van chemische analyse technieken binnen 
het medicijn ontwikkelings traject. Tevens wordt er ter introductie van de pure shift 
experimenten die beschreven staan in hoodstuk 5, 6 en 7 van dit proefschrift dieper 
ingegaan op de verschillende aspecten van homonuclear ontkoppeling in 1D-1H 
NMR spectra.  
Hoodfstuk 2 beschrijft de formatie en identificatie van oestrogene metabolieten die 
gevormd zijn door P450BM3 enzymen. Er wordt een geavanceerde screening assay 
beschreven waar twee analyses parallel aan elkaar uitgevoerd worden: (i) bio-
activitieit van de gegenereerde metabolieten voor de estrogene receptors α en β; (ii) 
hoge-resolutie massa spectrometrie als een snelle methode voor het verkrijgen van 
informatie over de structuur van de metabolieten. NMR spectroscopie wordt 
vervolgens off-line toegepast om de exacte structuur van de gevormde 
metabolieten te bepalen. 
Cytochroom P450BM3 enzymen kunnen op een dusdanige manier ontworpen 
worden om een gewenste reactie te laten plaatsvinden. In Hoofdstuk 3 laten we 
zien dat een enkele mutatie (A82W) in de active site van P450BM3 mutanten M01 
en M11 resulteert in een sterke toename in regioselectiviteit voor de hydroxylatie 
van steroïden op positie 16β. Deze mutatie (A82W) zorgt ook voor een hogere 
bindings affiniteit en koppelings efficiëntie, wat weer resulteert in verbeterde 
catalytische activiteit. Met behulp van T1 paramagnetische relaxatie NMR laten we 
verder zien dat deze enkele mutatie zorgt voor een verandering in de oriëntatie van 
testosterone in de active site van de M11A82W mutant in vergelijking met de 
orientatie van testosterone in M11. Deze geprefereerde orientatie verklaart zeer 
waarschijnlijk de verbeterde selectiviteit voor steroïd hydroxylatie in de D-ring 
(16β). 
In hoofdstuk 4 wordt een micro-fluidische hoge-resolutie NMR flow probe 
beschreven. Deze flow probe heeft een detectievolume van slechts 600nL en een 
gevoeligheid die ongveer 3.4 keer hoger is dan een conventionele 5mm NMR 
probe. De excellente lijnbreedte (lijnbreedte op halve hoogte < 1Hz) wordt 
gedemonstreerd aan de hand van pure ethanol. Er worden twee 
toepassingsgebieden van deze flow probe beschreven (i) in-situ monitoren van de 
reactiekinetiek van een reactie die plaatsvindt in een micro-reactor; (ii) analyse van 
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een monster met een beperkte hoeveelheid materiaal. Toepassingsgebied (i) wordt 
geïllustreerd door de reactie van benzylalcohol in de aanwezigheid van DIPEA te 
volgen over tijd en toepassingsgebied (ii) wordt beschreven door 600nL 
hersenvloeistof te analyseren.  
Om complexe systemen (bv. complexe moleculen of mengsels) te analyseren met 
behulp van NMR spectroscopie is een hoge resolutie van cruciaal belang. Een van 
de spectrale parameters die de resolutie van NMR spectra kan beperken is de J-
koppeling. De splitting van NMR resonanties door J-koppelingen veroorzaakt 
relatief brede multipletten die met elkaar overlappen. Hierdoor is het vaak erg 
moeilijk of onmogelijk om spectra te interpeteren en te gebruiken voor een 
kwantitatieve analyse.  
Hoofdstuk 5 beschrijft een pure shift NMR experiment waar brede multipletten 
vereenvoudigd worden tot singletten. In het bijzonder wordt de acquisitie van 
breedband homonuclear ontkoppelde 1D-1H NMR spectra van monsters met een 
relatief lage concentratie (50μM testosterone in 40 minutes) gedemonstreerd. Er 
wordt tevens aangetoond dat dit experiment kwantitatief is, wat dus betekent dat dit 
pure shift NMR experiment gebruikt kan worden om concentraties te bepalen. De 
gevoeligheid van het hier beschreven pure shift NMR experiment is ongeveer een 
order van grote hoger dan de pure shift experimenten die eerder beschreven zijn in 
de literatuur. Als een voorbeeld van de hoge resolutie spectra die opgenomen 
kunnen worden met dit experiment wordt er een mengsel gedemonstreerd van de 
steroïd hormonen cortisone en testosterone.  
Hoofdstuk 6 laat een toepassing van het pure shift NMR experiment dat 
geïntroduceerd is in hoofdstuk 5 zien. Het complexe 1D-1H NMR spectrum van 
een mengsel bestaande uit testosterone en drie metabolieten geproduceerd door een 
cytochroom P450BM3 enzyme wordt aanzienlijk vereenvoudigd door het opnemen 
van een pure shift NMR experiment. De vereenvoudiging van het spectrum maakt 
het mogelijk om de aanwezige componenten te identificeren en kwantificeren aan 
de hand van ‘fingerprint-profiling’. In hoofdstuk 6 wordt ook een geautomatiseerde 
procedure beschreven voor het identificeren van componenten in een mengsel.  
In hoofdstuk 7 wordt het pure shift experiment, zoals beschreven in hoofdstuk 5 en 
6, tot in detail uitgelegd. Ten eerste wordt de acquisitie van dit experiment 
beschreven en vergeleken met de originele pure shift NMR experimenten. Ten 
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tweede wordt de reconstructie en processing van de FIDs beschreven en als laatste 
onderdeel worden de paramters die invloed hebben op de integraal beschreven.  
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8.3 Future Perspectives 
In this thesis NMR based methodologies were applied and developed with a 
particular focus on applications in the pharmaceutical industry. There can be 
thought of many future directions to continue the research presented in this thesis. 
A few are summarized here. (1) Expand the hyphenated screening assay as 
described in Chapter 2 by using other scaffold compounds, other biosynthetic 
enzymes or electro chemistry to generate novel bioactive metabolites. (2) By 
coupling the hyphenated screening on-line with NMR spectroscopy the throughput 
of the screening assay can be increased (e.g. by using the stripline NMR probe 
which is described in Chapter 4 of this thesis). (3) Development of large libraries 
of P450BM3 enzymes in order to easily select a set of P450BM3 enzymes which 
suite a particular application (e.g. regioselective hydroxylation with high 
conversion rates for production purposes). (4) Implement the pureshift NMR 
experiment as shown in chapter 5, 6 and 7 into the world of metabonomics (serum, 
urine and cerebrospinal fluid analysis). (5) Design of a large pure shift NMR 
library and the development of a fully automated screening procedure for 
identification and quantification of components present in mixtures. (6) Besides 
these scientific points, it is most likely as important to ‘sell’ the methodologies and 
experiments presented in this thesis to a broad audience. This might result in a 
large interest and might guarantee continuation, by companies and/or research 
groups, of the work initiated here.  
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